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INTRODUCTION 

9The global burden of malaria is largely carried by the world’s malaria-endemic 
countries, where the highest death toll is seen in children below five years of age 
(1). Patients and medical personnel in these areas often have to cope with limited 
medical facilities and a shortage of beds in intensive care units. In contrast, when 
patients from high-income countries acquire malaria during international travel 
to endemic areas, they will usually have access to solid health care systems once 
they have returned back home. 
Imported malaria, however, has its own challenges. Due to the low incidence and 
the non-specificity of the initial symptoms of the disease, the diagnosis is easily 
missed. A study in the United Kingdom showed an inverse relationship between 
the incidence and case fatality of imported malaria (2) and in a London based 
study in children, the diagnosis was found to be delayed in 53% (3). Diagnosing 
malaria outside endemic areas is frequently hampered by a lack of sufficiently 
skilled and experienced laboratory personnel. Hospitals often rely on rapid tests, 
without possibilities for reliable species differentiation and quantification of the 
parasite load. Once diagnosis has been made, appropriate treatment forms the 
next challenge. Few hospitals are experienced in caring for patients with malaria 
and signs and symptoms indicating a complicated infection might not be promptly 
recognized. Moreover, appropriate medication is not always readily available. In a 
survey among all hospitals in the Netherlands in 2008, it was found that 22% did 
not have intravenous medication for the treatment of severe malaria available and 
6.6% did not have any kind of antimalarial treatment stocked (4).
The Harbour Hospital and Institute for Tropical Diseases in Rotterdam, the 
Netherlands, serves as a national referral center for imported diseases and is one 
of the country’s centers of expertise in malaria. This thesis aims to answer several 
questions raised while caring for patients with malaria in this institution, and to 
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improve the care for patients with imported malaria in general. The research ques-
tions and outline of the thesis will be formulated at the end of this chapter.
Malaria
Malaria is a parasitic disease, caused by infection with protozoa of the genus 
Plasmodium. Four species within this genus, Plasmodium falciparum, Plasmodium 
vivax, Plasmodium ovale and Plasmodium malariae, are strictly human patho-
gens and cause the vast majority of infections in man. Zoonotic transmission 
of non-human species was considered rare until 1965, when the first case of a 
naturally acquired human infection with Plasmodium knowlesi, a species primarily 
found in South East Asian macaques, was reported (5-7). More recently, a natu-
rally acquired infection of another simian Plasmodium species, Plasmodium cyno-
molgi, has been described. Although several other simian Plasmodium species 
have been proven to be transmittable to humans in an experimental setting, no 
naturally acquired infections with these species have been reported to date (8).
Life cycle
Malaria is transmitted by the bite of an infected female mosquito of the genus 
Anopheles (Figure 1).  The mosquito carries the sporozoite form of the Plasmodium 
parasite in her salivary glands and, while taking a blood meal, she injects her saliva, 
containing the sporozoites, into the human skin. The inoculum is usually small, 
and only a fraction of the injected sporozoites manage to enter the bloodstream 
and make their way to the liver (9).
After invasion of the hepatocytes, a process of asexual division is started, each 
sporozoite forming tens of thousands of daughter merozoites over the course of 
5 to 8 days. These hepatic schizonts burst and release their merozoites into the 
blood, where they invade erythrocytes and change into ring-form trophozoites. 
While feeding on haemoglobin, the parasite starts another phase of asexual divi-
sion within the red blood cell to form erythrocytic schizonts. This erythocytic 
cycle takes approximately 48 hours for P. falciparum, P. vivax, and P. ovale, 72 hours 
for P. malariae, and 24 hours for P. knowlesi. At the end of the cycle the schizonts 
rupture to release 8 to 24 merozoites, which are each capable of infecting another 
erythrocyte to start a new erythrocytic cycle. Simultaneously, some of the blood-
stage parasites mature into sexual forms, the male or female gametocytes, which 
can be picked up by a feeding mosquito. Oocysts are formed in the mosquito gut 
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after sexual reproduction. Subsequently, the oocysts release sporozoites, which 
migrate to the salivary glands and inoculate humans during the mosquito’s next 
blood meal (5, 10).
Hepatic-stage parasites of P. vivax and P. ovale, but not of the other species, may 
turn into hypnozoites, which can remain in their dormant stage for months to 
years before resuming replication and thus causing a relapse (5, 10).
Pathogenesis
P. falciparum causes the most severe pathology and causes by far the highest 
mortality of all Plasmodium species. Several factors are responsible for its viru-
lence. P. falciparum and P. knowlesi, as opposed to P. vivax, P. ovale and P. malariae, 
do not have a specific affinity for a particular erythrocyte stage and are thus 
capable of infecting huge numbers of red blood cells, causing very high parasi-
taemias. The percentage of parasitized erythrocytes in infections with P. vivax, 
P. ovale, and P. malariae does usually not exceed 1%, while in P. falciparum infection 
percentages of more than 10% are not uncommon and values as high as 80% 
have been reported in fatal cases (5, 11).
The hallmark of P. falciparum however, is its capability to cause trophozoite- and 
schizont-infected erythrocytes to adhere to the microvascular endothelium. 
This process, known as sequestration, is mediated by parasite proteins of the 
P. falciparum erythrocyte membrane protein 1 (PfEMP1) family. Once expressed 
on the surface of the infected erythrocyte, these proteins bind to adhesion mole-
cules on the endothelium of various organs and tissues, causing obstruction of 
microcirculatory flow, endothelial activation and pro-inflammatory and pro-co-
agulatory responses (5, 12, 13). Microcirculation is further compromised by the 
reduced deformability of both parasitized and unparasitized erythrocytes, which 
is thought to be caused by oxidative damage to the erythrocyte membrane by 
haemozoin, a haemoglobin breakdown product formed by the parasite during the 
erythrocytic cycle and released in large quantities during schizont rupture (14, 15).
Clinical characteristics
During the first days after the Plasmodium parasite is transferred into the human 
host, the infection remains subclinical, reflecting the liver stage of the Plasmodium 
life cycle. Symptoms start to arise when the asexual parasites enter the blood 
stream and reach a density of about 50 parasites / µL, which is approximately 
100 million parasites in total. The initial non-specific symptoms are a direct 
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consequence of erythrocyte invasion and destruction and the elicited host 
inflammatory response and commonly include general malaise, fatigue, head-
ache, myalgia and fever. In uncomplicated cases, these symptoms persist and 
may be accompanied by mild anaemia, jaundice, and sometimes splenomegaly. 
Fever may start to appear in a regular pattern after about one week of illness, and 
is thought to be caused by a synchronized formation and rupture of blood schi-
zonts (5, 10).
In severe P. falciparum cases, sequestration of erythrocytes in the microvascula-
ture can cause failure of multiple organs. The degree and site of microvascular 
obstruction correlates with the clinical symptoms. In post-mortem studies of 
patients with cerebral malaria, a severe and often lethal complication of severe 
P. falciparum infection that is characterized by seizures or decreased conscious-
ness, marked sequestration of the cerebral microvasculature has been found 
(5, 16, 17). The frequency with which various symptoms of severe malaria occur 
depends on age. Anaemia and convulsions are seen more often in children, while 
the incidence of hyperparasitemia, jaundice and renal insufficiency increases with 
age. Coma and metabolic acidosis are seen at similar rates in all age groups (18). 
The reported mortality rate of severe malaria is around 23-35% in endemic areas 
(5) and around 11-25% in imported cases in non-endemic countries (19-22). In 
imported P. falciparum infection, several factors have been found to be associated 
with an increased risk of severe malaria, including older age, short stays (<21 days), 
inadequate use of chemoprophylaxis, initial visit to a general practitioner, longer 
time to diagnosis, and diagnosis during the fall–winter season, which is likely due 
to more frequent misdiagnosis of the initial symptoms as influenza (23).
Plasmodium knowlesi, although not capable of causing significant sequestration, 
can cause high parasitaemia and severe disease leading to organ dysfunction 
and death (24, 25). The other Plasmodium species have classically been reported 
to cause relatively mild infections with very low mortality rates. However, severe 
manifestations of P. vivax infection, including severe anaemia, coma and shock, 
have been reported and this species in increasingly recognized as a potential 
cause of severe and even fatal disease (26).
Diagnosis
The gold standard for diagnosis of malaria is the examination of Giemsa-stained 
thick and thin blood smears by light microscopy. If performed by an experienced 
laboratory technician, detection of parasite densities as low as 50 parasites / µL 
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(equivalent to 0.001% parasitized erythrocytes) can be achieved. Microscopic 
examination is also essential to differentiate between the various Plasmodium 
species and to quantify the parasite load in case of P. falciparum infection (27). 
Fluorescence microscopy methods have been introduced to further increase the 
detection sensitivity. The quantitative buffy coat (QBC) technique uses a fluores-
cent dye with affinity for the parasite nucleus to stain a centrifuged and compressed 
red cell layer. The sensitivity for detection of low parasite densities (less than 100 
parasites/μl or 0.002%) has been found to range from 41 to 93% (27).
Rapid diagnostic tests (RDTs) are mostly based on lateral flow immunochroma-
tography. The majority of the many different commercial RDTs that are currently 
available are designed to target one ore more of the following three parasite anti-
gens: Plasmodium falciparum histidine-rich protein-2 (PfHRP2), Plasmodium 
lactate dehydrogenase (pLDH), and aldolase. PfHRP2 is a P. falciparum-specific 
antigen. PfHRP2-based RDTs can detect low P. falciparum parasite densities, but 
may remain positive up to several weeks after a successfully treated infection. 
pLDH and aldolase are enzymes produced by all pathogenic Plasmodium species, 
and RDTs targeting these enzymes become negative after parasite clearance. 
They have a lower sensitivity for P. falciparum detection than PfHRP2-based tests, 
especially at low parasite densities. The sensitivity for non-falciparum species of 
pLDH- and aldolase-based RDTs are comparable (28).
Polymerase chain reaction (PCR) assays are mostly used for research purposes 
and for species confirmation in clinical cases, which is particularly useful in infec-
tions with multiple Plasmodium species. 
Treatment and prevention
The artemisinin derivatives artesunate and artemether have replaced quinine as 
the drugs of choice for severe malaria, as they were found to significantly reduce 
mortality (29-31). While quinine is effective only against the more matured and 
cytoadhering parasite stages, artemisinin also kills young ring-stage parasites 
before they can cause the erythrocytes to sequester in the microvasculature. 
Moreover, treatment with quinine is frequently complicated by severe adverse 
reactions, and is now only recommended when artemisinin derivates are unavail-
able (32, 33). The preferred treatment is intravenous or intramuscular artesunate; 
artemether has a smaller survival benefit in severe cases (34). As the half-life of 
artesunate is short, treatment should always be followed by a full oral treatment 
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course (33). The efficacy and safety of exchange transfusion (ET) as adjunc-
tive therapy for severe falciparum malaria has always been controversial (35, 36).
Shorter parasite clearance times were found when ET was added to treatment 
with intravenous quinine, but since the introduction of artesunate as the first-
choice therapy, the additional effect of ET is lost (37, 38).
Uncomplicated P. falciparum infection can be treated orally, with artemisinin 
combination therapy (ACT, such as artemether-lumefantrine or artenimol- 
piperaquine) or atovaquone-proguanil as preferred regimens. Uncomplicated 
non-falciparum infections can be treated with oral chloroquine or hydroxychlo-
roquine if acquired in areas without chloroquine resistance, or with ACT or atova-
quone-proguanil if resistance is expected. In P. vivax and P. ovale infections, 
primaquine is added to target the hepatic hypnozoite forms (33, 39).
Chemoprophylaxis is recommended for travelers to malaria endemic areas. The 
drugs of choice are atovaquone-proguanil and mefloquine. Doxycyline is also 
effective but is not registered as prophylaxis in the Netherlands and can only be 
prescribed off-label. The prophylactic efficacy of chloroquine has become limited 
by widespread resistance (33, 40).
Despite large amounts of effort, a fully effective malaria vaccine has not yet been 
developed. One of the most promising vaccine candidates currently being inves-
tigated is the RTS,S/AS01 vaccine, which targets an antigen on the surface of the 
P. falciparum sporozoite. Although this vaccine showed an initial efficacy against 
clinical malaria in African children, this protective effect is of limited duration and 
is offset by a rebound in later years, when immunity wanes (41).
Acquired immunity against malaria
Repeated infection in holoendemic areas leads to a form of acquired immunity, 
which protects against the development of high parasitemia and symptoms. This 
effect is evident by the declining incidence of malaria with increasing age and a 
reduction in average malaria parasite density with increasing age in holoendemic 
regions. Immunity declines after leaving an endemic region, but how quickly 
protection is lost is subject to debate (42).
Epidemiology 
One of the Millennium Development Goals set by the World Health Assembly 
and other global institutions was to have halted and begun to reverse the global 
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incidence of malaria by 2015. This goal has been met; between 2000 and 2015 
the incidence of malaria is estimated to have decreased by 37%. The estimated 
number of cases fell from 262 million in the year 2000 to 214 million in 2015 and 
the estimated number of deaths declined from 839 000 to 438 000. The vast 
majority of malaria fatalities (around 90%) occur in sub-Saharan Africa, where 
the disease mostly affects children under five (43).
Compared to the huge number of infections that occur in inhabitants of malaria 
endemic areas, the burden of imported malaria is small. Every year an estimated 
25–30 million Europeans travel to areas with malaria transmission, and the 
number of cases imported to Europe approximates 5000 annually (39, 44).
The Rotterdam Malaria Cohort
The Harbour Hospital and Institute for Tropical Diseases is a 161-bed general 
hospital, located in Rotterdam, the Netherlands, which also serves as a national 
referral centre for travel medicine and provides healthcare to ill sailors in close 
collaboration with the Port of Rotterdam. 
To study the epidemiology and clinical characteristics of patients with imported 
malaria, the Rotterdam Malaria Cohort (RMC) was started in 1998. Since then, 
anonymized demographic, clinical and laboratory data of all patients diagnosed 
with malaria in the Harbour Hospital are routinely collected and stored in an elec-
tronic database and form the RMC. As patients are entered into this database 
regularly, it is a dynamic and gradually expanding cohort.
Patient characteristics
On January 1st, 2016 the cohort comprised 724 patients. Of these patients, 518 
had a Plasmodium falciparum infection and 200 were infected by a non-falciparum 
species (137 P. vivax, 49 P. ovale, 13 P. malariae and 1 P. knowlesi). Of the remaining 6 
patients, 5 had a mixed infection with P. falciparum and a non-falciparum species 
and in one patient the species could not be determined as only a single tropho-
zoite was seen in the quantitative buffy count (QBC) analysis, without parasites 
visible in the thick and thin blood slides.
The majority (72%) of the patients was male and the median age was 39 years 
(interquartile range 30 - 47). The most common reasons for travel were visiting 
friends or relatives (26%), tourism (22%) and business (16%). Eight percent of 
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patients were sailors and 6% were Dutch expatriates. The rest of the patients 
mentioned other reasons for travel (7%) or the reason was not documented 
(15%). The most commonly presenting complaints were fever (86%), headache 
(58%) and myalgia or arthralgia (44%).
Most infections (78%) were acquired in Africa, followed by Asia (10%) and South 
America (3%). The vast majority of the severe P. falciparum infections (94%) 
occurred after travel to an African country. Reversely, malaria occurring after travel 
to Africa was caused by P. falciparum in 85% of cases, while malaria after returning 
from Asia or South America was mostly caused by non-falciparum species (75%) 
(Figure 2). Figure 3 shows a map with the countries of acquisition of the malaria 
infections of the patients in the Rotterdam Malaria Cohort.
The majority of patients reported to have not taken antimalarial prophylaxis at 
all (63%) or to have used it inadequately (17%). Reportedly 14% acquired malaria 
despite correct use of prophylactic medication. In the patients with severe malaria 
only 5% reported adequate use of prophylaxis, in 13% the use was inadequate and 
no prophylaxis was taken in 78%. 
Severe malaria
The World Health Organisation (WHO) introduced the malaria severity criteria in 
1990, in order to assist clinical and epidemiological studies by creating a case defi-
nition of severe malaria (45). These criteria have been revised in the year 2000, in 
2010 and most recently in 2014. Due to these changes, different case definitions 
of severe malaria have been used in this thesis. The 2010 and 2014 WHO severity 
criteria are shown in Table 1 and Table 2, respectively.
Of the 724 patients, 64 (9%) were classified as severe malaria using the 2014 defi-
nitions. The most commonly met criteria, on presentation or later during admis-
sion, were jaundice (38 of 64 patients or 59%), hyperparasitaemia (n=26, 41%), 
acute kidney injury (n=21, 33%) and acidosis (n=15, 23%). None of the patients 
had prolonged bleeding and hypoglycaemia was observed only in one patient 
(Table 3).
Treatment and outcome
Oral treatment was given to 82% of patients, most commonly atovaquone / 
proguanil. In 131 patients initial treatment was given intravenously with either 
quinine (n=77) or artesunate (n=54). Artesunate became available in the 
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Netherlands in 2007 as an orphan drug. Although it is still awaiting formal regis-
tration at the European Medical Agency (EMA), it gradually took over the place of 
quinine in the treatment of severe malaria, as evidence of its superiority accumu-
lated (29, 30). In the Rotterdam Malaria Cohort the first patients were treated with 
artesunate in 2007. The prescription of quinine declined quickly, and it was not 
prescribed anymore after 2010. Exchange transfusion was performed as an addi-
tional treatment to intravenous antimalarials in 46 patients.
Patients stayed in hospital for a median of 3.0 days (interquartile range 1.5-4.5). 
One-hundred-and-twelve patients (15%) were admitted to the intensive care unit 
(ICU).
Two patients in the Rotterdam Malaria Cohort died. Both acquired a severe P. falci-
parum infection in sub-Sahara Africa, where they travelled without using chemo-
prophylaxis. The two deaths yield a mortality rate of 0.3% for all malaria cases, and 
3.1% for severe P. falciparum infections in this cohort. 
Changing incidence of imported malaria
Between 2000 and 2007 there has been a significant decline of the incidence of 
imported malaria in the Netherlands, which is thought to be due to a decreasing 
malaria transmission in endemic areas rather than to a change in prophylaxis 
use (46). This decline is also clear in the Rotterdam Malaria Cohort (Figure 4). In 
recent years however, an upsurge in the national incidence of malaria has been 
noted, which is mostly due to an increasing number of immigrants from the Horn 
of Africa seeking refuge in the Netherlands, and a rise in the incidence of predom-
inantly P. vivax infections in this group (47). This recent development shows that 
the incidence of imported malaria is volatile and is influenced by many factors, 
including distant wars and conflicts.
18
Outline of the thesis
The aim of this thesis is to answer several questions raised while caring for patients 
with imported malaria in Rotterdam. 
As described at the beginning of this chapter, the challenge in the care for patients 
with imported malaria lies in the fact that most hospitals in non-endemic coun-
tries have little experience in diagnosing and treating the infection and in recog-
nizing patients at risk for a severe course of the infection. Therefore, in Part I of 
this thesis, we question which parameters could help to improve the identifica-
tion of patients at risk for a severe infection. In the first chapters, we focus on the 
novel host parameters triggering receptor expressed on myeloid cells 1 (TREM-1), 
neopterin and procalcitonin (Chapter 2) and copeptin (Chapter 3). In Chapter 4 
 we explore the dynamics of leukocyte count changes in detail in a Controlled 
Human Malaria Infection trial and we investigate whether the routinely measured 
differential leukocyte count can be used to predict a severe course of the disease 
in Chapter 5. In the last two chapters we focus on parasite-derived parameters 
that can be obtained from routinely performed malaria rapid tests (Chapter 6) or 
blood slides (Chapter 7).
In Part II we aim to gain insight in two morbidities frequently encountered in the 
clinical practice of imported malaria. In Chapter 8 we study the frequency of 
the occurrence of acute kidney injury (AKI) in imported malaria and Chapter 9 
describes a pilot study that examines whether the novel marker Neutrophil 
Gelatinase-Associated Lipocalin (NGAL) could help to early identify malaria 
patients at risk for AKI. Hereafter we question how commonly hyponatraemia 
occurs in imported malaria and whether there is an association with severity of the 
disease (Chapter 10) and we aim to gain insight in its pathophysiology (Chapter 11). 
In the Appendix we summarize and discuss our findings and the future perspec-
tives of imported malaria.
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Figure 1.  Life cycle of parasites of the genus Plasmodium that cause malaria  
(courtesy of Centers of Disease Control, Alexander J. da Silva, PhD, Melanie Moser)
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Figure 2.  The continent of acquisition of the patients from the Rotterdam 
   Malaria Cohort. 
The numbers within the bars indicate the absolute number of cases. The continent of acquisition was 
unknown in 25 cases (not shown).
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Figure 3.  World map showing the countries where patients from the Rotterdam 
   Malaria Cohort acquired the infection. 
The colour indicates the number of infections acquired in the particular country. 
Panel A. shows P. falciparum infections and panel B. non-falciparum infections.
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50 or more cases 
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Figure 4.  Number of cases per year in the Rotterdam Malaria Cohort. 
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Table 1. The 2010 World Health Organisation criteria for severe malaria.
2010 WHO malaria severity criteria
Severe malaria is defined, in the absence of other obvious cause, when P. falciparum asexual parasi-
taemia is accompanied by one or more of the following clinical or laboratory features
Clincal features
Impaired consciousness or unrousable coma
Prostration, i.e. generalised weakness so that the patient is unable to walk or sit up without 
assistance
Failure to feed
Multiple convulsions - more than two episodes in 24h
Deep breathing, respiratory distress (acidotic breathing)
Circulatory collapse or shock, systoloc blood pressure <70 mmHg in adults and <50 mmHg in 
children
Clinical jaundice plus evidence of other vital organ disfunction
Haemoglobinuria
Abnormal spontaneous bleeding
Pulmonary oedema (radiological)
Laboratory findings
Hypoglycaemia (blood glucose <2.2 mmol/l)
Metabolic acidosis (plasma bicarbonate <15 mmol/l)
Severe normocytic anaemia (Hb< 5 g/dl, packed cell volume <15%)
Haemoglobinuria
Hyperparasitaemia (>2% or 100 000/μl in low transmisson areas or >5% or 250 000/ μl in high 
stable malaria transmission areas)
Hyperlactataemia (lactate > 5 mmol/l)
Renal impairment (serum creatinine >265 μmol/l)
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Table 2. The 2014 World Health Organisation criteria for severe malaria.
2014 WHO malaria severity criteria
For epidemiological and research purposes, severe malaria is defined as one of the following, 
occuring in the absence of an identified alternative cause, and in the presence of P. falciparum 
asexual parasitaemia
Impaired 
consciousness
A Glasgow Coma Score 
<11 in adults or a Blantyre coma score < 3 in children
Acidosis
A base deficit of >8 meq/l or, if unavailable, a plasma bicarbonate of 
<15mM or venous plasma lactate >5mM. 
Hypoglycaemia Blood or plasma glucose <2.2 mM
Severe malarial 
anaemia
A haemoglobin concentration <5 g/dL or a hematocrit of <15% in 
children <12 years of age (<7 g/dLand <20% respectively in adults) 
together with a parasite count > 10 000/μl
Renal impairment Plasma or serum creatinine >265 μM or blood urea >20 mM
Jaundice
Plasma or serum bilirubin > 50 μM together with a parasite count > 
10 000/μl
Pulmonary oedema
Radiologically confirmed, or oxygen saturation < 92% on room air 
with a respiratory rate >30/min, often with chest indrawing and 
crepitations on auscultation
Significant bleeding
Including recurrent or prolonged bleeding from nose, gums or 
venepuncture sites, haematemesis or melaena
Shock
Compensated shock is defined as capillary refill >3s or tempera-
ture gradient on leg (mid to proximal limb) but no hypotension. 
Decomensated shock is defined as systolic blood pressure <70 
mmHg in children or <80 mmHg in adults with evidence of impaired 
perfusion (cool peripheries or prolonged capillary refill)
Hyperparasitaemia P. falciparum parasitemia >10%
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Table 3. The number of patients that met each of the 2014 WHO criteria for 
   severe malaria.
2014 WHO malaria severity criterion Frequency
Jaundice 38
Hyperparasitaemia 26
Renal impairment 21
Acidosis 15
Severe malarial anaemia 9
Pulmonary oedema 6
Impaired consciousness 5
Shock 2
Hypoglycaemia 1
Significant bleeding 0
A total of 64 patients were diagnosed with severe malaria after meeting one or more of these criteria
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CHAPTER 2
Neopterin and procalcitonin are suitable 
biomarkers for the exclusion of severe 
Plasmodium falciparum disease in 
travellers with imported malaria
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Abstract
Background: Most clinicians in developed, non-malaria endemic countries 
have limited or no experience in making clinical assessments of malaria 
disease severity and subsequent decisions regarding the need for parenteral 
therapy or high-level monitoring in febrile patients with imported malaria. 
In the present study, the diagnostic accuracy of plasma soluble Triggering 
Receptor Expressed on Myeloid cells 1 (TREM-1), neopterin and procalci-
tonin levels as biomarkers for severe Plasmodium falciparum disease was 
evaluated in 104 travellers with imported malaria (26 patients with non-P. 
falciparum malaria, 64 patients with uncomplicated P. falciparum malaria and 
14 patients with severe P. falciparum malaria). 
Methods: TREM-1, neopterin and procalcitonin were determined in stored serum 
samples using commercially available ELISA or EIA tests. The diagnostic perfor-
mance of these biomarkers for severe disease was compared with the reference 
marker plasma lactate, a well-validated parameter for disease severity in patients 
with malaria. Severe malaria was defined according to the modified WHO criteria.
Results: No significant differences in TREM-1 levels were detected between the 
different patient groups. Patients with severe P. falciparum malaria had signifi-
cantly higher neopterin and procalcitonin levels on admission when compared 
to patients with uncomplicated P. falciparum malaria or non-P. falciparum 
malaria. Receiver Operating Characteristic (ROC) curve analysis showed 
that neopterin had the highest Area-Under-the-ROC curve (AUROC 0.85) 
compared with plasma lactate (AUROC 0.80) and procalcitonin (AUROC 
0.78). At a cut-off point of 10.0 ng/ml, neopterin had a positive and negative 
predictive value of 0.38 and 0.98 whereas procalcitonin, at a cut-off point of 
0.9 ng/ml, had a positive and negative predictive value of 0.30 and 1.00.
Conclusion: Although the diagnostic value of neopterin and procalcitonin 
is limited, the high negative predictive value of both neopterin and procalci-
tonin may be helpful for a rapid exclusion of severe malaria disease on admis-
sion. This may be a valuable tool for physicians only occasionally dealing with 
ill-returned travellers from malaria-endemic regions and who need to decide 
on subsequent oral anti-malarial treatment or timely referral to a specialized 
center for high-level monitoring and intensified parenteral treatment.
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Background
Travellers from industrialized countries and inhabitants of malaria-endemic 
regions clearly represent two distinct worlds of malaria (1). The global burden of 
malaria is largely carried by the world’s malaria-endemic regions with as many as 
500 million cases annually and a death toll of 1 to 3 million children each year. 
Severe malaria in areas of endemicity is associated with a mortality of 15 to 40% 
(2, 3). In many malaria-endemic regions, strict triage for admission to ICU facilities 
must be applied because the ICU capacity is usually limited. Recently, a 5-point 
Coma Acidosis Malaria (CAM) score based on only acidosis (base deficit) and 
cerebral malaria (measured with Glasgow Coma Scale) was introduced, which 
could identify adult patients with severe malaria who were at high risk of death (4). 
In striking contrast, in non-endemic industrialized countries malaria is only 
seen as an occasionally imported disease (5) and is usually associated with 
a low case-fatality rate (6, 7). Even in the pre-artesunate era, the mortality of 
severe malaria in non-endemic regions was significantly lower when compared 
with regions of malaria endemicity (6-8), probably reflecting the availability of 
adequate supportive care facilities in industrialized countries.
Industrialized countries, however, have to face other -more trivial- problems. For 
instance, the expertise on diagnosis and treatment of malaria is usually focused 
in some specialized hospitals and institutes but many ill-returning travellers 
may present to non-specialized hospitals or even general practitioners. Making 
a proper diagnosis of malaria may be troublesome under these circumstances, 
for instance, by lack of experience in the examination of malaria thick and thin 
blood smears and in the assessment of parasite load. These non-specialized 
centers therefore often rely on rapid diagnostic tests for the diagnosis of malaria 
(9). Although sensitive in diagnosing P. falciparum malaria, these rapid tests do not 
provide any information about the severity of the infection. Moreover, although 
artesunate, which is now considered the parenteral drug of choice for treatment 
of severe falciparum malaria, is available as an orphan drug in The Netherlands, it 
is currently only in stock in some specialized centers but certainly not available in 
every Dutch hospital. Some of these general hospitals do not even have any drug in 
stock for the treatment of malaria (10). To prevent unnecessary delay in diagnosis 
of severe malaria and institution of proper parenteral treatment, a simple, well-val-
idated, laboratory-based biomarker that predicts or excludes severe disease 
accurately would be of great help for those clinicians occasionally dealing with 
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febrile travellers returning from malaria endemic regions. These clinicians have to 
decide on subsequent oral anti-malarial treatment or a timely referral to a special-
ized center for high-level monitoring and intensified parenteral treatment. In the 
present study, the diagnostic accuracy of plasma soluble Triggering Receptor 
Expressed on Myeloid cells 1 (TREM-1), neopterin and procalcitonin were evalu-
ated as potential markers for malaria disease severity in travellers with imported 
malaria. These bio-substances are all involved in the systemic pro-inflamma-
tory response of the host to invading pathogens. Some of these biomarkers are 
already in use for the diagnosis and follow-up of sepsis or used in treatment algo-
rithms, resulting in a successful reduction of antibiotic use and duration (11, 12).
Methods
Study population
The Harbour Hospital is a 161-bed general hospital located in Rotterdam. It also 
harbours the Institute for Tropical Diseases, which serves as a national reference 
center. In the period 1999-2008 almost 500 cases of imported malaria were diag-
nosed (13). For the majority of these cases, demographic, clinical and laboratory 
data and serum samples were available. For the present study, a representative 
sample of this cohort was taken and analysed. 
Definitions
• Patients were classified as having severe P. falciparum malaria if they met one 
or more of the WHO criteria for severe malaria, as modified by Tran et al (14): 
• A score on the Glasgow Coma Scale of less then 11 (indicating cerebral malaria).
• Anaemia (haematocrit < 20%) with parasite counts exceeding 100,000/μl 
(roughly corresponding to 2% parasitaemia) on a peripheral blood smear. 
• Jaundice (serum bilirubin > 50 μmol/l) with parasite counts exceeding 
100.000/μl on a peripheral blood smear. Renal impairment (urine output < 
400 ml/24 h and serum creatinine > 250 μmol/l). 
• Hypoglycaemia (blood glucose < 2.2 mmol/l).
• Hyperparasitaemia (> 10% parasitaemia).
• Systolic blood pressure < 80 mm Hg with cold extremities (indicating shock). 
Study design
In previous studies (6, 13, 15) these severity criteria were also used to define severe 
malaria in non-immune travellers. In the present study the occurrence of severe 
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malaria was considered a primary end-point. This contrasts with the design of 
many studies in patients with severe malaria in regions of malaria endemicity 
where the severity criteria are used as an entry criterion. In the present study, 
plasma lactate was used as a surrogate parameter for acid-base dysbalance and 
reference biomarker. It was evaluated in a previous study in non-immune travel-
lers with imported malaria (15). The diagnostic performance of TREM-1, procal-
citonin and neopterin for malaria disease severity was compared with that of 
plasma lactate, which is routinely measured at the Institute for Tropical Diseases 
in ill-returning travellers. 
Procedures
On admission, blood samples were taken for analysis of the red blood cell count, 
haematocrit, white blood cell count, platelet count, serum electrolytes, total bili-
rubin, serum creatinine, liver enzymes, and blood glucose. In addition, a serum 
sample was taken on admission which was stored at -20°C until analysis. For the 
determination of plasma lactate, a separate blood sample was drawn on admis-
sion without congestion and placed on melting ice after which it was immediately 
analysed after isolation of plasma. Malaria was diagnosed by QBC (Quantitative 
Buffy Coat) analysis, by a rapid diagnostic antigen test for malaria (Binax NOW® 
Malaria Test, Binax Inc., Maine, USA) and by conventional microscopy of stained 
thick and thin blood smears. In case of P. falciparum infections, parasite density 
was determined. When the parasitaemia was less than 0.5% infected erythro-
cytes, parasites were counted per 100 leucocytes in thick smears. When the para-
sitaemia was equal or higher than 0.5% infected erythrocytes, infected erythro-
cytes were counted in thin blood smear and expressed as a percentage of the total 
erythrocytes. The number of parasites per microliter was subsequently calculated 
from these data. 
TREM-1 and neopterin levels were determined in serum samples using commer-
cially available ELISA tests (R&D Systems, Abingdon, UK; DRG, Marburg, Germany, 
respectively). Procalcitonin levels in serum samples were determined using a 
commercially available EIA test (VIDAS BRAHMS Procalcitonin, bioMérieux, 
Lyon, France). All tests were performed according to manufacturer’s instructions. 
Detection limits were 3.88 pg/ml for TREM-1, 0.2 ng/ml for neopterin and 0.05 ng/
ml for procalcitonin, respectively. According to the manufacturers, normal serum 
values are < 100 pg/ml for TREM-1, < 3 ng/ml for neopterin and < 0.1 ng/ml for 
procalcitonin. 
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Statistical methods
For comparison between groups, the Mann-Whitney U-test was used and 
P-values of < 0.05 were considered statistically significant. The diagnostic perfor-
mance of each biomarker was reported as sensitivity, specificity, positive and 
negative predictive value for severe P. falciparum malaria and their corresponding 
95% confidence intervals. Of each test a Receiver Operating Characteristic 
(ROC) curve, a graphical plot of sensitivity (true positive rate) versus 1-specificity 
(false positive rate), was constructed as a summary statistic and the area under 
the ROC curve (AUROC) and its corresponding 95% confidence intervals were 
calculated. Youden’s index J (J = sensitivity+specificity-1) was used to choose the 
most appropriate cut-off point for each biomarker. All statistical analyses were 
performed using SPSS 15.0. 
Results
Patient characteristics
In total 104 travellers with imported malaria were included in this study, of which 26 
patients were diagnosed with a non-P. falciparum infection (Plasmodium malariae 
n = 2; Plasmodium ovale n = 5; Plasmodium vivax n = 19) and 78 patients were diag-
nosed with P. falciparum infection. The general characteristics of all patients are 
shown in Table 1. 
Characteristics of patients with severe malaria 
Thirteen patients fulfilled the criteria for severe malaria at initial presentation. 
Another patient did not fulfill these criteria on admission, but the clinical course 
deteriorated shortly hereafter with impaired consciousness and hyperparasi-
taemia. Procalcitonin and neopterin levels were already increased on admis-
sion in this particular patient. Eventually, at admission to the ICU, all 14 patients 
fulfilled one or more of the severity criteria (GCS < 11, n = 1; anaemia with a parasite 
count exceeding 100,000 trophozoites per μl, n = 2; icterus with a parasite count 
exceeding 100,000 trophozoites per μl, n = 8; acute oliguric renal insufficiency, 
n = 0; hypoglycaemia, n = 0; hyperparasitaemia, n = 5 and shock, n = 1, respec-
tively). Five patients had an impaired conscious level but a GSC above 11; eight 
patients had a parasitaemia > 5%, respectively. The first arterial blood gas analysis 
on ICU showed a median bicarbonate level of 22 mmol/l (range 17 to 26 mmol/l) 
and a median base deficit of 2 (range -3 to 8). Median GCS was 15 (range 9 to 15). 
One patient needed mechanical ventilation. Eleven patients received exchange 
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transfusion as an adjunct therapy. No case fatalities were observed. The labora-
tory results on admission of travellers with imported severe P. falciparum malaria 
were further characterized by significantly lower platelet counts and haemoglobin 
levels and by significantly higher plasma lactate, bilirubin and C-reactive protein 
levels and erythrocyte sedimentation rates, respectively (Table 1). 
Analysis of biomarkers for severe malaria
TREM-1
No statistically significant differences were observed in TREM-1 levels in serum, 
between patients with severe P. falciparum malaria, uncomplicated P. falciparum 
malaria and non-P. falciparum malaria (Figure 1A). 
Neopterin
Neopterin levels on admission were significantly higher in travellers with severe P. 
falciparum malaria when compared to travellers with uncomplicated P. falciparum 
malaria (p<0.0001) and travellers with non-P. falciparum malaria (p<0.0001) 
(Figure 1B). ROC curve analysis showed an AUROC of 0.85 (95% Confidence 
Interval 0.76-0.94), suggesting a good accuracy (Figure 2). As shown in Table 2, 
at a cut-off point of 10.0 ng/ml, neopterin had an excellent sensitivity and nega-
tive predictive value but a poor specificity and positive predictive value for severe 
disease. 
Procalcitonin
Procalcitonin levels were significantly higher in travellers with severe P. falciparum 
malaria when compared to travellers with uncomplicated P. falciparum malaria 
(p=0.0022). However, no significant differences were noted in comparison to 
travellers with non-P. falciparum infections (p=0.17) (Figure 1C). ROC curve anal-
ysis showed an AUROC of 0.78 (95% CI 0.66-0.91), compatible with a fair accu-
racy (Figure 2). At a cut-off point of 0.9 ng/ml, procalcitonin had an excellent 
sensitivity and negative predictive value, whereas specificity and positive predic-
tive value for severe P. falciparum malaria was poor (Table 2). 
Plasma lactate 
Plasma lactate levels were significantly higher in travellers with severe P. falciparum 
malaria when compared to travellers with uncomplicated P. falciparum malaria 
(p=0.0012) and travellers with non-P. falciparum malaria (p=0.0040). ROC curve 
analysis of plasma lactate levels showed an AUROC of 0.80 (95% CI 0.65-0.96) 
compatible with a good accuracy (Figure 2). At a cut-off point of 1.8 mmol/l, lactate 
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had an excellent sensitivity and negative predictive value, but a poor specificity and 
positive predictive value for severe P. falciparum malaria (Table 2), respectively.
Combination of various biomarkers for severe falciparum disease
Analysis of various combinations of newly tested biomarkers and the use of 
different cut-off levels did not result in better discrimination of patients with 
severe P. falciparum malaria. 
Discussion
Severe malaria is disreputable for its high case-fatality rate, but the outcome of 
severe P. falciparum infections has significantly improved since the introduction 
of artesunate as first line treatment of severe malaria, in particular in developing 
countries (2). In industrialized countries such as The Netherlands, the case-fa-
tality rate of imported malaria is low and fatal cases are only occasionally reported. 
In the present study, in which the biomarkers TREM-1, neopterin and procalcitonin 
were evaluated for their potential to be used as a marker for severe malaria disease 
upon admission. This contrasts with the design of many studies in regions of 
malaria endemicity where severe malaria is usually the entry criterion. For reasons 
of comparability, the same set of criteria for severe malaria was strictly applied for 
the diagnosis of severe malaria in this study, even though the study population 
comprised of presumably non-immune travellers and some authors even suggest 
a threshold of 5% in stead of 10% parasitized erythrocytes to define hyperparasi-
taemia in non-immune individuals.
The quantification of soluble TREM-1 levels on admission did not result in proper 
discrimination of severe P. falciparum malaria from uncomplicated P. falciparum 
malaria and non-P. falciparum malaria. In contrast, travellers with severe P. falci-
parum malaria had significantly higher levels of neopterin and procalcitonin on 
admission as compared with travellers with uncomplicated P. falciparum malaria 
or non-P. falciparum malaria, respectively. These findings correspond with the 
results of several other studies performed in semi-immune malaria patients 
living in malaria-endemic regions (16-18). When the ROC curve characteristics of 
neopterin and procalcitonin were compared to that of plasma lactate, the AUROC 
of neopterin appeared superior whereas the AUROC of procalcitonin appeared 
inferior to that of lactate, suggesting that neopterin pro- vided the most accurate 
diagnostic performance for severe P. falciparum malaria in this cohort of travellers. 
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Unfortunately, the applicability of these tests in the initial clinical assessment of 
patients with severe P. falciparum malaria will probably be limited by the poor posi-
tive predictive value of neopterin and procalcitonin indicating that neither test can 
serve as a valuable tool for the diagnosis of severe P. falciparum malaria. For illus-
tration, applying a procalcitonin level > 0.9 ng/ ml or a neopterin level > 10.0 ng/
ml as a guide to intensified monitoring and treatment would result in more than 20 
of 64 patients with uncomplicated P. falciparum malaria receiving more intensive 
monitoring and treatment than strictly necessary. On the other hand, the high 
negative predictive value of both neopterin and procalcitonin suggests that these 
tests can still be of value by providing a tool for exclusion of severe disease. With 
either a procalcitonin level of less than 0.9 ng/ml or a neopterin level of less than 
7.9 ng/ml in serum on admission as a cut-off point for severe P. falciparum malaria, 
no patient with severe disease would have been denied access to high-level 
monitoring and intensive treatment. In a previous study, in which a semi-quan-
titative ‘point-of-care’ procalcitonin test as a diagnostic tool for severe P. falci-
parum malaria was evaluated prospectively, all 6 patients with severe P. falciparum 
malaria had procalcitonin values classified as either “moderate” or “high” (corre-
sponding to a procalcitonin level ≥ 2 ng/ml), but never as “normal” or “low” (12). 
This is compatible with the findings of the current retrospective serum sample-
based study in which procalcitonin was measured quantitatively. 
Although severe or fatal malaria rarely results from infections with the non-se-
questering Plasmodium species vivax, ovale and malariae, increased neopterin and 
procalcitonin serum levels were also observed in the majority of these patients, 
although levels were lower than compared with severe P. falciparum malaria 
patients. Although speculatively, these observations suggest that the mechanism 
whereby neopterin and procalcitonin levels increase in malaria, is not specific for 
severe P. falciparum malaria alone. Therefore, it may not accurately reflect the 
pivotal pathophysiological events in complicated P. falciparum malaria, such as 
the sequestration of infected red blood cells in the microcirculation of vital organs 
and disturbance of microcirculatory flow. Whereas an increased plasma lactate 
level conceivably reflects a significant reduction in microcirculatory flow in vital 
organs, the elevated neopterin and procalcitonin levels are probably the result of 
activation of a common inflammatory host response evoked by infection with 
the respective Plasmodium parasites. In fact, some reports even suggest that P. 
falciparum malaria per se is not associated with a stronger host response than P. 
vivax or P. ovale malaria, but that the parasite burden of the causative Plasmodium 
species may also modulate the extent of the host inflammatory response (19). 
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CONCLUSION
Although neither neopterin nor procalcitonin can probably serve as a useful 
single diagnostic tool for severe P. falciparum malaria, the high negative predictive 
value of both neopterin and procalcitonin may be helpful for a rapid exclusion of 
severe P. falciparum malaria on admission. This may be a valuable tool - particu-
larly if available as a rapid diagnostic test - for physicians only occasionally dealing 
with ill-returned travellers and who need to decide on subsequent oral anti-ma-
larial treatment or a timely referral to a specialized center for high-level monitoring 
and intensified parenteral treatment. 
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Table 1.  General characteristics and laboratory results on admission of 
   patients with various species of malaria.
 Non- P. falciparum P. falciparum
 (n=26) Uncomplicated
(n=64)
Severe
(n=14)
Demographics   
Male/female 20/6 51/13 6/8
Age (years) 40 (17-62) 40 (11-67) 40 (26-57)
Continent of acquisition   
Africa 12 (46%) 60 (94%) 12 (86%)
Asia 9 (35%) 3 (5%) 1 (7%)
South America 5 (19%) 1 (2%) 1 (7%)
Patient immunity   
Non-immune 20 (77%) 35 (55%) 10 (72%)
Partially immune 6 (23%) 28 (44%) 4 (28%)
Semi-immune 0 1 (2%) 0
Vital signs on admission   
Body temperature (Celsius) 38,8 (36,1-41,5) 38,7 (36,1-40,6) 38,8 (36,8-40,6)
Pulse rate 
(beats per minute)
90 (60-130) 95 (68-120) 108 (78-140)
Systolic blood pressure 
(mmHg)
123 (100-196) 120 (95-185) 118 (80-160)
Glasgow coma score   
normal (=15) 26 (100%) 63 12 (86%)
mildly impaired (11 - 14) 0 1 (2%) 1 (7%)
severely impared (<11) 0 0 1 (7%)
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 Non- P. falciparum P. falciparum
 (n=26) Uncomplicated
(n=64)
Severe
(n=14)
Laboratory parameters   
Parasite load 
(trophozoites/ul)
ND 5502 
(1,0-385.000) *
205.600 
(80.500-860.000)
Plasma lactate (mmol/l) 1,4 (0,7-3,0) * 1,5 (0,5-4,4) * 2,6 (0,9-5,8)
Haemoglobin (mmol/l) 8,2 (6,1-10,1) 8,7 (5,3-11,1) * 7,6 (3,8-10,2)
Leucocytes (*10e9/l) 5,2 (1,9-9,3) 5,5 (1,8-11,3) 6,6 (3,2-18,5)
Platelets (*10e9/l) 93,0 (10,0-205,0) * 78,5 (16,0-247,0) * 27,0 (3,0-152,0)
C-reactive protein (mg/l) 86,5 (18,0-208,0) * 109,0 (5,0-278,0) * 190,0 (91,0-265,0)
Serum creatinine (umol/l) 94,0 (66,0-149,0) 103,5 (63,0-208,0) 102,5 (70,0-199,0)
Total bilirubin (µmol/l) 24,0 (6,0-84,0) * 25,0 (7,0-164,0) * 54,0 (20,0-269,0)
* p<0.01. P-values as compared with severe P. falciparum malaria. ND = not determined
Table 2.  Descriptive statistics of diagnostic accurary of neopterin, procalci- 
   tonin as compared zith lactate for the diagnosis of severe falciparum 
   malaria on admission. 
   The data within brackets are the 95% confidence intervals.
 Neopterin Procalcitonin Lactate 
Optimal cut-off value 10 ng/ml 0.9 ng/ml 1.8 mmol/l
Youden's index 0.60 0.53 0.58
Sensitivity 0.93 (0.64-1.00) 1.00 (0.70-1.00) 0.92 (0.60-1.00)
Specificity 0.67 (0.54-0.78) 0.53 (0.40-0.66) 0.66 (0.51-0.78)
Positive predictive value 0.38 (0.23-0.56) 0.30 (0.17-0.47) 0.39 (0.22-0.59)
Negative predictive value 0.98 (0.86-1.00) 1.00 (0.87-1.00) 0.97 (0.83-1.00)
Table 1.  Continued
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Figure 1 Concentrations of potential biomarkers for disease severity in 
   malaria patients on admission. 
Individual data are shown with the median value of each biomarker; TREM-1 (panel A), neopterin (panel 
B), procalcitonin (panel C) and plasma lactate (panel D). Significant differences in biomarker concen-
trations between patient groups (black square = non-P. falciparum malaria; black triangle up = uncom-
plicated P. falciparum malaria; black triangle down = severe P. falciparum malaria) with P-values < 0.0001 
and < 0.005 are indicated by * and **, respectively.
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Figure 2. Receiver Operating Curves (ROC) characteristics of the diagnostic 
   performance of neopterin, procalcitonin and lactate for severe 
   P. falciparum malaria.
The ROC curve is a graph of sensitivity (true positive fraction) plotted against 1-specificity (false positive 
fraction). The performance of a diagnostic variable can be quantified by calculating the area under the 
ROC curve (AUROC). The ideal test would have an AUROC of 1, whereas a random guess would have an 
AUROC of 0.5.
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CHAPTER 3
Copeptin does not accurately 
predict disease severity in 
imported malaria 
50
Abstract
Background: Copeptin has recently been identified to be a stable surro-
gate marker for the unstable hormone arginine vasopressin (AVP). 
Copeptin has been shown to correlate with disease severity in leptospi-
rosis and bacterial sepsis. Hyponatraemia is common in severe imported 
malaria and dysregulation of AVP release has been hypothesized as an 
underlying pathophysiological mechanism. The aim of the present study 
was to evaluate the performance of copeptin as a predictor of disease 
severity in imported malaria.
Methods: Copeptin was measured in stored serum samples of 204 
patients with imported malaria that were admitted to our Institute for 
Tropical Diseases in Rotterdam in the period 1999-2010. The occur-
rence of WHO defined severe malaria was the primary end-point. The 
diagnostic performance of copeptin was compared to that of previously 
evaluated biomarkers C-reactive protein, procalcitonin, lactate and 
sodium.
Results: Of the 204 patients (141 Plasmodium falciparum, 63 non-fal-
ciparum infection), 25 had severe malaria. The Area Under the ROC 
curve of copeptin for severe disease (0.66 [95% confidence interval 
0.59-0.72]) was comparable to that of lactate, sodium and procalci-
tonin. C-reactive protein (0.84 [95% CI 0.79-0.89]) had a significantly 
better performance as a biomarker for severe malaria than the other 
biomarkers.
Conclusion: C-reactive protein but not copeptin was found to be an 
accurate predictor for disease severity in imported malaria. The appli-
cability of copeptin as a marker for severe malaria in clinical practice is 
limited to exclusion of severe malaria.
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Background 
Arginine vasopressin (AVP), also known as the antidiuretic hormone, is a key 
hormone in maintaining fluid balance and vascular tone. Despite its clinical rele-
vance, measurement of mature AVP is difficult and subject to (pre)analytical 
errors. Recently, copeptin, a 39-amino acid glycopeptide that comprises the 
C-terminal part of the AVP precursor was found to be a stable and sensitive surro-
gate marker for AVP release (1, 2). In recent studies in patients with bacterial sepsis 
but also in patients with leptospirosis it was shown that copeptin levels correlate 
well with disease severity and outcome when compared to other commonly used 
biomarkers like C-reactive protein (CRP) and more experimental biomarkers 
like procalcitonin (3, 4). Copeptin levels may even be used as a valuable tool to 
guide management of critically ill patients (4). Leptospirosis and bacterial sepsis 
are strikingly similar to severe malaria in terms of case-fatality rates and clinical 
presentation including the presence of hyponatraemia (5). Hyponatraemia was 
found to be highly prevalent in severe malaria and suggested to be the result of a 
dysregulated vasopressin release (6-9). 
The present study, therefore, aimed to evaluate copeptin as a pathophysiologic 
predictor of disease severity in patients with imported malaria. The diagnostic 
performance of copeptin was compared to that of several previously validated 
biomarkers to provide the clinician with the most accurate tool for clinical deci-
sion making in the acute care setting. A reliable test, easily discriminating severe 
from non-severe disease in malaria, would be clinically useful, especially in the 
setting of imported malaria, given the observation that most clinicians in non-en-
demic areas have little expertise with identifying severe malaria but these patients 
require a rapid triage for parenteral anti-malarials and intensive monitoring.
Methods
The Harbour Hospital is a 161-bed general hospital located in Rotterdam, The 
Netherlands. It also harbours the Institute for Tropical Diseases, which serves 
as a national reference centre. In the period 1999-2010 more than 500 cases of 
imported malaria were diagnosed. The characteristics of the Rotterdam Malaria 
Cohort in the period 1999-2008 were previously described (9). For the majority of 
these cases, demographic, clinical and laboratory data and serum samples were 
available. In the present study copeptin and procalcitonin were retrospectively 
measured in stored serum samples of 204 patients with imported malaria. The 
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tested serum samples were not from consecutive patients entering this cohort but 
based on availability. The occurrence of severe malaria was considered a primary 
end-point given the low case-fatality rate of imported malaria in the Netherlands. 
Because severe malaria can also occur in non-falciparum infections (albeit rare in 
returning travellers), patients with non-falciparum infections were not excluded. 
This contrasts with the design of many studies in patients with severe malaria 
in regions of malaria endemicity where the severity criteria are usually used as 
an entry criterion (10) and focus on P. falciparum malaria. In the present study, 
the previously validated biomarkers plasma lactate (11), procalcitonin (12, 13), 
sodium and CRP (9) were used as comparative biomarkers for copeptin to eval-
uate its accuracy for use in clinical practice to differentiate severe from non-se-
vere malaria. For that purpose, the patients with non-severe P. falciparum malaria 
and non-severe non-falciparum malaria were grouped as the non-severe malaria 
patients.
Procedures
On admission, blood samples were taken for analysis of the red blood cell count, 
haematocrit, white blood cell count, platelet count, CRP, serum electrolytes, total 
bilirubin, serum creatinin, liver enzymes, and blood glucose. A separate blood 
tube was drawn on admission for determination of plasma lactate, which was 
immediately analysed after isolation of plasma. Malaria was diagnosed by QBC 
(Quantitative Buffy Coat) analysis, by a rapid diagnostic antigen test for malaria 
(Binax NOW® Malaria Test, Binax Inc. Maine, USA) and by conventional micros-
copy of stained thick and thin blood smears to identify the causative Plasmodium 
species. In case of Plasmodium falciparum infections, parasite density was deter-
mined. When the parasitaemia was less than 0.5% infected erythrocytes, para-
sites were counted per 100 leucocytes in thick smears. When the parasitaemia 
was equal or higher than 0.5% infected erythrocytes, infected erythrocytes were 
counted in thin smear and expressed as a percentage of the total erythrocytes. 
The number of parasites per microliter was subsequently calculated from these 
data. Since non-falciparum infections are naturally limited by their specific pref-
erence for certain erythrocytic subpopulations, non-falciparum malaria infection 
were not routinely quantified. Patients were classified as having severe malaria if 
they met one or more of the WHO criteria for severe malaria, as published (14). 
Procalcitonin levels were determined in serum samples using a commercially 
available EIA test (VIDAS BRAHMS Procalcitonin, bioMérieux, Lyon, France). 
Normal serum values for procalcitonin are <0.1 ng/ml. Copeptin was measured 
with a commercial sandwich immunoluminometric assay (Brahms Copeptin, 
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Thermo Fisher Scientific, Hennigsdorf/Berlin, Germany). Normal values for serum 
copeptin are 1.70-11.25 pmol/L (2).
Statistical methods
Differences between patients with severe malaria, non-severe P. falciparum 
malaria and non-severe non-falciparum malaria were analysed with the Kruskall-
Wallis test followed by Dunn’s post-hoc tests. Two group comparisons were 
done by Student’s unpaired t-test, Student’s unpaired t-test with Welch correc-
tion or with the non-parametric Mann Whitney test depending on the distribu-
tion of the data. The diagnostic performance of each biomarker was reported as 
sensitivity, specificity, positive and negative predictive value for severe malaria 
and their corresponding 95% confidence intervals. Youden’s index J (J= sensi-
tivity+specificity-1) was used to identify the most appropriate cut-off point for 
each biomarker. Of each test a Receiver Operating Characteristics (ROC) curve, a 
graphical plot of sensitivity (true positive rate) versus 1-specificity (false positive 
rate), was constructed as a summary statistic and the area under the ROC curve 
(AUROC) and its corresponding 95% confidence intervals were calculated. The 
AUROC of each of the biomarkers was compared to that of copeptin in a pair-wise 
comparison with the method of DeLong et al (15). 
Results
Patient characteristics
In total, 204 travellers with imported malaria were included in this study; 63 patients 
were diagnosed with a non-falciparum infection (45 with Plasmodium vivax, 15 with 
Plasmodium ovale, three with Plasmodium malariae) and 141 patients were diag-
nosed with P. falciparum infection. Of the patients with P. falciparum infections, 25 
(17.7%) patients had severe malaria. There were no cases of severe non-falciparum 
malaria. The infection was most frequently acquired in Africa (n=156), followed by 
Asia (n=27) and South America (n=14). Thirty (14.7%) patients reported adequate 
use of malaria chemoprophylaxis, 24 (11.8%) used it inadequately and 143 (70.1%) 
patients did not use any chemoprophylaxis (data on prophylaxis use were not 
available in seven patients). The general characteristics of all patients are shown 
in Table 1. 
54
Characteristics of patients with severe malaria
Twenty-one of 25 patients (84.0%) with severe malaria acquired a P. falciparum 
infection in West-Africa. The others acquired severe malaria in East-Africa (n 
= 2), South-East Asia (n = 1) and South-America (n = 1). Twenty-four patients 
with severe malaria did not use any form of malaria chemoprophylaxis and one 
patient was using it inadequately. At admission to the intensive care unit (ICU), 
the 25 patients with severe malaria all fulfilled one or more of the severity criteria 
(Glasgow Coma Score ≤ 11, n = 2; haematocrit < 0.20 L/L n = 5; creatinine > 250 
μmol/L n = 2; bilirubin > 50 μmol/L n = 12; lactate > 5.0 mmol/L n = 5; hyperpara-
sitaemia > 5% n = 14; schizontaemia n = 14). The first arterial blood gas analysis on 
the ICU showed a median bicarbonate level of 21mmol/L (range 9 to 25 mmol/L) 
and a median base excess of -2 mmol/L (range -18 to 3). The median Glasgow 
Coma Scale score was 15 (range 11 to 15). Two patients required mechanical 
ventilation. Two patients were referred to another hospital for renal replacement 
therapy because of persistent acute oliguric renal insufficiency. Thirteen patients 
received exchange transfusion as an adjunct therapy to parenteral anti-malarial 
treatment. One case fatality was observed. The laboratory results of travellers with 
severe malaria were further characterized by significantly lower platelet counts 
and haemoglobin levels and by significantly higher plasma lactate, bilirubin and 
CRP levels compared to patients with non-severe P. falciparum malaria (Table 1). 
Analysis of biomarkers for severe malaria
In order to evaluate the diagnostic accuracy of copeptin for severe malaria, the 
performance of copeptin was compared to that of sodium, CRP, lactate and 
procalcitonin. Assuming that AUROCs are a measure of diagnostic accuracy, the 
performance of copeptin for severe malaria was comparable to that of sodium, 
lactate and procalcitonin, as is shown in Figure 1. The AUROC of copeptin did not 
statistically differ from the AUROC of sodium, lactate and procalcitonin in a pair-
wise comparison (Table 2). As shown in Figure 1 and Table 2, CRP had a signifi-
cantly better performance than either copeptin, sodium and lactate for prediction 
of severe malaria but its usefulness in clinical practice is probably limited. For illus-
tration, when a hypothetical decision rule for severe malaria was created solely 
based on a CRP cut-off level of ≥ 155 mg/L, 10 of 62 (or 16.1%) evaluable patients 
with non-falciparum disease and 26 of 116 (or 22.4%) evaluable patients with 
uncomplicated P. falciparum would have been falsely diagnosed as having severe 
malaria. In contrast, the diagnosis severe malaria would not have been considered 
in 5 of 24 (20.8%) evaluable patients with severe disease. Addition of either lactate, 
sodium or copeptin as a secondary selection criterion to the prediction rule did 
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not result in a proper identification of all patients with severe disease on admis-
sion. Only after adding procalcitonin (at a cut-off of ≥ 0.9 ng/mL) as a secondary 
selection criterion to the prediction rule, all evaluable patients with severe malaria 
would have been correctly identified on admission (See Supplementary Table 1). 
However, still nine of 29 evaluable patients with non-severe P. falciparum malaria 
and 10 of 15 evaluable patients with non-severe, non-falciparum malaria would 
have been falsely diagnosed with severe malaria, respectively (Supplementary 
Figure 1).
Analysis of biomarkers in relation to the number of severity criteria in 
patients with severe disease
When focusing on the 25 patients with severe malaria, 11 patients fulfilled a single 
criterion for severe malaria on admission, 11 patients fulfilled two malaria severity 
criteria, 2 patients fulfilled 3 malaria severity criteria and one patient fulfilled 
4 malaria severity criteria on admission to the ICU, respectively. As a conse-
quence of this distribution a proper stratification by numbers of malaria severity 
criteria present on admission was not feasible. When the severe malaria patients 
fulfilling a single malaria severity criterion on admission were compared to the 
patients with more than one criterion for severe malaria on admission, only for the 
biomarker plasma lactate a statistically significant difference was found (1.8±0.6 
versus 3.3±1.6 mmol/L, p=0.0042). See Supplementary Table 1 for further details. 
Discussion
In the present study, the diagnostic performance of several biomarkers for severe 
malaria was evaluated. In contrast to studies in patients with severe bacte-
rial sepsis (3) and severe leptospirosis (4), copeptin was not found to be a more 
accurate marker to predict severe disease in malaria than the previously validated 
biomarkers procalcitonin, sodium, and lactate. This may suggest that the major 
clinical manifestations of severe bacterial sepsis and leptospirosis may follow 
other pathophysiologic pathways than in patients with severe malaria. In the 
group of malaria patients, CRP had a clearly superior performance as compared to 
the previously mentioned biomarkers including copeptin. This finding is certainly 
of clinical relevance since measurement of CRP protein is not only widely avail-
able in industrialized countries but also readily available during night shifts in the 
acute care setting. 
In addition, there may be another pitfall with CRP-based decision rules in malaria. 
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As is known from studies in patients with severe malaria, co-infections may 
occur frequently in patients with malaria, which in itself may lead to a rise in CRP 
levels, irrespective of the malaria disease severity. For example, in a large cohort 
of 400 cases of imported severe malaria, 96 first episodes of co-infection were 
seen, in particular pneumonia (n=61), bacteraemia (n=18) and urinary tract infec-
tions (n=12). Interestingly, these episodes were related to both community-ac-
quired (n=30) as well as nosocomial infections (n=66) (16). In our study blood 
cultures of patients with severe malaria did not demonstrate presence of co-ex-
isting bacteraemia on admission.
These abovementioned observations underline the limited value of these 
biomarkers for a rapid diagnosis of severe disease in the acute care setting in 
non-endemic industrialized countries; as for now, a biomarker-based decision 
rule can certainly not replace the current clinical evaluation. It is noteworthy that 
all currently studied biomarkers were characterized by high negative predictive 
values, which may be helpful for exclusion of severe malaria on admission. The 
combined use of biomarkers may look promising since they allow correct identifi-
cation of all patients with severe malaria but their use in the current clinical prac-
tice is hampered by their poor positive predictive values and lack of prospective 
validation. 
In conclusion, copeptin was not found to be a good biomarker for severe malaria 
in imported malaria. Instead, CRP appeared to be a more accurate predictor for 
disease severity than the other investigated biomarkers. The main clinical appli-
cability of the current biomarkers or combination of biomarkers is probably limited 
to a rapid exclusion of severe disease given their high negative predictive values 
and low positive predictive values. 
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Table 1.  Characteristics of malaria patients at initial presentation
Severe malaria
[all P. falciparum]
(n=25)
Non-severe 
P. falciparum
(n=116)
Non-severe
Non-
falciparum
(n=63)
P-value
Demographics
Age, years 44 
(23 – 70)
41 
(11 – 69)
38
(8 – 62)
n.s.
Male, female, n (%) 15 (60), 
10 (40)
92 (79), 
24 (21)
44 (70), 
19 (30)
n.s.
Duration of complaints, n (%)
Less than 1 week
1-2 weeks
3-4 weeks
More than 4 weeks
16 (64)
8 (32)
0 (0)
0 (0)
83 (72)
20 (17)
8 (7)
1 (1)
31 (49)
15 (24)
5 (8)
3 (5)
0.0905
Vital signs on admission
Body temperature, °C 38.4 
(35.7 – 40.6)
38.6 
(35.7 – 41.0)
38.3
(36.0 – 41.2)
n.s.
Pulse rate, 
beats per minute
108 
(75 – 140 )A <0,001; B <0,01
90
(68 – 130)
90
(58 – 138)
0.0005
Systolic blood pressure, 
mm Hg
118 
(80 – 150)
120 
(88 – 185)
120 
(95 – 196)
n.s.
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Severe malaria
[all P. falciparum]
(n=25)
Non-severe 
P. falciparum
(n=116)
Non-severe
Non-
falciparum
(n=63)
P-value
Laboratory data on admission
Parasite density 
(parasites/μL)
284,005 
(39,600-1,380,600)
22,657 
(2-156,600)
n.a. <0.0001
C-reactive protein, mg/L 186 
(71 -407)A <0,001; B <0,001
95 
(7 – 310)
83 
(14 – 348)
<0.0001
Hemoglobin, mmol/L 7.8 
(2.5 – 10.2)A <0,05
8.5 
(5.3 – 11.1)
8.3 
(5.6 – 10.7)
0.0281
Haematocrit, L/L 0.37 
(0.12 – 0.50)A <0,05
0.41 
(0.24 – 0.52)
0.39 
(0.26 – 0.53)
0.0067
Leucocyte count, x 109/L 6.9 
(2.5 – 18.5)A <0,05
5.0 
(2.2 – 12.6)
5.3
(1.9 – 11.0)
0.0361
Thrombocytes, x 109/L 36 
(11 – 164)A <0,001; B < 0,001
93 
(16 – 385)
95
 (10 – 292)
0.0004
Serum glucose, mmol/L 6.8 
(4.1 – 8.8)
6.8 
(4.4 – 26.0)
6.4 
(4.2 – 22.1)
n.s.
Serum sodium, mmol/L 131 
(124 – 139)A<0.05;B <0,01
134
(122 – 141)C <0,05
136  
(127 – 141)
<0.0001
Serum creatinine, μmol/L 110 
(70 – 1081)B <0,001
97 
(51 – 208)C <0,05
91 
(46 – 126)
0.0010
Serum urea, mmol/L 7.6
(3.8 – 55.8)A <0,01; B <0,01
5.2 
(2.2 – 18.7)
5.1 
(2.7 – 10.9)
0.0018
Plasma lactate, mmol/L 2,3 
(1,0 – 5,8)A <0,001; B <0,05
1,4
(0,5 – 5,5)
1.7 
(0.7 – 4.0)
0.0014
Procalcitonin, ng/mL 1.9 
(0.9-42.3)A<0.01
0.6 
(0.0 – 11.2)
1.6 
(0.0 – 42.6)
0.0057
Copeptin, pmol/L 22.9
(5.1 – 91.5)B <0,05
13.9 
(1.6 – 67.8)
12.0 
(1.9 – 82.9)
0.0249
Duration
hospitalisation, days
7 
(3 – 13)A <0,001; B <0,001
5
(0 – 10)C <0,001
2
(0 – 9) <0.0001
Statistical analysis: Kruskall-Wallis (P-values in column) followed by Dunn’s post-hoc tests (P-values in 
superscript); n.s. denotes “not significant”; n.a. denotes “not applicable”. A: severe malaria vs non-severe >> 
Table 1.  Continued
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<< P. falciparum malaria; B: severe malaria vs non-severe non-falciparum malaria; C: non-severe P. falci-
parum malaria vs non-severe non-falciparum malaria. Comparison of parasite density was calculated 
for P. falciparum infections only (Mann Whitney test).
Table 2.  Descriptive statistics of diagnostic accuracy of the various 
   biomarkers for severe malaria.
Copeptin
(pmol/L)
Sodium
(mmol/L)
Lactate
(mmol/L)
C-reactive 
protein
(mg/L)
Procalcitonin
(ng/mL)
Cut-off value ≥ 21 ≤ 132 ≥ 1.6 ≥ 155 ≥ 0.9
Youden’s index 0.33 0.44 0.41 0.59 0.51
Sensitivity 60 
(39-78)
72
(50-87)
86
(64-96)
79
(57-92)
100
(68-100)
Specificity 73
(66-79)
72
(64-78)
56
(45-65)
80
(73-85)
51
(38-64)
Positive Predictive 
Value
31
(25-38)
26
(0.17-0.38)
29
(19-42)
35
(23-49)
28
(15-44)
Negative Predictive 
Value
93
(87-96)
95
(89-98)
95
(85-99)
97
(92-99)
100
(86-100)
Area Under 
the ROC curve
0.66
(0.59-0.72)
0.72
(0.66-0.78)
0.74
(0.66-0.81)
0.84
(0.79-0.89)
0.76
(0.65-0.86)
P-value* P=0.4289 P=0.6546 P=0.0237 P=0.6479
Data are given as mean (95% confidence interval). *P-values of pair-wise comparison of ROC curves 
(with copeptin ROC curve as comparator)
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Figure 1. Receiver Operating Curves (ROC) characteristics of the diagnostic 
   performance of copeptin for severe malaria, compared to that of 
   sodium, lactate, CRP and procalcitonin.
The ROC curve is a graph of sensitivity (true positive fraction) plotted against 1-specificity (false posi-
tive fraction). The performance of a diagnostic variable can be quantified by calculating the area under 
the ROC curve (AUROC). The ideal test would have an AUROC of 1, whereas a random guess would 
have an AUROC of 0.5. The results of the pair-wise comparison of ROC curves are shown (with copeptin 
ROC curve as comparator). Figure 1A: copeptin vs sodium (n=204 pairs, P-value not significant); Figure 
1B: copeptin vs lactate (n=124 pairs, P-value not significant); Figure 1C: copeptin vs CRP (n=202 pairs, 
p=0.02); Figure 1D: copeptin vs procalcitonin (n=70 pairs, P-value not significant). The copeptin graphs 
are not all identical due to missing values in pair-wise comparisons. 
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Supplementary Figure 1. 
A two-step decision rule involving the combined use of C-reactive protein and 
Procalcitonin to identify all patients with severe malaria on admission.
Legend
SF  Severe P. Falciparum malaria
NSF Non-severe P. Falciparum malaria
NSNF Non-Severe, Non-Falciparum malaria
CRP C-Reactive Protein
PCT Procalcitonin
   
204 malaria patients
25 SF patients
116 NSF patients
63 NSNF patients
2 patients missing CRP
1 SF patient
1 NSNF patient
55 malaria patients
19 SF patients
26 NSF patients
10 NSNF patients
47 malaria patients
3 SF patients
29 NSF patients
15 NSNF patients
25 malaria patients
0 SF patients
20 NSF patients
5 NSNF patients
202 malaria patients
24 SF patients
116 NSF patients
62 NSNF patients
147 malaria patients
5 SF patients
90 NSF patients
52 NSNF patients
100 patients missing PCT
2 SF patients
61 NSF patients
37 NSNF patients
22 malaria patients
3 SF patients
9 NSF patients
10 NSNF patients
CRP ≥ 155 mg/L
PCT < 0.9 ng/mL
CRP < 155 mg/L
PCT ≥ 0.9 ng/mL
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Supplementary Table 1. 
Impact of the number of severity criteria on the level of the biomarker on admis-
sion in malaria patients with severe disease
Parameter Patients with a single 
criterion for severe 
disease
(N=11)
Patients with more 
than one criterion for 
severe disease
(N=14)
P-value
C-reactive protein (mg/L) 161 (111-210) 225 (177-272) P=0.058
Sodium (mmol/L) 133 (130-135) 131 (128-133) P=0.349
Lactate (mmol/L) 1.8 (1.0-2.7) 3.3 (2.4-4.3) P=0.004
Copeptin (pmol/L) 25.4 (13.1-37.7) 30.5 (15.7-45.2) P=0.687
Procalcitonin (ng/mL) 4.1 (-2.3-10.6) 17.4 (-7.1-42.0) P=0.360
Data are given as mean (95% confidence interval)
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CHAPTER 4
Total and differential leukocyte 
count changes in a Controlled 
Human Malaria Infection
in malaria-naïve Dutch volunteers
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Abstract
Background: Both in endemic countries and in patients with imported 
malaria, changes in total and differential leukocyte count during 
Plasmodium falciparum infection have been described. To study the 
exact dynamics of the changes of the differential leukocyte counts 
and their ratios, they were monitored in a group of healthy non-immune 
volunteers who were exposed to a Controlled Human Malaria Infection 
(CHMI) with P. falciparum.
Methods: The study was performed as a substudy of two CHMI trials 
in which 15 and 24 healthy malaria-naive volunteers, respectively, were 
exposed to bites of infected mosquitos, using .the Plasmodium falci-
parum research strain NF54 and the novel clones NF135.C10 and NF166.
C8. After mosquito bite exposure, all volunteers were followed up clini-
cally and twice-daily blood draws were taken to detect the development 
of parasitemia in peripheral blood,and to monitor the total and differ-
ential leukocyte counts. All subjects received a course of atovaquone / 
proguanil when meeting the treatment criteria.
Results: A rise in total leukocyte, lymphocyte and monocyte count 
was observed during the liver phase of the malaria infection. Hereafter 
a leukocytopenia (nadir median 3.3 x 109 leukocytes/L), lymphocyto-
penia (nadir median 0.7 x 109 lymphocytes/L) and a borderline neutro-
penia (nadir median 1.5 x 109 neutrophils/L) developed in the para-
sitemic subjects. The neutrophil to lymphocyte count ratio (NLCR) 
reached a maximum of 4.0. Significant correlations were found between 
parasitemia and absolute lymphocyte count and between parasitemia 
and NLCR. All parameters normalized after parasite clearance. No 
changes in differential cell counts or their ratios were observed in the 
four non-parasitemic subjects.
Conclusion: A not previously described rise in leukocyte count, lympho-
cyte and monocyte count was observed during the liver phase of a 
CHMI. Subsequently a marked lymphocytopenia and rise in the NLCR 
was observed, both correlating with the parasite load.
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Background
Changes in total and differential leukocyte count during Plasmodium falciparum 
infection have been described previously, both in endemic countries and in 
patients with imported malaria (1-4). In patients diagnosed with malaria, the most 
pronounced change is the decrease of peripheral lymphocytes. Lymphocytopenia 
has been observed in 45% to 63% of patients with an imported P. falciparum infec-
tion, but was less prominent in patients with some degree of antimalarial immu-
nity (5, 6). In a recent large cross-sectional study on leukocyte count changes 
in returning travellers, malaria was the second most common cause of absolute 
lymphocytopenia (7).
Recently, several studies have focused on the value of differential leukocyte 
count ratios as parameters in critical illness. The neutrophil to lymphocyte count 
ratio (NLCR) was introduced by Zahorec et al. as a parameter of systemic inflam-
mation in critically ill surgical and medical patients (8). The NLCR outperformed 
traditional infection markers including C-reactive protein (CRP) in predicting 
bacteremia and the severity and outcome of community-acquired pneumonia 
(9). In patients with imported malaria, the NLCR correlated with parasitemia and 
normalized after parasite clearance (5, 6). One study on imported malaria showed 
correlations between parasitemia and both the monocyte to lymphocyte count 
ratio (MLCR) and neutrophil to monocyte count ratio (NMCR) (5). The exact 
dynamics and underlying pathophysiological mechanism of leukocyte count 
changes in malaria are not fully understood yet.
Controlled Human Malaria Infection (CHMI) is a well-established clinical model 
that was developed for the evaluation of candidate malaria vaccines (10). In this 
model, healthy volunteers are infected by malaria sporozoites via exposure to 
the bites of infected mosquitos. CMHI studies have traditionally been performed 
using the P. falciparum strain NF54, which is thought to originate from Africa (11). 
To extend the genetic diversity of strains available for laboratory use, the clones 
NF135.C10, and NF166.C8, originating from P. falciparum strains from Cambodia 
and Guinea, respectively, have been acquired in recent years. (12, 13). 
In the present study the changes of differential leukocyte counts and their ratios 
were monitored during the liver phase and during the development of detectable 
blood parasitaemia in a group of healthy non-immune volunteers in the CHMI 
model using the NF54, NF166.C8 and NF135.C10 Plasmodium falciparum strains.
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Methods
Study design
The present study was performed as a substudy of the Controlled Human Malaria 
Infection study CHMI-b, which is one of two CHMI studies that were performed 
using the well-established Plasmodium falciparum research strain NF54 and the 
novel clones NF135.C10 and NF166.C8. The primary objective of CHMI-a was to 
compare parasite dynamics of these isolates during infection and that of CHMI-b 
was to determine the proportion of subjects in each group who developed patent 
parasitaemia in relation to the number of infected mosquito bites. Secondary 
objectives of both studies included clinical parameters and further measures of 
parasite kinetics (14). 
Healthy malaria-naïve adult Dutch volunteers were recruited at the Harbour 
Hospital, Rotterdam, after signing informed consent. The screening procedures 
have been described previously (15). In CHMI-a, fifteen subjects were randomly 
allocated to three groups of n=5, to be infected by bites of five mosquitoes per 
subject carrying either the NF54 strain of P. falciparum, the NF135.C10 clone or 
the novel NF166.C8 clone. In CHMI-b, 24 subjects were randomly allocated to 
six groups of n=4, to bites by one, two or five mosquitoes carrying either NF135.
C10 or NF166.C8. Sporozoite-carrying mosquitoes were allowed to feed for ten 
minutes on the forearms of the volunteers. If the predetermined number of bites 
was not achieved after this exposure, the subjects were exposed to additional 
mosquitoes. From day 5 after exposure, subjects were seen in clinic twice daily for 
registration of vital parameters and adverse events and for venous blood draws 
for thick blood smear, qPCR, and a wide range of laboratory parameters including 
differential leukocyte counts. Plasmodium falciparum parasitaemia was quantified 
by qPCR as described before (16). In CHMI-a, subjects were treated with atova-
quone-proguanil 1000/400mg daily for three days upon their first positive thick 
blood smear, defined as ≥2 parasites per 225 high-powered fields (equivalent to 
0.5 µl blood). In CHMI-b, subjects were treated with the same regimen as soon as 
2 consecutive blood samples were positive by qPCR, defined as >500 parasites/
ml. This change in treatment initiation between the two studies was implemented 
to minimize safety risks following a cardiac serious adverse event in a previous 
study (15) (17). Daily thick blood smears and qPCR were continued after treatment 
until complete clearance of asexual parasites. These studies were approved by the 
Netherlands’ Central Committee on Human Research (CCMO NL41004.078.12 
and NL48704.000.14, respectively) and are registered with ClinicalTrials.gov 
(registration numbers NCT01627951 and NCT02149550, respectively).
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Data selection for the substudy
For the present substudy the data of CHMI-b were used, as this study had 
included a larger number of participants. The described differences in method-
ology regarding the initiation of treatment did not permit combination of blood 
phase CHMI-a and CHMI-b data. However, data from the liver phase of CHMI-a 
were used to confirm findings during the liver phase of CHMI-b subjects.
Statistical analysis
To determine whether the parameters of interest changed over time a Friedman 
test was performed. Next, a more detailed analysis of the timing of these changes 
was done using a linear model. Correlations were tested with the Spearman's rank-
order correlation. Data were not Normally distributed and given as median (inter-
quartile range) unless stated otherwise.
Definitions
• Leukocytopenia: Leukocyte count < 4.0 × 109/L; 
• Lymphocytopenia: Lymphocyte count < 1.0 × 109/L; 
• Neutropenia: Neutrophil count < 1.5 × 109/L
• Day of treatment (DT): The day the subject started a 3-day course of atova-
quone / proguanil, directly upon meeting the treatment criteria. The days 
from two days before until three days after this day are named DT-2 to DT+3.
• Liver phase: The subjects who eventually developed parasitemia were 
regarded as being in the liver phase on day 5 and 6 of the study protocol, 
when the peripheral blood samples of all subjects were still qPCR negative
• Detectable blood parasitaemia: Detectable blood parasitaemia is defined 
as qPCR positive, a method with a detection limit of 100 parasites per ml.
Results
Development of parasitemia and phases of the infection
Of the 24 volunteers in CHMI-b, 13 (54%) were female and the median age was 
22 (range 19-34). Twenty of the twenty-four volunteers (83%) developed para-
sitemia. The median time between exposure to mosquitoes and the develop-
ment of blood parasitemia detected by qPCR was 7 days (range 7 - 9 days) and the 
median time between exposure and the day the treatment criteria were met (here-
after called day of treatment [DT]) was 8 days (range 7 – 11 days). All 20 subjects 
who developed detectable parasitemia were still qPCR negative at day 5 and 6 of 
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the study protocol, and the infection was therefore regarded as being in the liver 
phase (18). 
The data from two days before DT (DT-2) until three days after DT (DT+3) were 
synchronized on DT (Figure 1). On DT-2, four subjects had a positive qPCR, all 
with a low parasitemia (385 to 713 parasites/ml) and did not meet the treatment 
criteria at that moment. The number of parasitemic subjects increased to nine 
subjects on DT-1. On DT all subjects met the treatment criteria. The median para-
site load on DT was 6,265 parasites per ml. Hereafter the parasite load declined to 
1,099 on DT+1 and 100 parasites per ml on DT+2. 
Changes in differential leukocyte counts and count ratios during the 
liver phase
During the liver phase of the infection (from baseline until day 6 after mosquito 
bite exposure), an increase of the lymphocyte count and the monocyte count 
was observed in the 20 subjects who developed parasitemia later on in CHMI-b. 
Changes in total leukocyte count, neutrophil count and the differential cell count 
ratios were not significant. No significant changes were observed in the four 
subjects who remained qPCR negative. As these changes during the liver phase of 
infected subjects were an unexpected finding, we reviewed the data of the CHMI-a 
study to see if this finding could be confirmed. In CHMI-a, all 15 subjects devel-
oped parasitemia, but, like in CHMI-b, all were still qPCR negative at day 5 and 6 
of the study protocol, and regarded as being in the liver phase during these days. 
The combined data of both CHMI studies also showed a significant increase of 
the total leukocyte count and the differential lymphocyte and monocyte counts 
(Table 1). 
Changes in differential leukocyte counts and count ratios after the 
liver phase
In the group of twenty subjects who developed parasitemia in CHMI-b, highly 
significant changes in the total leukocyte count and differential cell counts of 
neutrophils, lymphocytes and monocytes were observed in the days before DT 
and during treatment (Table 2 and Figure 1). These changes were not seen in 
non-parasitemic individuals (Supplementary Table 1 and Supplementary Figure 1). 
Of interest, both parasitemic and non-parasitemic individuals received antima-
larial treatment, thus excluding an effect of atovaquone/proguanil treatment on 
the observed changes. 
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Linear model analysis showed that in the individuals who develop parasitemia, 
the leukocyte count remained stable until DT-1 and then showed a fall, which 
continued until it reached its nadir on DT+2, with a median of 3.3 x 105 leuko-
cytes/L. On day DT+2, a leukocytopenia was observed in 70% (14 / 20) of the 
subjects. The absolute neutrophil count started to decrease on DT-1 to a median 
value of 1.5 x 105 neutrophils/L on DT+3. Neutropenia was found in 40% (8 / 20) of 
the subjects on this day. A steady fall in absolute lymphocyte count was observed 
from DT-2 until DT+2, when the median lymphocyte count was 0.7 x 105 lympho-
cytes/L. The percentage of subjects with an absolute lymphocytopenia increased 
from 30% (6 / 20) on DT to 70% (14 / 20) two days later. The median absolute 
monocyte counts remained within the normal range, but showed a mild drop on 
DT+2. On day 35 of the study protocol, all parameters had returned to baseline 
values. The evaluated parameters did not differ significantly between subjects 
infected with NF166.C8 and NF135.C10 (not shown).
The differential cell count ratios were also found to change significantly over time 
using the Friedman test (Table 1 and Figure 2). The linear model analysis showed 
a gradual rise of the NLCR, reaching a maximum of 4.0 on DT+1. After DT+1 a rapid 
decrease was observed. The MLCR showed a rise from DT-2 to DT+1 after which it 
decreased. The NMCR seemed to show a rise followed by a fall but these changes 
were not significant in the linear model analysis. 
In the four subjects that remained qPCR negative throughout the study period, the 
differential leukocyte counts remained within normal values and no significant 
changes in cell counts or cell count ratios were observed. All four received a full 
course of atovaquone / proguanil at day 13 of the study protocol (Supplementary 
Table 1 and Supplementary Figure 2).
Correlations 
Significant correlations were found between parasite load and absolute lympho-
cyte count (p <0.001, correlation coefficient - 0.46) and between parasite load 
and NLCR (p < 0.001, correlation coefficient 0.50). Correlations between para-
site load and total leukocyte count, MLCR and NMCR were significant, but weak 
(p = 0.004, Spearman’s rho (rs) -0.23, p < 0.001, rs 0.36 and p = 0.003, rs 0.23, 
respectively). There was no significant correlation between parasite load and 
absolute neutrophil count or absolute monocyte count.
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Discussion 
The present study shows an increase in total leukocyte, lymphocyte and mono-
cyte count during the liver phase of infected subjects. After the liver phase, a 
decrease of total leukocyte , neutrophil, lymphocyte and monocyte count is 
observed; these changes clearly relate to the occurrence of blood parasitemia 
and are not caused by treatment with atovaquone / proguanil, as shown by the 
control group of four subjects who did not develop parasitemia. 
The increase of the total leukocyte count, lymphocytes and monocytes during 
the liver phase has not been described in other CHMI studies, which generally 
focus on the blood stage of the infection. During the liver phase of malaria, only 
a relatively low number of hepatocytes become infected and the host immune 
responses to this stage of the parasite are poorly understood and the liver phase 
is often referred to as immunologically silent (19). The finding that the total leuko-
cyte count, lymphocyte count and monocyte count show an increase during the 
liver phase is remarkable and further studies are needed to confirm this finding 
and to elucidate its underlying pathophysiological mechanism.
The most pronounced change is a fall in lymphocyte count that starts on DT-2 
and reaches its nadir at 0.7 x 105 lymphocytes/L on DT+2, when 65% of subjects 
are lymphocytopenic. The neutrophil count only starts to show a significant fall 
after DT. These changes are reflected in the NLCR, which shows a steep rise to 
4.0 on DT+2. In comparison, in a previous study on patients with imported malaria 
the median NLCR on admission of all patients was 3.2, and 3.5 in patients with a 
severe P. falciparum infection (6). 
Lymphocytopenia has been described in several large cohorts of patients with 
malaria (3, 20-22) and is highly prevalent in symptomatic travelers with imported 
malaria (6). The correlations between parasite and lymphocyte count and between 
parasite load and NLCR were also demonstrated in a study by Berens-Riha et al (5), 
in which patients were stratified according to their immune status. Both the MLCR 
and the NLCR were found to be lower in semi-immune patients as compared to 
non-immune patients. In the present study, all subjects were non-immune. White 
blood cell count changes have also been described in previous CHMI studies. In a 
study on clinical manifestations in CHMI with P. falciparum, Church et al described 
a decrease in total white blood cell count and in neutrophil count, but not in 
lymphocyte count, with the nadir occurring two days after therapy initiation (23). 
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 A decrease in lymphocyte count was observed in several studies involving sporo-
zoite infection after mosquito bite exposure (24-27) and in a study using exper-
imental inoculation with a low number of parasitized erythrocytes (28). These 
observations are in line with the findings described here. As no measurements are 
available between DT+3 and the end of the study protocol at day 35, we are not 
able to monitor when the changes observed, started to normalize after treatment. 
This is an important limitation of the study.
Several mechanisms have been proposed as an explanation for malaria induced 
lymphocytopenia. A temporary reallocation of lymphocytes has been suggested, 
which is supported by the observation that lymphocytes rapidly re-emerge in 
the peripheral circulation after treatment is initiated (29). The destination of the 
lymphocytes, however, is unknown. Others suggest that the soluble Fas ligand 
induces apoptosis of lymphocytes, which has been observed both in vitro and in 
healthy donors from endemic areas (30-34), and a previous CHMI study found an 
increased production of Granzyme B, which is also know to induce apoptosis, in 
exposed individuals, (35). Both mechanisms though might be partly responsible 
for the observed fall in lymphocyte cell count. 
Conclusion
In a setting of controlled human malaria infection in 24 healthy non-immune 
volunteers, an initial increase of peripheral total leukocyte count and differential 
lymphocytes and monocytes was observed during the liver phase of the infec-
tion which has never has been described before. This rise seems to indicate the 
presence of a malaria infection and is followed 2-3 days later by the appearance 
of parasites in the peripheral blood, which is accompanied by a marked decrease 
in total leukocyte count, lymphocyte count and the neutrophil count and a rise 
of the NLCR. Both the lymphocyte count and the NLCR correlated with blood 
parasitemia, and all parameters had normalized 3 to 4 weeks after parasite clear-
ance. The non-parasitemic control group in this study excludes a treatment- 
related effect.
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Table 1.  The course of differential leukocyte counts and their ratios during the 
   liver phase in the subjects who developed malaria. 
Leuko-
cytes
X109/L
Neutro-
phils
X109/L
Lympho-
cytes
X109/L
Mono-
cytes
X109/L
NLCR MLCR NMCR
CHMI-b (n=20)
 Baseline 5.1
(4.9-6.1)
2.8
(2.5-3.1)
1.6
(1.5-2.0)
0.48
(0.35-0.60)
1.8
(1.1-2.0)
0.3
(0.2-0.3)
5.8
(4.7-8.3)
 Day 5 5.7
(5.4-7.2)
3.1
(2.2-3.6)
2.0 
(1.7-2.5)
0.49
(0.43-0.60)
1.3
(1.0-2.1)
0.2
(0.2-0.3)
5.9
(4.8-7.2)
 Day 6 6.0
(5.3-6.9)
3.0
(2.4-3.8)
2.2
(1.9-2.4)
0.53
(0.46-0.65)
1.4
(1.1-1.8)
0.2
(0.2-0.3)
5.3
(4.6-7.1)
 P-value 0.051 0.195 0.004 0.012 0.165 0.196 0.848
CHMI-a (n=15)
 Baseline 5.8
(5.3-6.5)
3.1
(2.9-3.3)
1.9
(1.9-2.3)
0.51
(0.48-0.58)
1.6
(1.4-1.7)
0.3
(0.2-0.3)
6.2
(5.0-7.9)
 Day 5 6.8
(6.1-7.3)
3.6
(2.9-4.0)
2.3
(2.0-2.5)
0.55
(0.46-0.63)
1.6
(1.4-1.8)
0.2
(0.2-0.3)
6.9
(4.9-8.6)
 Day 6 6.9
(5.8-7.6)
3.2
(2.7-4.1)
2.4
(1.9-2.7)
0.55
(0.49-0.58)
1.3
(1.1-1.9)
0.2
(0.2-0.3)
6.0
(5.5-7.2)
 P-value 0.105 0.721 0.140 0.208 0.623 0.983 0.633
Combined (n=35)
 Baseline 5.5
(5.0-6.2)
2.9
(2.6-3.2)
1.9
(1.6-2.2)
0.50
(0.38-0.60)
1.7
(1.3-2.0)
0.3
(0.2-0.3)
6.1
(4.8-8.4)
 Day 5 6.1
(5.5-7.2)
3.3
(2.5-3.7)
2.2
(1.8-2.5)
0.50
(0.43-0.54)
1.5
(1.1-1.9)
0.2
(0.2-0.3)
6.1
(4.9-8.1)
 Day 6 6.1
(5.5-7.0)
3.0
(2.6-3.9)
2.2
(1.9-2.6)
0.54
(0.47-0.62)
1.4
(1.1-1.8)
0.2
(0.2-0.3)
5.7
(4.8-7.2)
P-value 0.005 0.413 0.001 0.038 0.121 0.368 0.971
Data in this table are not Normally distributed and shown as median (interquartile range). P-values in 
this table were derived from Friedman tests
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Table 2. The course of differential leukocyte counts and their ratios in the 
   subjects who developed malaria in CHMI-b (n=20)
Leuko-
cytes
X109/L
Neutro-
phils
X109/L
Lympho-
cytes
X109/L
Mono-
cytes
X109/L
NLCR MLCR NMCR Parasite 
load
Parasites/ml
Baseline
5.1
(4.9-6.1)
2.8
(2.5-3.1)
1.6
(1.5-2.0)
0.48
(0.35-0.60)
1.8
(1.1-2.0)
0.3
(0.2-0.3)
5.8
(4.7-8.3)
N/A
DT-2 5.8
(5.4-6.8)
3.0
(2.3-3.7)
2.1
(1.9-2.4)
0.49
(0.43-0.61)
1.4
(1.0-1.7)
0.2
(0.2-0.3)
5.6
(4.3-6.8)
0
(0-0)
DT-1 5.8
(5.3-6.6)
2.9
(2.6-3.5)
2.0
(1.5-2.3)
0.55
(0.46-0.65)
1.4
(1.1-2.1)
0.3
(0.2-0.3)
5.2
(4.5-6.7)
0
(0-374)
DT 5.6
(4.8-6.1)
3.1
(2.8-3.6)
1.6
(0.9-2.0)
0.53
(0.40-0.58)
2.2
(1.4-3.8)
0.4
(0.4-0.5)
6.4
(5.0-8.0)
6,265
(1,306-12,152)
DT+1 4.4
(3.9-4.7)
3.0
(2.5-3.2)
0.8
(0.6-1.1)
0.44
(0.30-0.60)
4.0
(2.2-5.3)
0.5
(0.5-0.6)
6.9
(5.4-9.5)
1,099
(159-19,494)
DT+2 3.3
(2.9-4.0)
1.9
(1.7-2.5)
0.7
(0.6-1.2)
0.32
(0.24-0.49)
2.6
(1.7-3.7)
0.5
(0.3-0.6)
6.2
(4.1-8.0)
100
(1-20,337)
DT+3 3.4
(2.7-3.7)
1.5
(1.3-1.9)
1.0
(0.8-1.3)
0.36
(0.28-0.60)
1.6
(1.1-2.2)
0.5
(0.3-0.6)
3.6
(2.8-5.4)
1
(0-305)
Day 35 6.2
(5.2-7.2)
2.8
(2.3-3.3)
2.2
(1.9-3.0)
0.53
(0.44-0.71)
1.2
(0.9-1.3)
0.2
(0.2-0.2)
5.6
(4.1-6.4)
0
(0-0)
P-value <0.0001 <0.0001 <0.0001 0.002 <0.0001 <0.0001 <0.0001 <0.0001
Data in this table are not Normally distributed and shown as median (interquartile range). P-values in 
this table were derived from Friedman tests 
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Figure 1.  Changes in total and differential leukocyte counts in the volunteers 
   who developed malaria in CHMI-b (n=20). 
The data are show as medians (dots) and interquartile ranges (whiskers). The data from DT-2 until DT+3 
were synchronized on DT.
Baseline day 5 day 6 DT-2 DT-1 DT DT+1 DT+2 DT+3 day 35
0.0
2.0
4.0
6.0
8.0
Liver phase
Leukocytes x10 9/L
Neutrophils x109/L
Log parasitemia
Lymphoctes x10 9/L
Monocytes x10 9/L
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Figure 2. Changes in differential cell count ratios in the volunteers who devel- 
   oped malaria in CHMI-b (n=20). 
The data are show as medians (dots) and interquartile ranges (whiskers). The data from DT-2 until DT+3 
were synchronized on DT.
Baseline day 5 day 6 DT-2 DT-1 DT DT+1 DT+2 DT+3 day 35
0.0
4.0
8.0
12.0
NLCR
MLCR
NMCR
Log parasitemia
Liver phase
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Supplementary Figure 1. 
Changes in total and differential leukocyte counts in the volunteers that did not 
develop malaria. 
The data are show as medians (dots) and interquartile ranges (whiskers). None of the changes in this 
group were statistically significant.
Baseline d5 d6 d11 d12 d13 d14 d15 d16 d35
0.0
2.0
4.0
6.0
8.0
10.0 Leukocytes x10
9
/ L
Neutrophils x10
9
/ L
Lymphoctes x10
9
/ L
Monocytes x10
9
/ L
TreatmentTreatment
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Supplementary Figure 2. 
Changes in differential cell count ratios in the volunteers that did not develop 
malaria. 
The data are show as medians (dots) and interquartile ranges (whiskers). None of the changes in this 
group were statistically significant.
Baseline d5 d6 d11 d12 d13 d14 d15 d16 d35
0.0
4.0
8.0
12.0
NLCR
MLCR
NMCR
TreatmentTreatment
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Supplementary Table 1. 
Differential leukocyte counts and their ratios in the non-parasitemic subjects.
Leuko-
cytes
X109/L
Neutro-
phils
X109/L
Lympho-
cytes
X109/L
Mono-
cytes
X109/L
NLCR MLCR NMCR
Baseline 6.3
(6.2-6.8)
3.9
(3.7-4.2)
1.8
(1.8-2.0)
0.54
(0.45-0.62)
2.1
(2.0-2.3)
0.3
(0.2-0.3)
8.1
(6.0-10.3)
Day 5 6.4
(6.1-6.8)
3.6
(3.1-4.0)
2.2
(2.1-2.3)
0.57
(0.51-0.63)
1.6
(1.4-2.0)
0.3
(0.2-0.3)
6.6
(5.5-7.5)
Day 6 6.6
(6.4-7.2)
3.8
(3.6-4.0)
2.1
(1.9-2.5)
0.53
(0.51-0.62)
1.7
(1.5-1.9)
0.3
(0.3-0.3)
6.9
(6.3-7.1)
Day 7 6.1
(5.9-7.1)
3.5
(3.2-4.5)
1.9
(1.8-2.1)
0.57
(0.52-0.59)
2.0
(1.7-2.4)
0.3
(0.2-0.3)
7.4
(6.4-8.9)
Day 8 6.6
(6.4-6.8)
3.5
(3.4-3.8)
2.1
(2.0-2.2)
0.56
(0.53-0.60)
1.6
(1.4-1.8)
0.3
(0.2-0.3)
6.6
(6.0-7.0)
Day 9 6.0
(5.1-7.2)
3.5
(2.9-4.4)
1.9
(1.7-2.1)
0.50
(0.46-0.51)
2.0
(1.8-2.2)
0.2
(0.2-0.3)
8.0
(6.8-9.1)
Day 10 6.4
(5.8-7.3)
3.7
(3.3-4.2)
2.2
(1.9-2.4)
0.57
(0.49-0.66)
1.7
(1.6-1.9)
0.3
(0.3-0.3)
6.5
(6.4-6.7)
Day 11 6.0
(5.8-6.2)
3.3
(2.9-3.6)
2.1
(2.0-2.2)
0.47
(0.42-0.52)
1.6
(1.3-1.9)
0.2
(0.2-0.3)
7.4
(6.6-7.7)
Day 12 5.6
(5.6-5.9)
3.2
(3.0-3.6)
1.8
(1.7-1.9)
0.47
(0.42-0.51)
1.9
(1.7-2.0)
0.3
(0.2-0.3)
7.2
(6.6-8.2)
Day 13^ 5.8
(5.5-6.0)
3.2
(3.0-3.3)
1.9
(1.8-1.9)
0.44
(0.39-0.50)
1.6
(1.5-1.8)
0.2
(0.2-0.2)
6.7
(6.6-7.0)
Day 14 6.2
(5.5-6.4)
3.7
(3.1-3.9)
1.8
(1.7-1.8)
0.39
(0.35-0.46)
2.0
(1.7-2.2)
0.2
(0.2-0.3)
8.3
(6.3-10.5)
Day 15 5.7
(5.0-6.3)
3.3
(3.0-3.5)
1.6
(1.5-1.8)
0.43
(0.40-0.45)
2.0
(1.6-2.3)
0.2
(0.2-0.3)
7.9
(6.5-9.4)
Day 16 6.8
(6.3-6.9)
3.8
(3.2-4.2)
2.0
(1.9-2.1)
0.53
(0.50-0.56)
1.8
(1.4-2.2)
0.3
(0.2-0.3)
6.5
(6.0-7.6)
End 7.2
(6.7-7.7)
3.9
(3.6-4.4)
2.2
(1.9-2.4)
0.58
(0.43-0.77)
2.1
(1.8-2.3)
0.3
(0.3-0.3)
7.0
(5.6-8.5)
P-value 0.21 0.66 0.10 0.08 0.28 0.74 0.65
Data are shown as median (interquartile range). P-values in this table were derived from Friedman tests. 
^Non-parasitemic subjects received a full 3-day course of atovaquone / proguanil, starting on day 13.
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CHAPTER 5
Predictive value of lymphocytopenia 
and the neutrophil-lymphocyte 
count ratio for severe imported malaria
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Abstract
Background: Lymphocytopenia has frequently been described in 
patients with malaria, but studies on its association with disease severity 
have yielded conflicting results. The neutrophil/lymphocyte count ratio 
(NLCR) has been introduced as a parameter for systemic inflammation 
in critically ill patients and was found, together with lymphocytopenia, 
to be a better predictor of bacteraemia than routine parameters like 
C-reactive protein and total leukocyte count. In the present study, the 
predictive value of the NLCR and lymphocytopenia for severe disease 
was evaluated in patients with imported malaria.
Methods: All patients diagnosed with malaria at the Harbour Hospital 
between January 1st 1999 and January 1st 2012 with differential 
white cell counts determined within the first 24 hours after admission 
were included in this retrospective study. Severe malaria was defined 
according to the WHO criteria. The performance of the NLCR and 
lymphocytopenia as a marker of severe malarial disease was compared 
back-to-back with that of C-reactive protein as a reference biomarker. 
Results: A total of 440 patients (severe falciparum malaria n = 61, 
non-severe falciparum malaria n = 259, non-falciparum malaria n=120) 
were included in the study. Lymphocytopenia was present in 52% of all 
patients and the median NLCR of all patients was 3.2. Total lymphocyte 
counts and NLCR did not differ significantly between groups. A signif-
icant correlation of total leukocyte count and NLCR, but not lympho-
cyte count, with parasitaemia was found. ROC analysis revealed a good 
negative predictive value but a poor positive predictive value of both 
lymphocytopenia and NLCR and performance was inferior to that of 
C-reactive protein. After complete parasite clearance a significant rise in 
total leukocyte count and lymphocyte count and a significant decrease 
in NLCR was observed.
Conclusion: The NLCR was found to correlate with parasitaemia, but 
both lymphocytopenia and the NLCR were inferior to C-reactive protein 
as markers for severe disease in patients with imported malaria. 
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Background
Changes in blood cell counts are a well-known feature of malaria. Alterations in 
leukocyte counts are often less pronounced than in the other blood cell lineages, 
but in general total leukocyte counts have been found to be low to normal 
in malaria (1, 2). Lymphocytopenia has frequently been described in malaria 
patients in endemic areas (3-6), and was found to be present in 63% of patients 
with imported Plasmodium falciparum infection (7). Studies on the correlation 
between lymphocyte count and malaria severity yielded conflicting results, as 
both lymphocytopenia (1, 3, 4) and lymphocytosis (8) have been reported to be 
associated with adverse outcome.
Lymphocytopenia accompanied by a rise in neutrophil count is commonly seen 
in various infectious and non-infectious causes of systemic inflammation and 
stress (9-13). Zahorec et al introduced the ratio of neutrophil to lymphocyte 
count as a parameter of systemic inflammation and stress in critically ill surgical 
and medical patients (14). The predictive value of both lymphocytopenia and the 
neutrophil-lymphocyte count ratio (NLCR) for bacteraemia was confirmed in a 
study in an emergency care setting, in which these parameters were found to be 
better predictors of bacteraemia than routine parameters like C-reactive protein 
(CRP) level, total leukocyte count or neutrophil count. Recently, another study 
evaluated this parameter in patients with a community-acquired pneumonia 
(CAP) (15) and it was found to predict severity and outcome of CAP with a higher 
prognostic accuracy as compared with traditional infection markers.
Although the NLCR is currently not routinely used as a clinical parameter, the 
above mentioned studies have demonstrated its value as an infection marker in 
critically ill patients. Unequivocal data concerning the predictive value of lympho-
cytopenia and the NLCR in malaria are not yet available.
In non-endemic countries, where malaria is only seen as an imported disease, 
non-specialized hospitals often rely on rapid diagnostic tests for the diagnosis of 
malaria and generally lack experience in the examination of thick and thin blood 
smears to asses the parasite load. There is, therefore, still a need for simple and 
readily available parameters for the early identification of patients at risk of severe 
or complicated disease. The present study evaluated lymphocytopenia and the 
NLCR as predictive markers of severe disease in a large cohort of patients with 
imported malaria.
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Methods
Patients
The Harbour Hospital is a 161-bed general hospital located in Rotterdam, The 
Netherlands. It also comprises the Institute of Tropical Diseases, which serves 
as a national referral centre. All patients diagnosed with malaria at our centre are 
included in the Rotterdam Malaria Cohort study. Demographic, clinical and labo-
ratory data of all these patients are collected using a standardized form and stored 
in an electronic database. For the present observational cohort study, patients 
diagnosed with malaria between January 1st 1999 and January 1st 2012 and with 
differential white cell counts determined within the first 24 hours after admission 
were included. 
Laboratory investigations
Total and differential leukocyte counts were measured using an automatic cell 
counters. During the study period three distinct cell counters were subsequently 
used after careful calibration (Sysmex NE 8000 [in the period January 1st 1999 -July 
31st 2002], Beckman Coulter HMX [July 31st 2002- July 31st 2010] and Sysmex 
XE 2100 [July 31st 2010 - January 1st 2012], respectively). Absolute numbers of 
lymphocytes and neutrophil subsets were obtained by multiplication of the abso-
lute leukocyte counts with their respective differential leukocyte counts. Manual 
confirmation of automatic cell count results was performed when immature or 
aberrant leukocytes, erythrocytes or platelet clumps were detected and when 
cell count results differed substantially from normal values. Other available labo-
ratory examinations included red blood cell counts, haematocrit, platelet counts, 
C-reactive protein levels, serum electrolytes, total bilirubin, serum creatinine and 
urea, sodium, potassium, liver enzymes, blood glucose and venous plasma lactate. 
Detection of Plasmodium parasites 
The standard procedure to diagnose malaria comprised a Quantitative Buffy Coat 
(QBC) analysis, a rapid diagnostic test (RDT) for malaria antigens (Binax NOW® 
Malaria Test Binax, Inc. Maine, USA), and thick and thin blood smears using freshly 
collected blood specimens from finger pricks. The RDT and the QBC analysis 
were performed according to the manufacturer’s instructions. QBC capillaries 
were examined independently by two technicians by microscopic analysis of two 
complete rows of the region between the bottom of the capillary and the polynu-
clear leukocyte layer using an Olympus BX-60 fluorescence microscope equipped 
with UV-filter, 50x objective and 12.5x oculars (total magnification 625x). These 
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two lanes represent about 100 microscopic fields (at 625 x magnification) and 
take an average examination time of 5 min. Subsequently, the polynuclear and 
mononuclear cell layer was screened for schizonts, gametocytes, malaria pigment 
and elderly trophozoites of Plasmodium vivax and Plasmodium ovale. 
Thick blood smears were stained with Field’s stain (Brunschwig Chemie, 
Amsterdam, the Netherlands) and thin smears with Diff Quick stain (Medion 
Diagnostics, Düdingen, Switzerland). Both staining procedures have been opti-
mized for optimal staining of Plasmodium parasites as well as Schüffner’s dots 
and Maurer’s clefts in infected erythrocytes. Thick and thin smears were exam-
ined with regular light microscopes at a total magnification of 1250x.
The same Plasmodium detection methods were used throughout the whole study 
period.
Definitions
Severe malaria 
Patients were classified as having severe malaria if they met one or more of the 
WHO criteria for severe malaria, as published (16), either on presentation or later 
during hospital admission. 
Leukocyte counts and NLCR 
Leukocytopenia was defined as a leukocyte count of less than 4.0 x109/L and leuko-
cytosis was defined as a leukocyte count exceeding 10.0 x 109/L. Lymphocytopenia 
was defined as a lymphocyte count of less than 1.0 x 109/L and lymphocytosis as a 
lymphocyte count more than 4.0 x 109/L. Neutropenia was defined as a neutrophil 
count of less than 1.5 x 109/L and neutrophilia as a neutrophil count of more than 
7.0 x 109/L. The neutrophil-lymphocyte count ratio was defined as the ratio of the 
absolute neutrophil count to the absolute lymphocyte count.
Estimation of immunity to P. falciparum
The degree of immunity to malaria was estimated as previously described (17). 
Adult immigrants from a malaria-endemic country living in the Netherlands were 
considered partially immune, because they had likely been exposed to P. falci-
parum during childhood. Patients who had been living in a malaria-endemic area 
for at least 2 years at the time of diagnosis were presumed semi-immune. Tourists 
from non-endemic regions who travelled to endemic areas were considered 
non-immune.
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Statistical analysis
Data were not normally distributed (Kolmogorov-Smirnov test) and are there-
fore presented as medians and range. Univariate comparisons were performed 
using the Chi-Square test and the Kruskall-Wallis test with Dunn's post-hoc tests 
(three groups), or the Mann-Whitney test and Fisher’s Exact test (two groups). 
Correlations with parasitaemia were calculated using Spearman’s rank correla-
tion. For the comparisons of differential leukocyte counts before and after treat-
ment, Wilcoxon’s matched pairs test was used. 
For clinical reference, the diagnostic performance of NLCR and lymphocytopenia 
for severe disease was compared to that of the classic biomarker serum CRP using 
receiver operating characteristic (ROC) analysis. The optimal cut-off point was identi-
fied using Youden’s index. The areas under the ROC curve (AUROCs) were compared 
to that of CRP in a pair-wise comparison by the method of Hanley and McNeil (18).
Results
Patient characteristics
Between January 1st 1999 and January 1st 2012 a total of 562 cases of imported 
malaria were seen. Differential leukocyte counts were available for 440 (78%) 
of the patients. Of these cases, 120 cases were caused by non-falciparum 
Plasmodium species: 88 by P. vivax, 27 by P. ovale, four by Plasmodium malariae and 
one by Plasmodium knowlesi. The majority of infections (320 or 72%) was caused 
by P. falciparum, including three patients who had a mixed infection; two with P. 
falciparum and P. ovale, one with P. falciparum and P. vivax. Sixty-one patients were 
classified as having severe malaria. All these patients met the severity criteria 
upon admission to the hospital, and no patients were re-classified as having 
severe malaria because of progression of disease during admission. Concomitant 
infection was present in 29 (7%) of patients and was more common in patients 
with severe malaria. None of the patients had positive blood cultures. The general 
characteristics of these patients are shown in Table 1.
Leukocyte counts and NLCR
Leukocytopenia was present in 23% (100/440) of all patients but in only 11% 
(7/61) of patients with severe malaria. Leukocytosis was seen in 4% (19/440) 
of all patients and was more common in patients with severe disease (13% or 
8/61) compared to those with non-severe falciparum malaria (2% or 6/259) and 
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non-falciparum malaria (4% or 5/120). Likewise, leukocyte counts were higher in 
patients with severe malaria compared to those with non-severe P. falciparum 
malaria and non-falciparum malaria (Figure 1 and Table 1). 
Lymphocytopenia was present in 52% (227/440) of all patients and was more 
frequently seen in patients with non-severe falciparum malaria (143/259 or 55%) 
than in patients with severe malaria (28/61 or 46%), and non-falciparum malaria 
(54/120 or 45%). Absolute lymphocyte counts did not differ significantly between 
the three groups. 
Neutropenia was found in 8% (36/440) of all patients and neutrophilia in 4% 
(17/440), but was more common in patients with severe malaria (7% or 4/61) 
compared to those with non-severe falciparum malaria and non-falciparum 
malaria (3% or 7/259 and 5% or 6/120, respectively). Neutrophil counts were 
higher in patients with severe malaria compared to those with non-severe P. falci-
parum malaria and non-falciparum malaria (Figure 1 and Table 1).
The median NLCR of all patients was 3.2. Although there was a trend towards 
higher values in patients with severe malaria (3.5) compared to those with non-se-
vere P. falciparum (3.3) and non-falciparum (2.8) malaria, these differences were 
not significant. 
Correlation with parasitaemia
Significant correlations were found between parasitaemia and total leukocyte 
count (r
s 
0.304, p<0.0001)and parasitaemia and NLCR (r
s
 0.165, p=0.03).
Correlations between parasitaemia and absolute lymphocyte or neutrophil 
counts were not significant.
Predictive value and ROC analysis
Analysis of the diagnostic performance of lymphocytopenia and the NLCR for 
the detection of severe malaria revealed good negative predictive value (0.87 and 
0.92 respectively) but poor positive predictive value (Table 2). The AUROCs of 
total leukocyte count, neutrophil count, lymphocyte count and NLCR were all 
significantly inferior to that of CRP (Table 2).
Leukocyte count changes during malaria treatment
Follow-up differential leukocyte counts were available for 40 (66%) patients 
with severe malaria and 114 patients with non-severe P. falciparum infection. By 
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the time of complete parasite clearance (confirmed by a negative QBC and thick 
blood smear) a significant rise in total leukocyte count and lymphocyte count and 
a significant decrease in NLCR was observed. A significant decrease in neutrophil 
counts after treatment was only seen in non-severe malaria patients, but not in 
patients with severe malaria (Table 3).
Discussion
In contrast to studies in bacterial sepsis, where lymphocytopenia and NLCR were 
found to outperform CRP in predicting the presence of bacteraemia, lymphocyte 
counts and NLCR did not allow for an accurate discrimination between malaria 
patients with severe disease and those without. Even though lymphocytopenia 
and NLCR had good negative predictive values, CRP was found to be a superior 
marker in back-to-back analyses. 
This lack of diagnostic power might partly be due to the fact that neutrophilia, while 
often marked in patients with bacterial sepsis, is not commonly seen in malaria. 
Some studies even report neutropenia (1). In the present study, neutrophil counts 
were in the lower range of normal. This is reflected in NLCR values that are much 
lower than those found in patients with bacteraemia (19) and might be an expla-
nation for the dissimilar performance of the NLCR in bacterial sepsis and malaria. 
Bacterial co-infection was present in 8% of patients with severe malaria, which is 
consistent with the findings of a large cohort study on patients with severe malaria 
admitted to the ICU (20). However, none of the patients in the present study had 
a positive blood culture. A major confounding effect of concomitant bacterial 
infections is, therefore, unlikely. Moreover, regarding the design of the study on 
NLCR in bacterial sepsis by de Jager et al (19), an important difference with the 
present study has to be taken into account. In the former study, lymphocytopenia 
and the NLCR were evaluated as predictors of the presence of bacteraemia in 
patients with suspected community-acquired bacteraemia, while in the present 
study these biomarkers were evaluated in a patient group with confirmed malaria. 
Considering this, the correlation of NLCR with peripheral parasite count and the 
fact that lymphocyte count increases and NLCR decreases after complete para-
site clearance are interesting findings; although NLCR lacks diagnostic power to 
accurately identify patients with severe malaria, a high parasite load does seem to 
result in relative lymphocytopenia. 
Surprisingly for such a common phenomenon (3-7, 21) the mechanism behind 
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malaria-associated lymphopaenia has still not been satisfactorily elucidated and 
remains the subject of debate (22). The rapid re-emergence of lymphocytes in 
the peripheral circulation following initiation of treatment has led some authors 
to suggest transient sequestration during malaria to be responsible (4, 5). The 
relatively large drop in peripheral lymphocyte numbers would suggest this to be 
a non-specific effect, e.g. pooling in the enlarged spleens of patients (5) rather 
than a response by malaria-specific lymphocytes only. Others have pointed 
to the increased propensity of lymphocytes from malaria patients to undergo 
spontaneous apoptosis in vitro (23, 24), possibly induced by soluble Fas ligand 
(sFasL)-Fas interaction (25). Interestingly, increased apoptosis is also seen in 
healthy donors from endemic areas, be it to a lesser extent (23, 24, 26), suggesting 
chronic stimulation of lymphocytes by environmental micro-organisms may be 
contributing through activation-induced cell death. Presumably both mech-
anisms are at work in tandem, with activated lymphocytes sequestering during 
malaria and rates of apoptosis, whether spontaneous or activation-induced, 
rising due to infection and peaking following treatment in order to restore homeo-
stasis (27).
CONCLUSION
The NLCR was found to correlate with parasitaemia, but both lymphocytopenia 
and the NLCR were inferior to CRP as markers of severe disease in patients with 
imported malaria in direct back-to-back comparisons. Although these parame-
ters may have proven their usefulness in predicting bacteriaemia, they are appar-
ently not useful as predictive markers of severe disease in imported malaria in the 
acute care setting.
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Figure 1.  Distribution of leukocyte counts and the NLCR in patients with 
   malaria grouped by severity and causative Plasmodium species
The gray areas depict the normal ranges
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Table 1.  General characteristics 
Severe 
P. falciparum
n=61
Non-
severe 
P. falciparum
n=259
Non-
falciparum 
n=120
P-value
Demographics
Age, years 44
(4-70)
39
(11-78)
36
(15-77)
0.0005*
Male / female, n (%) 39 
(64%) / 22 
(36%)
191
(74%) / 68 (26%)
83
(69%)/37 (31%)
NS#
Immunity to P. falciparum 0.0029#
Non-immune 42
(69%)
123
(47%)
N/A
Partially immune 19
(31%)
118
(46%)
N/A
Semi-immune 0
(0%)
3
(1%)
N/A
Unknown 0
(0%)
16
(6%)
Continent of acquisition NS#
Africa, n (%) 56
(92%)
240
(93%)
42
(35%)
Asia, n (%) 3
(5%)
11
(4%)
50
(42%)
South & Central America, n (%) 1
(2%)
5
(2%)
26
(22%)
Unknown, n (%) 1
(2%)
3
(1%)
2
(2%)
Duration of signs/symptoms 0.007#
<8 days, n (%) 38
(62%)
177
(68%)
58
(48%)
8-14 days, n (%) 17
(28%)
45
(17%)
24
(20%)
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Severe 
P. falciparum
n=61
Non-
severe 
P. falciparum
n=259
Non-
falciparum 
n=120
P-value
15-28 days, n (%) 2
(3%)
20
(8%)
11
(9%)
>28 days, n (%) 0
(0%)
5
(2%)
8
(7%)
Unknown, n (%) 4
(7%)
12
(5%)
19
(16%)
Use of malaria chemoprophylaxis <0.0001#
No chemoprophylaxis, n (%) 49
(80%)
182
(70%)
51
(43%)
Inadequate use, n (%) 8
(13%)
46
(18%)
15
(13%)
Adequate use, n (%) 2
(3%)
20
(8%)
42
(35%)
Unknown, n (%) 2
(3%)
11
(4%)
12
(10%)
Vital signs on admission
Body temperature, °C 38.4
(35.7-41.2)
38.5
(35.5-41.0)
38.9
(36.0-41.2)
NS*
Pulse rate, beats per minute 103
(50-150)
90
(45-140)
90
(58-138)
0.0005*
Systolic blood pressure, 
mm Hg
117
(80-160)
120
(73-185)
120
(90-196)
N.T.
Impaired consciousness 
(GCS<15), n (%)
8
(13%)
1
(0%)
0
(0%)
N.T.
Coma (GCS≤11), n (%) 3
(5%)
0
(0%)
0
(0%)
N.T.
Table 1.  Continued
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Severe 
P. falciparum
n=61
Non-
severe 
P. falciparum
n=259
Non-
falciparum 
n=120
P-value
Laboratory data on admission
Haemoglobin, mmol/L 7.8
(2.5-10.9)
8.4
(4.0-11.1)
8.2
(4.6-11.2)
N.T.
Thrombocytes, x 109/L 39
(3-188)
101
(18-293)
95
(10-292)
<0.0001*
C-reactive protein, mg/L 182
(65-476)
85
(5-320)
71
(14-348)
<0.0001*
Serum creatinine, μmol/L 114
(39-1081)
93
(47-238)
90
(53-255)
N.T.
Serum sodium, mmol/L 131
(115-146)
135
(119-145)
135
(124-148)
<0.0001*
Lactate dehydrogenase, U/L 485
(139-2038)
268
(118-947)
246
(127-775)
<0.0001*
Total bilirubin, μmol/L 53
(13-416)
22
(4-164)
22
(3-99)
N.T.
Plasma lactate, mmol/L 2.3
(0.6-6.2)
1.4
(0.5-4.6)
1.3
(0.6-4.0)
<0.0001*
Leukocyte counts
Total leukocyte count, x 109/L 6.9
(2.5-18.5)
4.9
(1.3-13.4)
5.3
(1.9-15.3)
<0.0001*
Neutrophil count, x 109/L 3.6
(0.6-10.4)
3.1
(0.4-11.0)
3.2
(1.0-11.6)
0.0064*
Neutrophil count % 60
(19-85)
64
(13-91)
64
(20-88)
NS*
Lymphocyte count, x 109/L 1.0
(0.2-4.2)
0.9
(0.1-5.0)
1.1
(0.3-6.1)
NS*
Lymphocyte count % 15
(4-45)
19
(2-74)
21
(5-74)
0.0036*
Table 1.  Continued
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Severe 
P. falciparum
n=61
Non-
severe 
P. falciparum
n=259
Non-
falciparum 
n=120
P-value
NLCR 3.5
(0.7-17.0)
3.3
(0.2-46)
2.8
(0.3-17.6)
NS*
Parasite count
P.falciparum load 
(asexual parasites/μL)
230,000 
(520-1,380,600)
4,288
(2-208,000)
N/A N.T.
Presence of P. falciparum 
schizonts (%)
33
(54%)
11
(4%)
N/A <0.0001^
Concomitant infection
All concomitant infections 8
(13%)
11
(4%)
10
(8%)
<0.0001#
Concomitant bacterial
infection
5
(8%)
3
(1%)
2
(2%)
0.004#
* Comparison of 3 groups using the Kruskal Wallis test, # Comparison of 3 groups using the Chi-Square 
Test. ^ Comparison of 2 groups using Fisher’s Exact test. Parameters that are included in the modified 
WHO severity criteria for severe falciparum malaria were not tested (N.T.).
Table 1.  Continued
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Table 2.  Descriptive statistics of diagnostic performance for severe malaria
Parameter Cut-off 
value
Sensitivity Specificity PPV NPV Youden’s AUROC
Total leuko-
cyte count
≥6.5 x 109/L 0.59 
(0.46-0.71)
0.75
(0.71-0.80)
0.28
(0.21-0.37)
0.92
(0.88-0.95)
0.34 0.70
(0.63-0.78)
Neutrophil 
count 
≥3.4 x 109/L 0.64
(0.51-0.76)
0.56
(0.51-0.61)
0.19
(0.14-0.25)
0.91
(0.86-0.94)
0.2 0.61
(0.53-0.69)
Lymphocyte 
count
< 0.7 x 109/L 0.33
(0.22-0.46)
0.72
(0.67-0.76)
0.16
(0.10-0.24)
0.87
(0.83-0.90)
0.05 0.51
(0.43-0.59)
NLCR ≥2.8 0.77
(0.64-0.86)
0.44
(0.39-0.49)
0.18
(0.14-0.24)
0.92
(0.87-0.96)
0.21 0.57
(0.50-0.64)
CRP >141 mg/L 0.80
(0.67-0.89)
0.76
(0.71-0.80)
0.33
(0.25-0.42)
0.96
(0.93-0.98)
0.56 0.84
(0.79-0.89)
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Table 3.  Leukocyte count changes during malaria treatment
On 
admission
Upon 
clearance of 
parasitaemia
n P-value
Severe P. falciparum
  CRP, mg/L 184
(108-373)
49
(1-206)
29 <0.0001
  Total leukocyte count, x 109/L 6.8
(2.5-18.5)
7.8
(3.1-16.4)
40 0.0045
  Neutrophil count, x 109/L 3.5
(1.2-10.4)
4.0
(1.4-10.7)
40 NS
  Lymphocyte count, x 109/L 0.9
(0.2-4.2)
2.1
(0.2-5.8)
40 <0.0001
  NLCR 4.0
(0.9-17.0)
2.1
(0.5-20.3)
40 0.0011
Non-severe P. falciparum
  CRP, mg/L 96
(5-284)
14
(1-250)
116 <0.0001
  Total leukocyte count, x 109/L 4.8
(1.3-13.4)
5.6
(2.2-16.9)
161 <0.0001
  Neutrophil count, x 109/L 3.0
(0.6-8.8)
2.5
(0.3-11.9)
114 0.0075
  Lymphocyte count, x 109/L 0.9
(0.2-3.1)
2.0
(0.3-4.5)
114 <0.0001
  NLCR 3.3
(0.5-19.0)
1.3
(0.3-11.0)
114 <0.0001
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CHAPTER 6
A simple and fast method to exclude 
high Plasmodium falciparum parasitaemia 
in travellers with imported malaria 
106
Abstract
Background: Counts of malaria parasites in peripheral blood are 
important to assess severity of Plasmodium falciparum malaria. Thin and 
thick smears are routinely used for this purpose. 
Methods: In this study the Binax NOW® Malaria Test, an easy-to- 
perform rapid diagnostic test, with Histidine Rich Protein-2 (HRP-2) and 
aldolase as diagnostic markers, was used for semi-quantitative assess-
ment of parasitaemia of P. faciparum. 
Results: In 257 patients with imported P. falciparum malaria, reactivity 
of aldolase increased with higher parasitaemia. In all patients with a 
parasitaemia above 50,000 asexual parasites/ µl (> 1%) co-reactivity 
of HRP-2 and aldolase was observed. Absence of aldolase reactivity in 
the presence of HRP-2 was a reliable predictive marker to exclude high 
(> 1%) parasitaemia in P. falciparum malaria. 
Conclusion: Assessment of HRP-2 and aldolase co-reactivity can be 
of help in clinical decision making in the acute care setting of returning 
travellers suspected of having malaria. 
107
A simple method to exclude high parasitaemia  /  CHAPTER 6
Background
 
The global burden of malaria is largely carried by the world’s malaria-endemic 
regions with as many as 225 million cases and a death toll of more than 750,000 
individuals in 2009 (1). In striking contrast, in non-endemic industrialized coun-
tries malaria is seen as an occasionally imported disease in non-immune trav-
ellers, but it still represents a potentially fatal disease (2, 3). Without prompt and 
proper treatment malaria may rapidly progress to complications and even death. 
Hence, all patients must be assessed for signs or symptoms suggestive of an 
increased risk for complications. Due to unfamiliarity with the disease in non-en-
demic countries, ill-returning travellers frequently present to physicians who have 
no tropical medicine expertise and to primary health care facilities that lack expert 
diagnostic capabilities. As a result, diagnosis of malaria may be delayed or even 
missed, resulting in more severe disease or even fatalities (4, 5).
Recent studies in non-endemic industrialized countries showed that rapid diag-
nostic tests (RDTs) for malaria provide an excellent tool for diagnosis of malaria as 
compared to peripheral blood smears (6). Although highly sensitive in diagnosing 
Plasmodium falciparum malaria, RDTs are not thought to provide sufficient infor-
mation about parasitaemia, one of the major determinants of disease severity 
(1). In the present multi-centre operational laboratory study it is shown that the 
FDA approved three-band immunochromographic RDT Binax NOW® Malaria 
Test allows a semi-quantitative assessment of parasitaemia and rapid exclusion 
of high P. falciparum parasitaemia, which may facilitate clinical decision making in 
the acute care setting. 
Methods
In order to assess the utility of this RDT as a semi-quantitative measure of P. 
falciparum load in routine clinical practice, an operational laboratory study was 
conducted at two hospital-based laboratories with expertise in malaria diagnosis 
in The Netherlands (Academic Medical Center, Amsterdam, The Netherlands; 
Harbour Hospital, Rotterdam, The Netherlands). Of all patients detailed demo-
graphic, clinical and laboratory data were available, as well as the outcome 
measures severe malaria and death. Severe malaria was diagnosed according 
to predefined WHO criteria in travellers (7). In both Dutch centres, parasitaemia 
was examined using the same protocol. Thick and thin smears were stained with 
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Giemsa (Giemsa improved R66 Gurr, BDH, diluted 1:10, PH 7,2, 30 min.) For an 
initial estimate of the parasite load, malaria thin smears were examined by light 
microscopy (100x objective and 12,5 ocular lens). If the parasitaemia was assumed 
to be ≤0.5% infected red blood cells, the exact parasite load was determined by 
counting the number of asexual parasites per 100 leukocytes in a thick smear. In 
case the initial parasitaemia was assumed to be 0.5-2.0%, the number of infected 
red blood cells was counted in 10 visual fields of a thin smear. The number of red 
cells per microscopic field in a thin smear was pre-calculated for the different 
microscopes in use. In case the initial parasitaemia was assumed to be >2.0%, 
the number of infected red blood cells was determined using a special ocular 
lens with a visual field area reduced to approximately 25%. Within this limited field 
of view both the total number of red blood cells and the number of infected red 
blood cells were counted in at least 10 visual fields. All counts were performed in 
duplicate and the final count was given as the average. In case of a discrepancy 
of >15% between the duplicate counts, a third count was performed. The number 
of asexual parasites/μl was finally calculated using the actual number of erythro-
cytes or leukocytes in a blood sample. 
The RDTs were performed on fresh blood samples, simultaneously with micros-
copy of the blood slides. Every RDT and blood slide was read by two independent, 
experienced laboratory technicians. The Binax NOW® Malaria Test was used as 
RDT and performed according to the manufacturer’s instructions. The Binax 
NOW® Malaria Test uses monoclonal antibodies that target the histidine-rich 
protein 2 (HRP-2) antigen specific to P. falciparum (the ’T1’ line) and the pan-ma-
larial antigen aldolase (the ‘T2’ line), common to all five Plasmodium species that 
can be detected in humans (P. falciparum, Plasmodium vivax, Plasmodium ovale, 
Plasmodium malariae and Plasmodium knowlesi) (8). Aldolase co-reactivity was 
defined as both a reactive HRP-2 line (T1 line) as well as a reactive aldolase line 
(T2 line). Absence of aldolase co-reactivity was defined as a non-reactive aldo-
lase (T2) but a reactive HRP-2 (T1) line (Figure 1).
For external validation of the reproducibility of the RDT findings in the Dutch 
centers, a reference center for malaria diagnosis participated (Institute of Tropical 
Medicine (ITM), Antwerp, Belgium). In this setting in thick and thin blood films, 
stained with Giemsa (Merck 1.09204.0500, diluted to 3.5% in pH 8.0, 20 min.), 
parasite densities were determined by counting asexual parasites against 200 
white blood cells (WBC) in thick blood films and converting this number to para-
sites/μl using the actual white blood cell count (9). Parasite densities were next 
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converted to % infected red blood cells using the red blood cell count. For the 
purpose of this study, ITM provided RDT findings in relation to the parasite loads 
of 73 consecutive patients, but did not contribute to the clinical data.
Results
A total of 257 patients with P. falciparum malaria were included. All patients had 
HRP-2 reactivity in the Binax NOW® Malaria Test. The general characteristics 
and laboratory findings of 184 evaluable patients from Amsterdam (Academic 
Medical Center) and Rotterdam (Harbour Hospital) are provided in Table 1. The 
23 patients with severe malaria presented with impaired consciousness in seven 
(three of them had a Glasgow Coma Score score < 11), severe anaemia in two, 
hyperbilirubinaemia in 12 and renal failure in three cases. Eleven patients had a 
parasitaemia > 5% (4 of them had a parasitaemia > 10%). Five patients received 
haemodialysis and one patient died. Of the 73 Belgian patients no clinical data 
were available. 
Co-reactivity of HRP-2 and aldolase was observed in blood specimens with 
both low and high parasitaemia, ranging from 56 to 558,000 (Amsterdam), 23 
to 1,380,600 (Rotterdam) and 26 to 400,000 asexual parasites/µl (Antwerp), 
respectively. The proportion of aldolase co-reactivity substantially increased with 
increasing parasitaemia (Figure 2). Aldolase co-reactivity was always present 
when parasitaemia was above 50,000 asexual parasites/μl (corresponding to 
approximately 1 % parasitized erythrocytes). This observation was valid not only 
in the centers in Rotterdam and Amsterdam, but also in the laboratory setting of 
Antwerp. All patients with severe malaria (n=23) invariably showed HRP-2 and 
aldolase co-reactivity. Hence, aldolase co-reactivity with HRP-2 had a sensitivity 
of 100% (95% confidence interval 85 –100%) for severe malaria, but a poor posi-
tive predictive value (PPV) of only 21% (95% CI 11-25%), since aldolase co-reac-
tivity was also present in 109 patients with uncomplicated malaria. In contrast, 
absence of aldolase reactivity (n=52) had a negative predictive value (NPV) of 
100% (95% CI 93 – 100%) for severe malaria. The implications of the RDT test 
outcomes for clinical decision- making are shown in Figure 1.
110
Discussion
The results of the present study indicate that the Binax NOW® Malaria Test allows 
a semi-quantitative assessment of parasitaemia in travellers returning with P. falci-
parum malaria. 
The combination of HRP-2 reactivity (T1) in absence of aldolase reactivity (T2), 
proved a reliable predictive marker for a low (< 1%) P. falciparum parasitaemia. In 
the current study population HRP-2 reactivity without aldolase reactivity was 
applicable to 30% of returning travellers with P. falciparum. When clinical findings 
and routine laboratory results in these patients also are not indicative of severe 
disease, the patient most likely has uncomplicated malaria. This knowledge is 
important for further clinical decision-making. 
Co-reactivity of aldolase and HRP-2 was present in all patients with a parasi-
taemia above 50,000 asexual parasites/μl (corresponding to approximately 
1% infected red blood cells). Others reported co-reactivity with Binax NOW® in 
80% of patients with P. falciparum parasitaemia > 40,000 parasites/µl (9). The 
authors suggested co-reactivity of HRP-2 and aldolase possibly could func-
tion as a semi-quantitative marker of high P. falciparum parasitaemia (10). In the 
present study this relation proved, however, not straightforward with co- reactivity 
of HRP-2 and aldolase also being present in patients with low parasitaemia (i.e. 
< 0.5%). As such co-reactivity of HRP-2 and aldolase is less reliable as marker for 
high parasitaemia.. 
The data of the present study suggest that aldolase and HRP-2 co-reactivity is 
present in all patients with severe malaria. Apparently HRP-2 and aldolase reac-
tivity, which depends on the load of these antigens in the blood specimen, is 
preserved because these antigens are derived not only from circulating viable and 
non-viable malaria parasites, but also from sequestered parasites that are abun-
dantly present in severe malaria. As a consequence of this sequestration, micro-
scopic determination of peripheral blood smears might underestimate the total 
parasitaemia. 
The relation between aldolase reactivity and P. falciparum parasitaemia, as 
observed with Binax NOW® in this study, could be dependent of the process of 
manufacturing. Other RDTs with a similar three-band configuration, therefore, 
should be studied in detail, to assess about the precise relationship between P. 
falciparum parasitaemia and aldolase reactivity. 
HRP-2 and aldolase co-reactivity may also be a feature of a mixed Plasmodium 
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infection. In a recent study of 2,847 cases of imported malaria in the Netherlands 
(11), 75% of the infections were solely caused by P. falciparum whereas the 
remainder was caused by P. vivax (15%), P. ovale (7%), and P. malariae (3%), respec-
tively. Only 0,7% of all infections was attributable to mixtures of species, mostly 
involving P. falciparum. Thus, in the Dutch setting, HRP-2 and aldolase co-reac-
tivity is far more likely to reflect a mono-parasitic P. falciparum infection rather 
than a mixed infection. 
Results of RDT’s may facilitate clinical decision making in patients suspected of 
having malaria. There are however also some drawbacks to consider. First, these 
tests cannot replace clinical assessment of the ill-returning patient and results 
of RDT tests should always be confirmed by thin or thick blood smears, including 
parasite counts in case of P. falciparum malaria (6, 12). Second, the diagnostic 
power of this RDT test is dependent on the epidemiological setting, in particular 
the prevalence of the disease. The current findings may not simply be extrapolated 
to regions of malaria endemicity where low-grade malaria infections are far more 
prevalent and empirical anti-malarial treatment is common use, which may lead 
to false-negative and false-positive RDT findings, respectively. In addition, the 
majority of the travellers in this study contracted P. falciparum infection in Africa; 
other malaria-endemic continents like South-East Asia and South-America were 
underrepresented. Caution is warranted with extrapolating the applicability of the 
current findings to imported malaria acquired outside Africa. False negative results 
have been suggested for certain genetic polymorphisms of HRP-2 geographically 
confined to the Asia-Pacific region (13) and for P. falciparum isolates from South 
America lacking HRP-2 (14). In addition, false negative test results may occur at 
high parasitaemia due to a so-called prozone effect, defined as false-negative or 
false-low results in immunological reactions due to an excess of either antigens or 
antibodies. The prozone effect was observed for HRP-2 in 16 of 17 RDTs (including 
the Binax NOW® Malaria Test), resulting in a false low HRP-2 signal, whereas aldo-
lase reactivity was not affected (15). Finally, the clinician must also consider the 
possibility of a P. knowlesi infection, which may give rise to severe disease and fatal 
complications as well (8). Even though early reports suggested that RDTs may not 
detect P. knowlesi infections, later studies demonstrated that P. knowlesi was reac-
tive with the aldolase band in the Binax NOW® Malaria Test, but not with HRP-2 
and that aldolase reactivity depended on the P. knowlesi parasitaemia (8).
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Conclusion
In conclusion, the RDT Binax NOW® Malaria Test allows a rapid semi-quantitative 
assessment of P. falciparum load in travellers with malaria returning from the 
tropics, especially for exclusion of high (>1%) parasitaemia in the acute care 
setting. This may facilitate clinical decision making for subsequent oral anti- 
malarial treatment or timely referral to a specialized centre for high-level moni-
toring and intensified parenteral treatment.
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Table 1.  General characteristics and laboratory findings at initial clinical 
   assessment of 184 patients with P. falciparum malaria
Parameter Amsterdam (AMC) Rotterdam (HZH)
Number of patients, n 77 107
Male/female 52/25 78/29
Age, median (range,) yrs 37 (0 – 61) 40 (16 – 70)
Purpose of travel
Immigrant, n (%) 4 (5.2) 0 (0.0) 
Visiting friends and relatives, n (%) 48 (62.3) 36 (33.6) 
Tourist, n (%) 6 (7.8) 20 (18.7) 
Business, n (%) 10(13.0) 27 (25.2) 
Expatriate, n (%) 0 (0.0) 4 (3.7) 
Sailor, n (%) 0 (0.0) 4 (3.7) 
Unknown, n (%) 9 (11.7) 11 (10.3)
Continent of acquisition
Africa, n (%) [West-Africa, n (%)] 73 (94.8) [63 (81.8)] 101 (94.9) [71 (66.4)]
South-America, n (%) 2 (2.6) 1 (0.9)
South East Asia, n (%) 2 (2.6) 7 (6.5)
Clinical assessment  
Severe malaria, n (%) 7 (9.1) 16 (15.0)
Non-severe malaria, n (%) 70 (90.9) 91 (85.0) 
Laboratory findings
Parasite load, median range, trophozoites/μL 4648 (50 – 558000) 10664 (2 – 1380600)
Malaria Now 77 (100) 107 (100)
HRP-2 and aldolase co-reactivity, n (%) 54 (70.1) 78 (72.9)
HRP-2 reactivity, n (%) 23 (29.9) 29 (27.1)
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HRP-2 (T1 line) reactivity
• No aldolase (T2 line) reactivity
• P. falciparum parasitaemia 
 < 1% or < 50.000 asexual parasites / μL
Aldolase co-reactivity (T1 + T2 line)
• P. falciparum parasitaemia variable
• Generally present in severe disease
Figure 1. Interpretation of the Binax NOW® Malaria test results in patients with 
   P. falciparum infection, related to microscopic parasitaemia. 
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Figure 2.  Co-reactivity of aldolase and HRP-2 bands in Binax NOW® Malaria 
   rapid diagnostic test in relation to P. falciparum parasitaemia. 
Aldolase co-reactivity was consistently present at a parasitaemia above 50,000 asexual parasites/μl, 
but variably present at lower parasitaemia indicating that absence of aldolase co-reactivity always was 
associated with a parasitaemia ≤ asexual 50,000 parasites/μl. The RDT findings (absence or presence 
of aldolase co-reactivity) of the participating three centres are shown in relation to category of parasi-
taemia and expressed as mean ± SD. The number of patients per category of parasitaemia is given within 
each respective bar. 
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CHAPTER 7
The prognostic value of 
schizontaemia in imported 
Plasmodium falciparum malaria
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Abstract
Background: In Plasmodium falciparum infection, peripheral para-
site counts do not always correlate well with the sequestered parasite 
burden. As erythrocytes parasitized with mature trophozoites and schi-
zonts have a high tendency to adhere to the microvascular endothe-
lium, they are often absent in peripheral blood samples. The appear-
ance of schizonts in peripheral blood smears is thought to be a marker 
of high sequestered parasite burden and severe disease. In the present 
study, the value of schizontaemia as an early marker for severe disease in 
non-immune individuals with imported malaria was evaluated.
Methods: All patients in the Rotterdam Malaria Cohort diagnosed with 
P. falciparum malaria between 1 January 1999 and 1 January 2012 were 
included. Thick and thin blood films were examined for the presence of 
schizontaemia. The occurrence of WHO defined severe malaria was the 
primary endpoint. The diagnostic performance of schizontaemia was 
compared with previously evaluated biomarkers C-reactive protein and 
lactate.
Results: Schizonts were present on admission in 49 of 401 (12.2%) 
patients. Patients with schizontaemia were more likely to present with 
severe malaria, a more complicated course and had longer duration of 
admission in hospital. Schizontaemia had a specificity of 0.95, a sensi-
tivity of 0.53, a negative predictive value of 0.92 and a positive predictive 
value of 0.67 for severe malaria. The presence of schizonts was an inde-
pendent predictor for severe malaria. 
Conclusion: Absence of schizonts was found to be a specific marker 
for exclusion of severe malaria. Presence of schizonts on admission 
was associated with a high positive predictive value for severe malaria. 
This may be of help to identify patients who are at risk of a more severe 
course than would be expected when considering peripheral parasi-
taemia alone.
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Background
Sequestration of infected erythrocytes in the microvasculature is one of the main 
pathological features of severe Plasmodium falciparum infection (1-4). Particularly, 
erythrocytes parasitized with mature trophozoites and schizonts have a high 
tendency to adhere to the microvascular endothelium and are therefore often 
absent in collected peripheral blood samples. However, the appearance of schi-
zonts in peripheral blood smears is thought to reflect a high sequestered parasite 
burden and was recognized as a sign of severe disease already in early field studies 
on malaria (5). The predominance of mature parasites on peripheral smears was 
found to reflect more severe disease by Silamut and White (6), but only a few other 
studies on the performance of schizontaemia as a predictor for severe disease 
have been done (7-9). In addition, data is only available from studies in areas with 
malaria endemicity where many inhabitants are believed to have some degree of 
immunity toward malaria (so-called semi-immunity). Data in non-immune indi-
viduals are lacking.
Although it is stated in the current WHO malaria guidelines that the presence of 
schizontaemia may be associated with a poor outcome in P. falciparum malaria, 
presence of schizonts is currently not a well-established WHO criterion for severe 
disease (9, 10). To further explore the value of schizontaemia as an early marker 
for severe disease in non-immune individuals with imported malaria, the prog-
nostic value of schizontaemia was assessed in a large cohort of travellers with P. 
falciparum malaria. 
Methods
Patients
The Harbour Hospital is a 161-bed general hospital located in Rotterdam, The 
Netherlands. It comprises the Institute of Tropical Diseases, which serves as a 
national referral centre. All patients in the Rotterdam Malaria Cohort diagnosed 
with P. falciparum malaria between 1 January 1999 and 1 January 2012 were 
included in this observational study. Of all patients identified, demographic, clin-
ical and laboratory data were collected using a standardized form and stored 
in an electronic database. Patients with a mixed infection of P. falciparum with 
another Plasmodium species were included in this study, but pure non-falciparum 
Plasmodium infections were excluded. Multiple malaria episodes in a single patient 
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were only regarded as separate cases if caused by true re-infection; recrudescent 
infections of P. falciparum were excluded. 
Laboratory investigations
Available laboratory examinations included red and white blood cell counts, 
haematocrit, platelet counts, C-reactive protein, serum electrolytes, total bilirubin, 
serum creatinine and urea, sodium, potassium, liver enzymes, blood glucose and 
venous plasma lactate. 
Detection of Plasmodium parasites 
The standard procedure to diagnose malaria comprised a quantitative buffy coat 
(QBC) analysis, a rapid diagnostic test (RDT) for malaria antigens Binax NOW 
Malaria Test (Binax, Inc, Maine, USA), and thick and thin blood smears using 
freshly collected blood specimens from finger pricks. The malaria rapid test and 
the QBC analysis were performed according to the manufacturer’s instructions. 
QBC capillaries were examined independently by two technicians by microscopic 
analysis of two complete rows of the region between the bottom of the capil-
lary and the polynuclear leukocyte layer using an Olympus BX-60 fluorescence 
microscope equipped UV- filter and 50x objective and 12.5x oculars (total magni-
fication 625x). These two lanes represented about 100 microscopic fields (at 625x 
magnification) and took an average examination time of 5 min. Subsequently, the 
polynuclear and mononuclear cell layer was screened for schizonts, gametocytes, 
malaria pigment and elderly tro- phozoites of Plasmodium vivax and Plasmodium 
ovale. 
Thick blood smears were stained with Field’s stain (Brunschwig Chemie, 
Amsterdam, The Netherlands) and thin smears with Diff Quick stain (Medion 
Diagnostics, Düdingen, Switzerland). Both staining procedures had been opti-
mized for optimal staining of Plasmodium parasites as well as Schüffner’s dots and 
Maurer’s clefts in infected erythrocytes. Thick and thin smears were examined 
with regular light microscopes at a total mag- nification of 1,250x. The Plasmodium 
species was identified on morphological characteristics in the thin and thick 
blood smears. Since a real-time quantitative PCR became available several years 
ago, a substantial proportion of the samples were additionally confirmed by PCR 
(without discrepant findings compared to classic light microscopy). 
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Parasite counting and identification of Plasmodium falciparum 
schizonts
Parasitaemia was determined by parasite counting as described before (11). 
Plasmodium falciparum schizonts were defined as clustered malaria pigment adja-
cent to two or more nuclei of P. falciparum in thick blood smears or QBC capil-
laries. Compared to thin and thick blood smears QBC analysis is the most sensi-
tive test to detect Plasmodium parasites. Plasmodium falciparum schizonts can be 
identified in the erythrocyte layer in the QBC capillary, but identification within 
the leukocyte layer is difficult due to the intense fluorescent signal of the leuko-
cyte nuclei. For this reason, this layer is also screened for quenched fluorescence 
by malaria pigment. If malaria pigment was detected in the leukocyte layer of the 
QBC capillary, the thick and thin blood smears were thoroughly examined for 
the presence of schizonts by analysis of at least 200 microscopic fields at 625x 
magnification. 
Definitions
Severe malaria 
Patients were classified as having severe malaria if they met one or more of the 
WHO criteria for severe malaria, as published [9], either on presentation or later 
during hospital admission.
Schizontaemia
Schizontaemia was defined as presence of one or more P. falciparum schizonts 
identified in QBC and/or blood smear examinations from a blood sample taken 
on admission.
Immunity to malaria. 
The degree of immunity to malaria was estimated as previously described (12). In 
brief, adult immigrants from a malaria-endemic country living in The Netherlands 
were considered partially immune. Immigrant patients who had been living in a 
malaria-endemic area for at least two years at the time of diagnosis were presumed 
semi-immune. Tourists from non-endemic countries who travelled to malaria-en-
demic regions were considered non-immune.
Statistical analysis. 
All data were not normally distributed (Kolmogorov-Smirnov test) and are there-
fore presented as medians and range. Univariate comparisons were performed 
using the Mann-Whitney U test and the Fisher’s Exact test. Trends between 
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categorical variables were done with the Chi square test for Trend. Odds ratios 
were calculated using the approximation of Woolf. For clinical reference, the diag-
nostic performance of schizontaemia for severe disease was compared to that 
of the classic biomarkers serum C-reactive protein and plasma lactate (13-15). 
Binary logistic regression analysis was used to analyse if schizontaemia was inde-
pendently associated with malaria severity. Malaria severity was entered as the 
dependent variable. To test its independence from parasite load and the previ-
ously evaluated markers lactate and C-reactive protein, these were entered as 
co-variants. As parasite load was a highly skewed continuous variable with a loga-
rithmic distribution, the data were transformed to log-parasitaemia to make them 
suitable for logistic regression analysis. 
Results
Patient characteristics
Between 1 January 1999 and 1 January 2012, a total of 562 cases of imported 
malaria were seen. Of these cases, 161 cases were caused by non-falciparum 
Plasmodium species; 401 infections were caused P. falciparum infections including 
three patients who had a mixed infection (two with P. falciparum and P. ovale, one 
with P. falciparum and P. vivax, respectively). No patient with a mixed P. falciparum 
infection presented with schizontaemia on admission. These 401 patients with 
either a pure P. falciparum infection or a mixed Plasmodium infection with P. falci-
parum were included in this study. 
Schizontaemia
Schizonts were present on admission in 49 of 401 (12.2%) patients. The general 
characteristics of the patients with presence and absence of schizonts on admis-
sion are shown in Table 1. Males were less likely to present with schizontaemia 
than female patients (Odds ratio 0.37 (95% confidence interval 0.20-0.67), p 
= 0.0018). Although the number of patients who acquired P. falciparum malaria 
outside of Africa was relatively low (n = 26), these patients tended to present with 
schizontaemia more frequently than patients who contracted malaria in Africa 
(Odds ratio 0.26 (95% CI 0.086-0.79), p = 0.0259). There were no differences 
between patients presenting with and without schizontaemia with regard to 
their immune status, ethnic background and use of malaria chemoprophylaxis, 
nor did they differ in duration of symptomatology. As detailed in Table 1, patients 
with schizontaemia presented more ill on admission: they had higher pulse rates, 
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were more likely to have impaired consciousness and laboratory parameters were 
compatible with more severe degree of liver and kidney injury as well as more 
compromised tissue perfusion given the higher plasma lactate levels. Other labo-
ratory parameters revealed that patients with schizontaemia also presented with 
significantly higher parasite loads, higher leucocyte counts, higher C-reactive 
protein levels and significantly lower platelet counts. When the WHO severity 
criteria for malaria (9) were assessed in both patient groups, patients with schi-
zontaemia were more likely to present with or develop severe and complicated 
disease and they had to stay significantly longer in hospital than patients without 
demonstrable schizontaemia on admission (Table 2). Death occurred in two of 
401 malaria patients, one with and one without schizontaemia on ad- mission. 
Presence of schizontaemia on admission significantly increased with increasing 
parasite loads on admission (Chi square test for Trend, p < 0.0001), as shown in 
Figure 1. 
The diagnostic accuracy of schizontaemia as a predictor for severe malaria was 
characterized by a high specificity, negative predictive value and an acceptable 
positive predictive value. When compared to the performance of plasma lactate, 
schizontaemia had a lower sensitivity but a higher specificity and positive predic-
tive value for severe disease. When compared to the performance of C-reactive 
protein, schizontaemia had a higher specificity and positive predictive value for 
severe disease (Table 3). Using binary logistic regression analysis, schizontaemia 
was found to be an independent predictor for severe malaria with odds ratios 
substantially exceeding that found for C-reactive protein and lactate but not that 
found for parasite load (Table 4). 
Discussion
Sequestration of parasitized erythrocytes in the microvasculature of vital organs 
is a cardinal feature of P. falciparum malaria and is a cause of major pathology in 
severe disease (1-4). Maturing P. falciparum parasites disappear from the periph-
eral blood after 24-26 hours to complete the asexual life cycle in the microvas-
culature, as the tendency to adhere to the endothelial wall increases during the 
maturation process (6). This process of sequestration accounts for the fact that 
peripheral parasite counts do not always correlate well with the sequestered 
parasite burden. This discrepancy was noted soon after the use of the peripheral 
parasitaemia to predict the outcome of P. falciparum infection became common 
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practice in the 1930s (5).
In the microvasculature, rupturing schizonts release up to 32 merozoites (7, 16), 
causing an exponential rise in parasitaemia. A high schizont count is therefore 
likely to precede a rise in parasitaemia and might be an early marker for severe 
disease . As compared to quinine, artemisinin derivatives like artesunate have 
an anti-malarial efficacy to the broadest spectrum of parasite stages, including 
the generally less drug-sensitive schizonts (1, 7). This may provide another argu-
ment to treat patients with schizontaemia with artemisinin derivatives given the 
convincing proof of past studies in regions of malaria endemicity showing that 
artesunate was superior over quinine for treatment of severe malaria in both chil-
dren and adult patients (17, 18), not only in terms of reduction of mortality and 
parasite clearance but also in ease of use. Recent studies in non-endemic indus-
trialized regions confirmed that in non-immune travellers with imported malaria, 
treatment with artesunate results in a comparable rapid parasite clearance to that 
observed in semi-immune individuals (19, 20). 
In the present study schizontaemia was found to be a useful marker for severe 
malaria. Although schizontaemia was more frequently seen in patients with high-
grade parasitaemia, the predictive power appeared to be independent of parasi-
taemia. In the study by Silamut and White (6) in adult Thai patients and children 
from The Gambia, it was demonstrated that a predominance of mature parasite 
forms in the peripheral blood reflect a greater sequestered parasite mass and the 
presence of >10 4 mature trophozoites and schizonts per μL of peripheral blood was 
found to have a high sensitivity (90%) and specificity (70%) for fatal outcome. The 
data of the present study confirm the prognostic value of schizontaemia for severe 
disease in predominantly non-immune travellers, comparable to that observed 
in semi-immune patients in region of malaria endemicity. However, it should be 
noted that besides differences in presumed immunity towards malaria, the current 
study also differed in its design with regard to outcome. In many studies in malar-
ia-endemic regions, the primary outcome measure is usually survival or death and 
studies are restricted to these severe cases using the WHO severity criteria as an 
entry criterion. Since case fatalities are less common in the western non-endemic, 
resource-rich setting (12) and malaria is only seen as a sporadic imported disease, 
the present study in patients with imported malaria focused on severe disease as 
the primary outcome, using the WHO criteria to define disease severity. 
Unfortunately, for the present study quantitative counts of the different parasite 
stages were not available. Although quantification would likely have resulted in a 
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more precise estimation of its prognostic value, the specificity of schizontaemia 
was found to be a useful tool for exclusion of severe disease. The negative predic-
tive value of schizontaemia is high, and comparable to that of CRP and lactate. 
Moreover, unlike C-reactive protein and lactate (13-15) schizontaemia on admis-
sion was also associated with a high positive predictive value. This may provide 
the clinician with a helpful tool for decision making in the acute care setting by 
allowing an early identification of those malaria patients who are at risk of a more 
severe and complicated course than would normally be expected when consid-
ering peripheral parasitaemia alone. 
Conclusion
Absence of schizonts on admission in travellers with imported P. falciparum 
malaria was found to be a specific marker for exclusion of severe disease; in 
contrast, presence of schizonts had a high positive predictive value for presence 
of severe disease and can thus help to identify patients that may be candidates in 
need of intensive monitoring and timely administration of preferably (parenteral) 
artemisinin derivatives. 
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Table 1. General characteristics of patients with imported Plasmodium falci-
   parum malaria grouped by presence or absence of schizontaemia on 
   admission
All patients Schizontaemia No schizontaemia P-value
n=401 n=49 n=352
Demographics
Age, years 39 (4-78) 41 (4-70) 39 (5-78) NS
Male, female, n (%) 292 (72.8), 
109 (27.2)
26 (53.1), 
23 (46.9)
266 (75.6), 
86 (24.4)
0.0018
Continent of acquisition 
Africa, n (%) 360 (89.8) 38 (77.6) 322 (91.5) 0.0196
Asia, n (%) 16 (4.0) 5 (10.2) 11 (3.1)
South and Central 
America, n (%)
10 (2.5) 3 (6.1) 7 (2.0)
Unknown, n (%) 15 (3.7) 3 (6.1) 12 (3.4)
Duration of signs/symptoms
<8 days, n (%) 259 (64.6) 30 (61.2) 229 (65.1) NS
8-14 days, n (%) 74 (18.5) 15 (30.6) 59 (16.8)
15-28 days, n (%) 27 (6.7) 0 (0) 27 (7.7)
>28 days, n (%) 8 (2.0) 0 (0) 8 (2.3)
Unknown, n (%) 33 (8.2) 4 (8.2) 29 (8.2)
Use of malaria chemoprophylaxis
No chemoprophylaxis, n 
(%)
272 (67.8) 35 (71.4) 237 (67.3) NS
Inadequate use, n (%) 72 (18.0) 6 (12.2) 66 (18.8)
Adequate use, n (%) 39 (9.7) 6 (12.2) 33 (9.4)
Unknown, n (%) 18 (4.5) 2 (4.1) 16 (4.5)
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All patients Schizontaemia No schizontaemia P-value
n=401 n=49 n=352
Vital signs on admission
Body temperature, °C 38.5 
(35.5-41.2)
38.7 
(35.7-41.2)
38.5 
(35.5-41.0)
NS
Pulse rate, beats per 
minute
95 (45-150) 105 (68-150) 92 (45-150) 0.0002
Systolic blood pressure, 
mm Hg
120 (64-190) 118 (64-160) 120 (73-190) NS
Impaired consciousness 
(GCS<15), n (%)
9 (2.2) 5 (10.2) 4 (1.1) 0.0019
Cerebral malaria (GCS≤11), 
n (%)
5 (1.2) 2 (4.1) 3 (0.9) NS
Laboratory data on admission
Haemoglobin, mmol/L 8.3 (2.5-11.1) 7.8 (3.8-10.9) 8.4 (2.5-11.1) NS
Leucocyte count, x 109/L 5.1 (1.3-18.5) 6.1 (2.5-18.5) 5.0 (1.3-13.4) 0.011
Thrombocytes, x 109/L 86 (2-385) 38 (10-164) 94 (2-385) <0.0001
C-reactive protein, mg/L 98 (5-476) 166 (22-476) 87 (5-373) <0.0001
Serum creatinine, μmol/L 95 (39-1,081) 110 (39-1,081) 95 (47-871) 0.0019
Serum sodium, mmol/L 135 (115-146) 132 (115-142) 135 (119-146) <0.0001
Lactate dehydrogenase, 
U/L
275 
(118-2,297)
435 
(135-2,038)
262 
(118-2,297)
<0.0001
Total bilirubin, μmol/L 24 (4-416) 44 (9-269) 23 (4-416) <0.0001
Plasma lactate, mmol/L 1.6 (0.5-6.2) 2.7 (0.6-6.2) 1.5 (0.5-4.7) <0.0001
 Parasite count
P. falciparum load 
(asexual parasites/μL)
8,400
(2-1,380,600)
162,000 
(144-1,380,600)
5,430 
(2-860,000)
<0.0001
Gametocytes, presence, 
absence, n (%)
64 (16.0), 
337 (84.0)
11 (22.4), 
38 (77.6)
53 (15.1), 
299 (84.9)
NS
Table 1. Continued
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Table 2.  Outcome measures of patients with imported Plasmodium falciparum 
   malaria, grouped by presence or absence of schizontaemia on admission
All 
patients 
(n=401)
Schizontaemia 
(n=49)
No 
schizotaemia
(n=352)
P-value Odds ratio 
(95% CI)
Case-fatalities, n (%) 2 
(0.5)
1 
(2.0)
1 
(0.3)
NS
Severe malaria, n (%) 62 
(15.5)
33
(67.3)
29 
(8.2)
<0.0001 23.0 
(11.3-46.6)
ICU admission, n (%) 92 
(22.9)
38 
(77.6)
54 
(15.3)
<0.0001 19.1 
(9.2-39.6)
Exchange transfusion, n (%) 40 
(10.0)
26 
(53.1)
14 
(4.0)
<0.0001 27.3 
(12.6-59.2)
Renal replacement therapy, 
n (%)
7 
(1.7)
4 
(8.2)
3 
(0.9)
0.0053 10.3 
(2.2-47.7)
Mechanical ventilation, n (%) 4 
(1.0)
3 
(6.5)
1 
(0.3)
0.0063 22.9 
(2.3-224.8)
Time in hospital, days (range) 5 
(0-56)
7 
(0-56)
5 
(0-19)
<0.0001
Table 3.  Descriptive statistics of schizontaemia, lactate and C-reactive protein 
   as predictors for severe malaria
Schizontaemia
(presence or absence)
Plasma lactate
(mmol/L)
C-reactive protein 
(mg/L)
Number 401 240 381
Median (range) N/A 1.6 (0.5-6.2) 98 (5-476)
Mean N/A 1.9 111
Standard deviation N/A 1.05 78
Optimal cut-off N/A ≥1.7 ≥142
Sensitivity 0.53 (0.40-0.66) 0.80 (0.67-0.89) 0.76 (0.63-0.86)
Specificity 0.95 (0.92-0.97) 0.63 (0.55-0.70) 0.75 (0.70-0.80)
Youden’s index 0.48 0.43 0.51
PPV 0.67 (0.52-0.80) 0.39 (0.30-0.49) 0.35 (0.27-0.45)
NPV 0.92 (0.88-0.94) 0.91 (0.85-0.95) 0.95 (0.91-0.97)
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Table 4. Results of binary logistic regression analysis of explanatory variables 
   for severe malaria
β S.E. β Wald’s χ df P-value Odds ratio (95% CI)
C-reactive protein 0.01 0.04 8.326 1 0.004 1.01 (1.00-1.02)
Log parasitaemia* 2.65 0.56 22.325 1 <0.001 14.13 (4.71-42.38) 
Plasma lactate 0.42 0.27 3.564 1 NS 1.52 (0.89-2.57)
Schizontaemia 1.87 0.62 9.024 1 0.003 6.52 (1.92-22.13)
Constant -16.63 2.93 32.133 1 <0.001 N/A
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Figure 1. The percentage of patients with schizontaemia on admission,
   stratified by peripheral parasite count.
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CHAPTER 8
Acute kidney injury in imported 
Plasmodium falciparum malaria
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Abstract
Background: Acute kidney injury (AKI) is a known complication of 
malaria, and is reported to occur in up to 40% of adult patients with a 
severe Plasmodium falciparum infection in endemic regions. To gain 
insight in the incidence and risk factors of AKI in imported P. falciparum 
malaria, a retrospective analysis was performed on a large cohort of 
mostly non-immune patients with imported P. falciparum malaria. 
Aiming to include not only severe but also milder forms of renal failure, 
the KDIGO criteria were used to define AKI. 
Methods: Clinical and laboratory data from 485 consecutive cases 
of imported P. falciparum malaria were extracted from the Rotterdam 
Malaria Cohort database. Acute kidney injury (AKI) was defined using 
the KDIGO criteria. Univariate and multivariate logistic regression anal-
yses were used to identify risk factors for AKI..
Results: AKI was seen in 39 (8%) of all patients and in 23 (38%) of the 
61 patients with severe malaria. Eight patients eventually needed renal 
replacement therapy (RRT); seven of them already had AKI at presen-
tation. Higher age, higher leucocyte count and thrombocytopenia were 
independently associated with AKI but their positive predictive values 
were relatively poor. 
Conclusion: AKI was found to be a common complication in adults 
with imported P. falciparum necessitating RRT in only a small minority 
of patients. The use of the KDIGO staging allows early recognition of a 
decline in renal function.
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Background
Acute kidney injury (AKI) is associated with a risk of chronic kidney disease and 
high mortality (1-3). The clinical course of Plasmodium falciparum malaria may 
be complicated by AKI, contributing to the high mortality rate of severe malaria 
(4). The pathogenesis of AKI in malaria is still not clearly understood. Blockage 
of renal microcirculation due to sequestration of infected erythrocytes, immune- 
mediated glomerular injury and volume depletion are some of the proposed 
hypotheses (4, 5). The main histopathological finding in malaria-associated AKI 
is acute tubular necrosis (ATN) with reports of interstitial nephritis and glomeru-
lonephritis (4-7). In malaria-endemic regions, AKI can occur in up to 40% of adult 
patients with severe P. falciparum malaria, and it is associated with a mortality as 
high as 75% when renal replacement therapy (RRT) is not started in time (8-11). In 
non-immune travellers with severe P. falciparum infection, AKI is reported to occur in 
34 to 52% of cases (12-15). In these studies, AKI is usually defined according to the 
WHO criteria for severe malaria, in which the creatinine threshold is preset at 265 
μmol/L (13-15). Using this relatively high threshold, less severe forms of renal failure 
are not taken into account. The present study, a retrospective analysis on a large 
cohort of patients with both severe and non-severe imported P. falciparum malaria, 
was designed to include these milder forms of renal failure in the analysis. To detect 
these, the criteria set by the Kidney Disease: Improving Global Outcomes (KDIGO) 
Acute Kidney Injury Work Group, in which the dynamics of the GFR changes are 
taken into account, were used to define renal failure (16). The study further aimed to 
determine which parameters are associated with the development of AKI. 
Methods
Patients
The Harbour Hospital is a 161-bed general hospital, located in Rotterdam, The 
Netherlands. It also harbours the Institute for Tropical Diseases, which serves as 
a national referral centre. The Rotterdam Malaria Cohort consists of all patients 
diagnosed with malaria at the Institute for Tropical Diseases since 1998. Of all 
patients, anonymized demographic, clinical and laboratory data are routinely 
collected and stored in an electronic database. For the present study, data from 
patients with imported P. falciparum malaria who entered the Rotterdam Malaria 
Cohort before January 1st, 2015 were analysed retrospectively. At that moment, 
the Rotterdam Malaria Cohort comprised 690 cases of imported malaria, of 
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which 491 were caused by P. falciparum. Six cases were excluded because of 
missing creatinine values at initial presentation, leaving 485 patients for the anal-
ysis. The six excluded cases had a favourable outcome and did not require RRT. 
As this is a retrospective study of patient files, ethical approval was not necessary, 
as stated in the Medical Research involving Human Subjects Act (WMO).
Laboratory investigations
All laboratory data were measured on admission with routine procedures, as 
described before (17). The standard procedure to diagnose malaria comprised a 
Quantitative Buffy Coat (QBC) analysis, a rapid diagnostic test (RDT) for malaria 
antigens (Binax NOW® Malaria Test Binax, Inc. Maine, USA), and thick and thin 
blood smears using freshly collected blood specimens from finger pricks. The RDT 
and the QBC analysis were performed according to the manufacturer’s instructions. 
QBC capillaries were examined independently by two technicians by microscopic 
analysis of two complete rows of the region between the bottom of the capillary and 
the polynuclear leukocyte layer using an Olympus BX-60 fluorescence microscope 
equipped with UV-filter, 50x objective and 12.5x oculars (total magnification 625x). 
Definitions
Acute Kidney Injury 
Acute kidney injury (AKI) was defined using the KDIGO criteria, which include 
three stages of progressive renal dysfunction (see Supplementary Table 1) (16). 
Since patients may present with renal dysfunction without a known baseline 
serum creatinine, a classification based on a change of creatinine or estimated 
glomerular filtration rate (eGFR) from baseline poses a significant limitation. To 
circumvent this problem, the following method, which was previously described 
as a suitable method by the ADQI Group (18), was used: in patients without 
previously measured creatinine levels, a normal premorbid renal function was 
assumed. A baseline creatinine level was then calculated, using the four-variable 
modification of diet in renal disease (MDRD) formula with an assumed normal 
eGFR. These calculated baseline values were used to estimate the change of renal 
function during infection (see Supplementary Table 2). 
 
Severe malaria 
Patients were classified as having severe P. falciparum malaria if they met the 
recently updated World Health Organization (WHO) criteria for severe malaria on 
admission or during hospitalization (see Supplementary Table 3) (19). 
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Immunity to malaria
Adult immigrants from a malaria-endemic country living in The Netherlands were 
considered partially immune, as they had likely been exposed to P. falciparum during 
childhood. Patients who had been born and raised and were still living in a malar-
ia-endemic area at the time of diagnosis were presumed semi-immune. However, 
given the low number of semi-immune persons in the Rotterdam Malaria Cohort, 
they were grouped with partially immune individuals for the statistical analysis. All 
other patients were considered non-immune.
Statistical analysis
All data were extracted from the original database. For statistical analysis IBM 
Statistical Package for the Social Sciences (SPSS) version 22 (IBM Inc, Chicago, IL, 
USA) was used. Differences between the groups “AKI” and “no AKI” were analysed 
using Fisher’s exact test or Chi square test for nominal variables. For continuous 
variables the unpaired two sample t-test or the Mann-Whitney U test was used. 
Normality of distribution of variables was tested with the Kolmogorov-Smirnov 
test. Univariate and multivariate logistic regression analyses were used to iden-
tify risk factors for AKI in malaria at initial presentation. Based on the univariate 
analysis, variables with a P-value <0.10 were included in the multivariate logistic 
regression. The details of the univariate and multivariate regression analysis are 
available as supplementary files (see Supplementary Table 4 and 5). For the vari-
ables that were significant in the multivariate analysis, the diagnostic performance 
for detecting KDIGO-defined AKI was evaluated, using the odds ratio, sensitivity, 
specificity, negative and positive predictive value at the optimal cut off point 
(determined using the Youden’s index) and the area under the receiver operating 
characteristics curve (AUROC). All reported P-values are two-tailed, and P-values 
less than 0.05 were considered statistically significant.
Results
Patient characteristics and incidence of AKI
The general characteristics on admission of the 485 included patients are shown 
in Table 1. Fifty-nine patients were treated as outpatient or finished their treat-
ment at home, all other patients were treated as inpatients. None of the patients 
had serum creatinine levels measured in our hospital prior to admission; the 
premorbid creatinine levels were therefore calculated according to the described 
method to subsequently apply the KDIGO classification. AKI, defined as a KDIGO 
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stage 1, 2 or 3, was seen in 39 (8%) of all 485 patients with imported falciparum 
malaria and in 23 (38%) of the 61 patients with severe malaria. Immunity differed 
significantly between the groups with and without AKI, with non-immunes being 
over-represented in the AKI group. The use of potentially nephrotoxic co-medica-
tion (non-steroidal anti-inflammatory drugs (NSAIDs), ACE-inhibitors, diuretics 
or lithium) did not differ significantly between groups. Pulse rate was significantly 
higher in the AKI group and the systolic blood pressure was significantly lower in 
comparison to patients without AKI. Apart from creatinine and urea, also leuko-
cytes, C-reactive protein (CRP), creatinine, total bilirubin, lactate, lactate dehy-
drogenase (LDH), alanine transaminase (ALAT), aspartate transaminase (ASAT) 
and parasite load levels were all significantly higher in the AKI group, while throm-
bocytes and serum sodium levels were significantly lower. There was no signifi-
cant difference in the number of patients with circulatory shock between the two 
groups (three in the AKI group versus 13 in the no-AKI group. Severe malaria was 
significantly more common in the AKI group, as might be anticipated since AKI is 
one of the defining criteria for severe malaria (see Supplementary Table 3). There 
were two deaths, both in the AKI group.
On admission, a concomitant infection was suspected in 64 patients and proven 
in 31 patients. Fourteen of these concerned a bacterial infection, of which 5 were 
in the AKI group (two with a pneumonia and three with an urinary tract infection). 
One of these had a positive blood culture with an Escherichia coli. All other blood 
cultures remained negative.
Deterioration of kidney function during admission
In 27 (69%) of the 39 patients with AKI, kidney injury was already present at 
presentation; in the other twelve the initial KDIGO stage was 0. A deterioration of 
kidney function, defined as a progression of KDIGO stage during admission, was 
seen in 17 (44%) of the 39 AKI patients. Eight patients eventually needed RRT; one 
of these patients had a normal renal function at initial presentation (Table 2). The 
maximal creatinine level was reached after a median of 
0.3 days (range 0 – 3.4 days) in non-RRT patients. In the 8 RRT patients, creati-
nine levels rose maximally with 414 μmol (median 209 μmol) after a median of 1.3 
days (range 0 – 3.4 days) before they were referred for dialysis.
KDIGO stage versus WHO defined malarial AKI
The 2014 WHO definition for renal failure, as a criteria for severe malaria, uses 
the serum creatinine level at a cut-off of 265 μmol/L. At initial presentation, this 
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criterium was met by 19 of the 485 patients (4%) or 31% of patients with WHO 
defined severe malaria (19/61). Among these 19 patients are 5 of the 8 patients 
(63%) that eventually needed RRT. Using the KDIGO classification, 7 of these 8 
patients (89%) would have been identified; two classified as stage 2 and five as 
stage 3 at presentation.
Predictors for the outcome AKI
Multivariate logistic regression analysis revealed that age, leucocytes and throm-
bocytes were independently associated with AKI. However, they all had relatively 
poor positive predictive values for AKI despite acceptable negative predictive 
values (Table 3). Creatinine and urea were not entered in the multivariate analysis, 
as they belong to the defining criteria for AKI.
Characteristics and outcome patients needing RRT
Eight patients were referred for RRT. Their median age was 52.5 (range 36 - 62) 
and 3 (38%) were female. Half of the patients were non-immune and half partially 
immune. All were admitted in the ICU and received intravenous treatment. 
Indications for dialysis were acidosis (4/8 patients), uremia (2/8 patients) and 
fluid overload (2/8 patients). None of the patients was hyperkalemic.
All patients met more than one of the WHO severity criteria during admission; two 
met two criteria, one three, two four, one five and two met nine severity criteria.
In five of the eight RRT patients (63%) renal function recovered fully during admis-
sion, but two patients progressed to end-stage renal disease (ESRD). In one of 
them the renal biopsy showed severe ischemic changes and a tubulo-interstitial 
nephritis with advanced scarring. She switched from hemodialysis to peritoneal 
dialysis and eventually received a renal transplantation. In the other patient with 
ESRD the renal biopsy remarkably showed a collapsing glomerulopahy, for which 
other causes were excluded. She is currently still on hemodialysis and is being 
prepared for a transplantation. Her case was described in detail previously (20). 
One patient died of a suspected central pulmonary embolism two weeks after 
admission, while still on intermittent hemodialysis for the malaria-induced AKI. 
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 Discussion
AKI is a frequently observed complication of malaria in adults, both in malar-
ia-endemic countries and in non-endemic regions (5-15). The overall prevalence 
of AKI, defined according to the KDIGO classification, in the Rotterdam Malaria 
Cohort was 8% in all patients with P. falciparum infection and 38% in patients 
with severe disease. Age, leucocytes and thrombocytes were found to be inde-
pendently associated with AKI.
Some authors report AKI incidence rates as high as 52.5% in patients with 
imported malaria (15) whereas others found incidences as low as 1% (21-23). 
There are several explanations for this large variation. Most importantly, different 
definitions of AKI have been used. Many studies on malaria in endemic regions 
use the WHO criteria for severe malaria, where the serum creatinine threshold for 
AKI is preset at 265 μmol/L. Other studies have used the RIFLE (acronym for risk, 
injury, failure, loss of renal function and end stage renal disease) staging (23, 24). 
 In the current study the KDIGO criteria were used. The optimal serum creati-
nine threshold for the detection of AKI, defined as a KDIGO stage 1 or higher, was 
found to be 120 μmol/L, which is much lower than the threshold used in the WHO 
criteria. The current consensus is to define AKI according to the KDIGO criteria.
Variation in incidence rates can also be explained by differences in the patient 
populations that are analysed. Many studies have reported the incidence of AKI in 
cohorts of patients with P. falciparum only (10-14, 21, 24), while some used cohorts 
with malaria caused by any Plasmodium species (22, 23, 25, 26), and several 
studies report on specific subsets of patients like patients with WHO defined 
severe P. falciparum infection (10, 12-14, 24). The immune status of the patient may 
also influence the risk of AKI. In previous studies it was shown that non-immune 
individuals with imported P. falciparum malaria have a higher risk of severe malaria 
and its complications including AKI, than partially- or semi-immune subjects 
(5, 7, 11, 27). In the present study, non-immune patients were overrepresented in 
the AKI group.
It was previously shown that in AKI in severe malaria a return to baseline creati-
nine occurs after 17 ± 6 days (10). Most patients with AKI do not require RRT and 
a return to baseline kidney function is achieved in the vast majority of patients in 
response to antimalarial therapy and fluid resuscitation alone (5, 10, 28). In line 
with these observations, only 8 patients of the Rotterdam Malaria Cohort needed 
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RRT, and 5 of these 8 patients had a full recovery of their renal function during 
admission. However, the long-term prognosis of recovered AKI patients has been 
a matter of debate. A meta-analysis of Coca et al showed that patients with AKI 
are more likely to develop chronic kidney disease later on (CKD) (1). As 3 of the 8 
RRT patients in our cohort were not residents of the Netherlands and returned to 
their home countries not long after being discharged, we are not informed about 
whether or not their recovered renal functions remained stable in the long term.
The most important limitation of this study is that, in the absence of data on 
premorbid creatinine levels, assumptions had to be made about the baseline 
kidney function of the included patients. Although these assumptions might be 
wrong in individual cases, there is no obvious reason to assume that the base-
line kidney functions of the patients in this cohort, which consists mostly of inter-
national travellers with little comorbidity, are in general any different from the 
reference values. The method has been proposed as a suitable option in case 
of missing baseline renal function by the Acute Dialysis Quality Initiative (ADQI) 
Group and has been used before in similar studies (18, 29). Still, the possibility 
remains that AKI was overdiagnosed, as some patients may have had some form 
of chronic kidney disease before admission with malaria. Also, we did not have 
information about comorbidity available for all patients in the database. The pres-
ence of comorbid risk factors might have contributed to the development of AKI 
in some patients. Another limitation is that follow-up creatinine levels were not 
available in the majority of patients who had a normal admission creatinine. We 
cannot exclude that some of these patients developed AKI later on, but, as this 
concerns patients with mild disease who were discharged after a short admission, 
we do not expect AKI to be a common complication in this group. 
If AKI is detected early, measures can be taken to prevent further deterioration 
of kidney function and the development of associated complications. These 
measures include timely institution of proper parenteral antimalarial treatment, 
fluid replacement, avoidance of nephrotoxic drugs and, if indicated, RRT (5, 9, 10, 
28). The use of the KDIGO classification allows for an early detection of changes in 
GFR, but nevertheless 12 of 39 AKI (31%) patients in the Rotterdam Malaria Cohort 
had no evidence of kidney injury at first presentation. This observation emphasises 
that the use of serum creatinine-based prediction models for AKI has limitations. 
In several animal model studies it has been shown that functional injury of the 
kidney, reflected in serum creatinine values, is preceded by structural injury (30). 
Prediction of AKI in malaria could theoretically become more accurate with the 
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use of markers of structural kidney injury, such as the novel biomarkers Neutrophil 
Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1). 
Recent studies, performed in a broad range of experimental and clinical settings 
including cardiac surgery, kidney transplantation, contrast-induced AKI and criti-
cally ill patients, show that the use of these markers may improve risk assessment 
(30-35). A study in adult malaria patients in Bangladesh showed that NGAL was 
not superior to creatinine to predict the requirement of RRT, but patients in this 
study generally presented severely ill and more than half of them already had a 
decreased eGFR at admission (36). One could speculate that findings in imported 
malaria, where patients usually tend to present much earlier in the course of the 
infection, could be different. 
Conclusion
AKI is a common complication in adults with imported P. falciparum infection, 
occurring in 8% of cases and in 38% of the patients with severe malaria. RRT was 
necessary in 8 of the 39 patients with AKI. The use of the KDIGO staging allows an 
earlier recognition of a decline in renal function in imported malaria as compared 
to the WHO criteria, but more research is needed to determine whether novel 
biomarkers can help to detect AKI in an earlier stage.
147
AKI in imported malaria /  CHAPTER 8
Table 1.  General characteristics on admission 
AKI
n=39
No AKI
n=446
P-value
Demographic findings
Age, years 47 (26-70) 39 (4-78) <0.001
Male gender 27 (69) 325 (73) 0.708
Ethnicity 0.078
Caucasian 24 (62) 189 (42) 0.028
African 11 (28) 218 (49) 0.018
Asian 2 (5) 14 (3) 0.374
Other 2 (5) 22 (5) 1.000
Adequate prophylaxis use 0 (0) 42 (9) 0.052
Symptoms ≥ 8 days 16 (41) 111 (25) 0.055
Immunity 0.038
Non-immune 28 (74) 218 (53) 0.007
Partially immune 10 (26) 188 (45) 0.060
Semi-immune 0 (0) 9 (2) 1.000
Nephrotoxic co-medication* 5 (20) 24 (5) 0.073
Clinical findings
Temperature °C 38.5 (1.3) 38,4 (1.3) 0.852^
Systolic blood pressure, mmHg 114 (21.3) 123 (18.3) 0.017^
Pulse rate beats/minute 104 (20.1) 94(17.3) 0.003^
Glasgow Coma Scale 15 (5-15) 15 (9-15) <0.001
Laboratory findings
Hemoglobin, mmol/L 8.1 (1.8) 8.3 (1.3) 0.929^
Leucocytes, x 10⁹/L 7.5 (3.2) 5.2 (2.0) <0.001^
Thrombocytes, x 10⁹/L 29 (2-188) 91(3-385) <0.001
CRP, mg/L 185 (16-476) 91 (1-363) <0.001
Creatinine, µmol/L 166 (77-1,081) 93 (39-175) <0.001
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AKI
n=39
No AKI
n=446
P-value
Urea, mmol/L 13.8 (4.1-55.8) 5.0 (1.5 -33.6) <0.001
Sodium, mmol/L 131 (6.2) 135 (4.0) <0.001^
Potassium, mmol/L 3.7 (0.6) 3.8 (0.4) 0.422^
Bilirubin total, µmol/L 52 (10-416) 22 (3-304) <0.001
ASAT, U/L 96 (9-394) 32 (9-326) <0.001 
ALAT, U/L 68 (12-655) 36 (3-265) <0.001 
LDH, U/L 488 (127-2,297) 268 (103-1,833) <0.001
Lactate, mmol/L 3.0 (1.0-6.2) 1.4 (0-5.5) <0.001
Parasitemia , parasites/µL 128,000 
(240-1,380,600)
8,400 
(2-784,000)
<0.001 
Concomitant bacterial infection 5 (13) 9 (2) 0.003
Treatment <0.001
quinine iv 19 (49) 54 (12) <0.001
artesunate iv 13 (33) 27 (6) <0.001
atovaquone / proguanil 4 (10) 279 (63) <0.001
halofantrine 1 (3) 54 (12) 0.108
artemeter / lumefantrine 0 (0) 4 (1) 1.000
unknown 2 (5) 28 (6) 1.000
Outcome
Severe malaria (WHO 2014) 29 (74) 32 (11) <0.001
Renal replacement therapy 8 (21) 0 (0) <0.001
Death 2 (5) 0 (0) 0.006
^ Normally distributed continuous variables, given as mean (standard deviation) with P-values derived 
from T-tests. All other continuous variables are not Normally distributed and given as median (range) 
with P-values derived from Mann Whitney U tests. Nominal variables are given as number (percentage). 
P-values <0.05 are considered significant.  * Self-reported use of non-steroidal anti-inflammatory drugs 
(NSAIDs), ACE-inhibitors, diuretics or lithium
Table 1.  Continued
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Table 2.  KDIGO score at initial presentation in relation to worst score during 
   admission
Worst KDIGO stage
0 1 2 3 Total
Initial KDIGO stage 0 446 8 2 2 458
1 9 3 0 12
2 6 2 8
3 7 7
Total 446 17 11 11 485
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Table 3.  Diagnostic performance of variables that are independently 
   associated with AKI
Variable Age Thrombocytes Leukocytes Creatinine
P-value 0.002 0.005 0.005 reference
Cut-off >43 years ≤32 x 10⁹/L >6.1 x 10⁹/L 120 µmol/L
Sensitivity 70 (54-83) 62 (45- 77) 62 (45-77) 85 (70 - 94)
Specificity 63 (59-68) 93 (90- 95) 74 (70-78) 92 (89 - 94)
PPV 15 (10-20) 43 (30- 57) 17 (11-24) 48 (36- 60)
NPV 96 (93-98) 97(94- 98) 96 (93-98) 99 (97-100)
AUROC 0.69 (0.65-0.73) 0.80 (0.77-0.84) 0.73 (0.69-0.77) 0.90 (0.88-0.93)
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Supplementary Table 1. 
KDIGO criteria
Stage Serum creatinine Urine output
1 1.5–1.9 times baseline OR
≥0.3 mg/dl (≥26.5 mmol/l) increase
< 0.5 ml/kg/h for 6–12 hours
2 2.0–2.9 times baseline < 0.5 ml/kg/h for ≥12 hours 
3 3.0 times baseline OR
Increase in serum creatinine to ≥4.0 mg/
dl (≥353.6 mmol/l) OR
Initiation of renal replacement therapy
OR, In patients <18 years, decrease in 
eGFR to <35 ml/min per 1.73 m2
<0.3 ml/kg/h for ≥24 hours OR 
Anuria for ≥12 hours
Table adapted from [16]
Supplementary Table 2.
Estimated baseline serum creatinine levels in mg/dL (and in μmol/L within 
brackets)
Age (years) Black males Other males Black females Other females
20–24 1.5 (133) 1.3 (115) 1.2 (106) 1.0 (88)
25–29 1.5 (133) 1.2 (106) 1.1 (97) 1.0 (88)
30–39 1.4 (124) 1.2 (106) 1.1 (97) 0.9 (80)
40–54 1.3 (115) 1.1 (97) 1.0 (88) 0.9 (80)
55–65 1.3 (115) 1.1 (97) 1.0 (88) 0.8 (71)
>65 1.2 (106) 1.0 (88) 0.9 (80) 0.8 (71)
Estimated glomerular filtration rate = 75 (mL/min per 1.73 m2) = 186 × (serum creatinine [sCr]) - 1.154 × 
(age) - 0.203 × (0.742 if female) × (1.210 if black) = exp(5.228 - 1.154 × In [sCr]) - 0.203 × In(age) - (0.299 if 
female) + (0.192 if black). Adapted from Bellemo et al. [18] 
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Supplementary Table 3.
WHO criteria for severe malaria (2014)
 
2014 WHO malaria severity criteria
For epidemiological and research purposes, severe malaria is defined as one or more of the following, 
occurring in the absence of an identified alternative cause, and in the presence of 
P. falciparum asexual parasitemia:
Impaired consciousness A Glasgow Coma Score <11 in adults or a Blantyre 
coma score <3 in children
Acidosis A base deficit of >8 meq/L or, if unavailable, a plasma 
bicarbonate of <15 mmol/L or venous plasma lactate 
>5 mmol/L. Severe acidosis manifests clinically 
as respiratory distress – rapid, deep and laboured 
breathing
Hypoglycemia Blood or plasma glucose <2.2 mmol/L (<40 mg/dL)
Severe malarial anemia A hemoglobin concentration <5 g/dL or a hemato-
crit of <15% in children <12 years of age (<7 g/dL and 
<20%, respectively, in adults) together with a parasite 
count >10,000/µL
Renal impairment 
(acute kidney injury)
Plasma or serum creatinine >265 μmol/L (3 g/dL) or 
blood urea >20 mmol/L
Jaundice Plasma or serum bilirubin >50 μmol/L (3 mg/dL) 
together with a parasite count >100,000/µL
Pulmonary oedema Radiologically confirmed, or oxygen saturation <92% 
on room air with a respiratory rate >30/min, often with 
chest indrawing and crepitations on auscultation
Significant bleeding Including recurrent or prolonged bleeding from nose 
gums or venepuncture sites; hematemesis or melena
Shock Compensated shock is defined as capillary refill ≥3 sec 
or temperature gradient on leg (mid to proximal limb), 
but no hypotension. Decompensated shock is defined 
as systolic blood pressure <70 mm Hg in children or 
<80 mm Hg in adults with evidence of impaired perfu-
sion (cool peripheries or prolonged capillary refill)
Hyperparasitemia P. falciparum parasitemia >10%. A 4% parasitemia in 
non-immune children or adults should be considered 
an indicator of high risk requiring supervised manage-
ment but not by itself a criterion of severe malaria
Table adapted from WHO 2014 criteria for severe malaria [19]
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Supplementary Table 4.
Descriptive statistics of diagnostic accuracy of various parameters at initial pres-
entation for acute kidney injury (AKI)
Parameter Cut-off 
value
Sensitivity Speci-
ficity
PPV NPV AUROC Youden P-value*
Creatinine >120 85
(70 - 94)
92
(89 - 94)
48
(36- 60)
99
(97-100)
0.90
(0.88-0.93)
0.765 refer-
ence
Age >43 70
(54-83)
63
(59-68)
15
(10-20)
96
(93-98)
0.69
(0.65-0.73)
0.332 <0.0001
Platelets ≤32 62
(45- 77)
93
(90- 95)
43
(30- 57)
97(94- 
98)
0.80
(0.77-0.84)
0.543 0.0996
Leuco-
cytes
>6.1 62
(45-77)
74
(70-78)
17
(11-24)
96
(93-98)
0.73
(0.69-0.77)
0.354 0.0004
CRP >141 78
(62 - 90)
74
(69-78)
20
(14-28)
98
(95- 99)
0.78
(0.74-0.82)
0.519 0.0347
Sodium ≤130 56
(40-72)
88
(85-91)
30
(20- 42)
96
(93- 98)
0.74
(0.70-0.78)
0.450 0.0125
Bilirubin >35 76
(59 - 88)
79
(75 - 83)
24
(17 - 33)
97
(95 - 99)
0.81
(0.78-0.85)
0.550 0.4778
Urea >6.8 90
(76 - 97)
83
(79 - 87)
32
(24 - 42)
99
(97-100)
0.91
(0.88-0.93)
0.729 0.8990
Lactate >1.6 94
(79 - 99)
21
(14 - 28)
21
(14 - 28)
99
(96-100)
0.85
(0.81-0.89)
0.561 0.4778
LDH >338 78
(61 - 90)
74
(70 - 78)
20
(14 - 27)
98
(95 - 99)
0.81
(0.78-0.85)
0.518 0.0437
ALAT >49 76
(60-89)
69
(64-73)
17
(12- 24)
97
(95- 99)
0.74
(0.70-0.78)
0.449 0.0110
ASAT >58 76
(59- 88)
79
(75- 83)
23
(16- 32)
98
(9 - 99)
0.81
(0.77-0.84)
0.548 0.1228
Para-
sitemia
>101,400 59
(42-74)
84
(80-87)
25
(16-34)
96
(93-98)
0.74
(0.70-0.78)
0.429 0.0101
Data are given as mean (95% confidence interval). PPV = positive predictive value, NPV = negative predic-
tive value, AUROC = Area Under the ROC curve. Youden = Youden’s index. *P-values of pair-wise compar-
ison of Area Under ROC curves are given (with creatinine ROC curve as comparator). 
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Supplementary Table 5. 
Multivariate logistic regression analysis of predictors for outcome Acute Kidney 
Injury (AKI) in imported P. falciparum malaria
Variable P-value Odds ratio (CI 95%)
Age years 0.002 1.076 (1.028-1.127)
Immunity Non- or partial 0.357 0.837 (0.573-1.223)
Systolic blood pressure mm Hg 0.336 0.987 (0.961-1.014)
Pulse rate beats/min 0.182 1.022 (0.990-1.056)
Glasgow coma score EMV score 0.091 0.576 (0.304-1.093)
Thrombocytes x 10⁹/L 0.005 0.976 (0.959-0.993)
Leucocytes x 10⁹/L 0.005 1.396 (1.106-1.762)
CRP mg/L 0.876 1.001 (0.993-1.008)
Sodium mmol/L 0.406 0.954 (0.852-1.067)
Bilirubin total µmol/L 0.275 1.007 (0.995-1.018)
LDH U/L 0.441 0.999 (0.996-1.002)
ALAT U/L 0.706 0.998 (0.987-1.009)
ASAT U/L 0.137 1.009 (0.997-1.020)
LogParasitemia parasites/uL 0.496 0.819 (0.461-1.456)
95% CI = 95% confidence interval (CI). Significant outcomes are given in bold.
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CHAPTER 9
Neutrophil Gelatinase-Associated 
Lipocalin (NGAL) predicts the 
occurrence of malaria-induced 
acute kidney injury
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Abstract
Background: Acute kidney injury (AKI) is a frequently encountered 
complication of imported Plasmodium falciparum infection. Markers of 
structural kidney damage have been found to detect AKI earlier than 
serum creatinine-based prediction models but have not yet been evalu-
ated in imported malaria. This pilot study aimed to explore the predictive 
performance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) 
and Kidney Injury Molecule-1 (KIM-1) for AKI in travellers with imported 
P falciparum infection.
Methods: Thirty-nine patients with imported P. falciparum malaria from 
the Rotterdam Malaria Cohort with available serum and urine samples 
at presentation were included. Ten of these patients met the criteria 
for severe malaria. The predictive performance of NGAL and KIM-1 as 
markers for AKI was compared with that of serum creatinine.
Results: Six of the 39 patients (15%) developed AKI. Serum and urine 
NGAL and urine KIM-1 were all found to have large area’s under the 
receiver operating characteristic curves (AUROC’s) for predicting AKI. 
Urine NGAL was found to have an excellent performance with a positive 
predictive value (PPV) of 1.00 (95% CI 0.54-1.00), a negative predictive 
value (NPV) of 1.00 (95% CI 0.89-1.00) and an AUROC of 1.00 (95% CI 
1.00-1.00). 
Conclusion: A good diagnostic performance of NGAL and KIM-1 for 
AKI was found. Particularly urine NGAL was found to have an excel-
lent predictive performance. Larger studies are needed to demonstrate 
whether these biomarkers are superior to serum creatinine as predictors 
for AKI in P. falciparum malaria.
161
NGAL predicts the occurrence of AKI /  CHAPTER 9
Background
Malaria-induced acute kidney injury (AKI) is an important contributing factor to 
the high mortality of severe malaria (1). In endemic regions, AKI occurs in up to 40% 
of adult patients with severe Plasmodium falciparum infection and it is associated 
with high mortality (2-5). In Western countries, AKI is also a frequently encoun-
tered complication of imported P. falciparum infection. In a recent study in travel-
lers with imported P. falciparum infection, AKI, defined according to the criteria set 
by the Kidney Disease: Improving Global Outcomes (KDIGO) AKI Work Group (6), 
was seen in 39 (8%) of all 485 patients and in 23 (38%) of the 61 patients with 
severe malaria (7). Although the KDIGO classification allows for an early detection 
of changes in glomerular filtration rate (GFR), the use of serum creatinine-based 
prediction models for AKI has limitations. Substantial rises in serum creatinine are 
only observed 48 to 72 hours after the initial injury to the kidney, and because of 
factors such as enhanced tubular creatinine secretion, significant renal injury can 
occur without an important rise of serum creatinine (8). This is illustrated by a recent 
study in which 12 (31%) of 39 patients with malaria-induced AKI had a normal 
serum creatinine at presentation (7). Because structural kidney injury precedes loss 
of renal function, a marker of structural kidney damage could theoretically detect 
AKI much earlier, in a way that has been compared to the role of troponin in the 
detection of myocardial injury (9).
A promising marker of structural kidney damage in AKI is Neutrophil Gelatinase-
Associated Lipocalin (NGAL), also known as lipocalin 2. This protein was initially 
discovered in activated neutrophils and was later found to be produced by many 
tissues, including renal tubular epithelial cells. Under physiologic conditions, NGAL 
is present at very low concentrations in the urine and plasma (10, 11, 12). Studies 
in animals showed NGAL to be one of the most upregulated genes in the kidney 
very early after AKI. As a consequence of the induction of NGAL-expression in the 
distal nephron and reduced proximal tubular re-uptake due to tubular damage, 
both urine and plasma NGAL concentrations rise quickly in the event of AKI (10, 
11). The value of NGAL as a predictor of AKI has been established in a large number 
of studies, predominantly performed in critically ill patients, after cardiac surgery 
and after kidney transplantation (11, 13, 14). In studies in endemic regions, urine 
NGAL has been shown to rise with increasing severity of AKI in severe malaria (2) 
but was not superior to creatinine in predicting in hospital requirement for renal 
replacement therapy (RRT) (15). However, NGAL has not yet been evaluated as a 
marker for AKI in patients with imported malaria.
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Another frequently used biomarker for kidney injury is Kidney Injury Molecule-1 
(KIM-1). KIM-1 is a transmembrane protein in tubular kidney cells that is undetect-
able in plasma of patients with undamaged kidneys. In damaged tubular epithe-
lial cells undergoing dedifferentiation and proliferation, KIM-1 is induced and 
can become detectable in plasma and urine (16). The exact function of KIM-1 
is unknown and reports have suggested its involvement in epithelial damage as 
well as in protection and restoration of the tubular epithelium (16). Urinary KIM-1 
concentrations were found to increase much earlier than blood urea nitrogen 
and plasma creatinine in studies in which proximal tubular injury was induced by 
cadmium or ischemia (8, 17, 18). Its performance as an early marker for AKI has 
been evaluated in several clinical settings, including contrast-induced nephrop-
athy and sepsis (19-21) but not during malaria. 
The aim of this pilot study was to explore the predictive performance of NGAL and 
KIM-1 in AKI in travellers with imported P. falciparum infection.
Methods
Patients
The Harbour Hospital is a 161-bed general hospital, located in Rotterdam, The 
Netherlands. It also harbours the Institute for Tropical Diseases, which serves as 
a national referral centre. The Rotterdam Malaria Cohort consists of all patients 
diagnosed with malaria at the Institute for Tropical Diseases since 1998. Of 
all these patients, anonymized demographic, clinical and laboratory data are 
routinely collected and stored in an electronic database. On January 1st, 2015, the 
Rotterdam Malaria Cohort comprised 690 cases of imported malaria, of which 
491 were caused by P. falciparum.
The present pilot study focussed on the diagnostic accuracy of serum NGAL 
(sNGAL), urine NGAL (uNGAL), and urine KIM-1 (uKIM-1) concentrations as 
predictive biomarkers for AKI. Patients with imported P. falciparum malaria that 
were included in the Rotterdam Malaria Cohort between February 2010 and 
February 2012 with available serum and urine samples at their initial presentation 
were included. The findings were compared with the performance of serum creat-
inine as a marker for AKI in P. falciparum malaria. 
163
NGAL predicts the occurrence of AKI /  CHAPTER 9
Laboratory investigations
All laboratory parameters were measured on admission with routine procedures, 
as described before (22). The standard procedure to diagnose malaria comprised 
a Quantitative Buffy Coat (QBC) analysis, a rapid diagnostic test (RDT) for malaria 
antigens (Binax NOW® Malaria Test Binax, Inc. Maine, USA), and thick and thin 
blood smears using freshly collected blood specimens from finger pricks. The RDT 
and the QBC analyses were performed according to the manufacturer’s instruc-
tions (23, 24). QBC capillaries were examined independently by two technicians 
by microscopic analysis of two complete rows of the region between the bottom 
of the capillary and the polynuclear leukocyte layer using an Olympus BX-60 fluo-
rescence microscope equipped with UV-filter, 50× objective and 12.5× oculars 
(total magnification 625×).
Measurements of sNGAL, uNGAL and uKIM-1 were done using residual patient 
material in November 2012. Samples of serum and urine had been collected at 
initial presentation and stored at -80 °C until analysis with a maximum storage 
time of two years and nine months, during which stability of NGAL and KIM-1 levels 
can be assumed (25). sNGAL, uNGAL and uKIM-1 were quantitatively determined 
with commercially available sandwich ELISA kits (NGAL Quantikine and KIM-1 
Quantikine kits from R&D Systems, Inc., Minneapolis, USA). 
Definitions
Acute Kidney Injury 
AKI was defined using the KDIGO criteria, which include three stages of progres-
sive renal dysfunction (see Supplementary Table 1) (6). Since patients may 
present with renal dysfunction without a known baseline serum creatinine, a clas-
sification based on a change of creatinine or estimated GFR (eGFR) from baseline 
poses a significant limitation. To circumvent this problem, the following method, 
which was previously described as a suitable method by the ADQI Group (26), 
was used: in patients without previously measured creatinine concentrations, a 
normal pre-morbid renal function was assumed. A baseline, creatinine concen-
tration was then calculated, using the four-variable modification of diet in renal 
disease (MDRD) formula with an assumed normal eGFR. These calculated base-
line values were used to estimate the change of renal function during infection 
(see Supplementary Table 2).
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Severe malaria
Patients were considered as having severe P. falciparum malaria if they met the 
recently updated World Health Organization (WHO) criteria for severe malaria on 
admission or during hospitalization (see Supplementary Table 3) (27). 
Statistical analysis
All data was extracted from the original secured database and reviewed for incon-
sistencies and missing values. For statistical analysis, IBM Statistical Package 
for the Social Sciences (SPSS) version 22 (IBM, inc, Chicago, IL, USA) was used. 
Differences between the groups having AKI or no AKI were analysed using the 
Fisher’s exact test or Chi square test for nominal variables. For continuous vari-
ables the Mann-Whitney U test was used. The diagnostic performance of sNGAL, 
uNGAL, the ratio between uNGAL and urine creatinine (uNGAL/uCreat) and the 
ratio between uKIM-1 and urine creatinine (uKIM-1/uCreat) was reported as sensi-
tivity, specificity, positive and negative predictive value for AKI with their corre-
sponding 95% confidence intervals (with the use of MedCalc version 15.6). Of each 
parameter a Receiver Operating Characteristics (ROC) curve was constructed as 
a summary statistic and the area under the ROC curve (AUROC) and its corre-
sponding 95% confidence intervals were calculated. The AUROC of each of the 
variables was compared to that of reference comparator variable serum creatinine 
in a pair-wise comparison using the method of Hanley and McNeil (28). Optimal 
cut-off points were determined using the Youden index. All reported P-values are 
two-tailed. P-values less than 0.05 were considered statistically significant.
Ethics approval and consent to participate
Ethical clearance for the storage and use of residual serum and urine samples for 
scientific purposes was granted by the Medical Ethics Review Board of the Erasmus 
MC, University Medical Center Rotterdam, the Netherlands (MEC 2012-047). 
Results
Patient characteristics and AKI at presentation 
and during admission
During the study period, 50 patients with P. falciparum malaria were included in 
the Rotterdam Malaria Cohort. Ten of these patients met the criteria for severe 
malaria and seven had AKI. Of 39 of these patients, including the ten patients with 
severe malaria and six of the patients with AKI, residual urine and serum samples 
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were available for analysis. The general characteristics on admission of these 39 
patients are shown in Table 1. 
Six patients (15%) developed AKI, defined as KDIGO stage 1, 2 or 3, during the 
course of their infection. In four of these patients (67%) AKI was already iden-
tified on admission; one patient was classified in KDIGO stage 1, two in stage 2 
and one in stage 3. Two of these patients later progressed to a more advanced 
KDIGO stage. Two patients did not meet the KDIGO criteria at presentation but 
progressed during admission to KDIGO stage 3 (see Table 2).
The non-AKI group contained more men than the AKI group but other demo-
graphic findings did not differ significantly. Pulse rate, parasitaemia and serum 
concentrations of creatinine, urea, lactate, sNGAL, uNGAL and uKIM-1 were 
significantly higher in the AKI group. Serum sodium and potassium concentra-
tions were significantly lower in the AKI group. The ratios uNGAL/sNGAL and of 
uNGAL/uCreat were significantly higher in the AKI patients. Intensive care unit 
admission was significantly more common in the AKI group. Since AKI is one of 
the defining criteria for severe malaria [23] severe malaria was also more common 
in the AKI group. 
Identification of AKI by NGAL and KIM-1 
Five out of six patients with AKI presented with elevated sNGAL. uNGAL was 
elevated in all six (Table 2). In contrast, only one of the AKI patients showed 
elevated uKIM-1 at presentation. All patients that were classified as KDIGO stage 3, 
either at presentation or later during admission, already showed elevated concen-
trations of both sNGAL and uNGAL at presentation. 
In seven patients, high concentrations of sNGAL, uNGAL or uKIM-1 on admis-
sion were found despite a seemingly normal kidney function throughout their 
admission; one had elevated sNGAL, uNGAL and uKIM-1, two patients showed 
elevated sNGAL and uNGAL with normal uKIM-1, three patients presented with 
only an elevated uNGAL, and in one patient only uKIM-1 was elevated. These data 
are available as a supplementary file (Supplementary Table 4). 
Diagnostic performance of sNGAL, uNGALand uKIM-1 
at presentation for AKI 
Analysis of the diagnostic accuracy of sNGAL, uNGAL, uKIM-1 and the ratios of 
uNGAL and uKIM-1 to urine creatine was performed by pair-wise comparison of 
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the AUROCs of these parameters to the AUROC of serum creatinine. All parame-
ters showed large AUROCs. However, none of these differences were statistically 
significant when compared to the AUROC of creatinine, likely due to the small 
sample size of this study. uNGAL was found to have an excellent performance 
with PPV of 1.00 (95% CI 0.54-1.00), an NPV of 1.00 (95% CI 0.89-1.00) and an 
AUROC of 1.00 (95% CI 1.00-1.00; Table 3). The ROC curves of serum creatinine, 
sNGAL, uNGAL, uKIM-1 are available as a figure (see Supplementary Figure 1).
Diagnostic performance sNGAL, uNGAL and uKIM-1 at 
presentation for KDIGO stage 3
Analysis of the diagnostic accuracy of creatinine, NGAL and KIM-1 for the most 
severe form of AKI, KDIGO stage 3, was also performed. uNGAL (0.99, 95% CI 
0.88-1.0) and sNGAL (0.97, 95% CI 0.86-1.00) were found to perform excellently. 
The AUROC of creatinine was found to be 0.75 (95% CI 0.59-0.87; p ). Again, 
differences were not statistically significant (see Supplementary Table 5).
Renal replacement therapy in relation to sNGAL, uNGAL 
and uKIM-1 at presentation
Three patients developed a need for RRT. One of these patients did not classify 
as AKI on admission but later progressed to KDIGO stage 3, one was in KDIGO 
stage 2 and one in stage 3. However, all three presented with elevated sNGAL and 
uNGAL and one also showed an elevated urine KIM-1 on admission. 
Follow-up measurements during admission
For two patients, sNGAL and uNGAL concentrations were available for follow-up 
during admission. Both patients showed elevated uNGAL at initial presentation, 
while serum creatinine concentrations were still normal (Supplementary Figure 2). 
One of the patients (patient 1, Supplementary Figure 2) started RRT on admission 
day 2, the other patient did not need RRT. No major changes of sNGAL concentra-
tions were seen during admission. 
Discussion
In the present pilot study it is demonstrated that sNGAL and uNGAL have an 
excellent predictive performance for malaria-induced AKI. 
Biomarkers for the early detection of AKI are under intense investigation and 
studies have revealed promising results in a broad variety of settings including 
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contrast-induced nephropathy, critically ill patients, cardiac surgery, and kidney 
transplantation (29-35). In several studies, both urine and serum NGAL concen-
trations were found to be superior to the serum creatinine concentration for the 
prediction of AKI (33, 36). 
Early detection of AKI in malaria could help to prevent further deterioration of kidney 
function by appropriate fluid management, avoidance of nephrotoxic drugs and 
close monitoring to assess the need for RRT (3, 4, 37). However, very few studies on 
biomarkers for AKI have been performed in malaria. The value of uNGAL was previ-
ously studied in adult patients with severe P. falciparum infection in Bangladesh. 
uNGAL was shown to increase with increasing severity of AKI (2), but creatinine 
was found to be superior to uNGAL in predicting the need for RRT (15). However, 
patients in this study generally presented severely ill and more than half of them 
already had a decreased eGFR on admission. One could speculate that the benefit 
of an early marker for AKI can be larger in the very different population of travellers 
with imported malaria, who tend to present in a much earlier stage of the infection.
In the present pilot study on biomarkers of AKI in imported malaria, highly prom-
ising results were observed for uNGAL, which was able to identify all 6 AKI patients 
at initial presentation. Follow-up measurements in two AKI patients revealed that 
uNGAL increased before serum creatinine started to rise (Supplementary Figure 2). 
 The AUROCs of sNGAL, uNGAL and uKIM-1 were large but, due to the very small 
sample size, the study was underpowered to demonstrate statistically signifi-
cant differences. This is a major limitation of the present study and larger studies 
should be performed to demonstrate whether these biomarkers truly outperform 
serum creatinine. 
The suggestion that uNGAL performs better than sNGAL, is an important discus-
sion in literature. A meta-analysis conducted by Haase et al. showed that both 
serum and urine NGAL concentrations appear to perform similarly well and provide 
a relevant advantage as compared with serum creatinine (13). It deserves further 
investigation whether this conclusion also applies to the performance of serum 
and urine NGAL in imported P. falciparum malaria. These results are important 
since oliguria is a common event in malaria-induced AKI (37) and the use of urine 
NGAL for diagnosis of malaria-induced AKI therefore has its limitations. Another 
ongoing debate is whether urine biomarker concentrations are better reported as 
absolute values or as a ratio to creatinine concentration (38). In the present study, 
the absolute values seemed to perform somewhat better than the ratio.
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Although uKIM-1 performed well when the cut-off level was set at 1.83 ng/ml, only 
one of the six patients with AKI had a uKIM-1 level above the upper limit of normal, 
which is 5.33 ng/ml, while all six patients had markedly raised uNGAL levels. The 
patient who did have an elevated uKIM-1 was already in KDIGO stage 3 at presen-
tation. These findings raise the question whether the rise of KIM-1 levels occurs 
later in the course of early AKI than NGAL. A study in children undergoing cardiac 
surgery suggests that this might indeed be the case (39). However, this study was 
performed in a study population which was much different from the present, and 
more research is needed to confirm this finding in other clinical settings.
Several patients were found to have elevated sNGAL, uNGAL or uKIM-1 but did 
not progress to a KDIGO stage 1 or higher. The clinical significance of increased 
NGAL concentrations without detectable changes in creatinine, previously inter-
preted as a shortcoming of the biomarker, has been found to indicate subclinical 
AKI and to be of prognostic importance in critically ill adult patients (40). NGAL 
can be influenced by extra-renal production by neutrophils caused by factors like 
concomitant systemic inflammation or malignancy (41). However, it is unlikely that 
such bias influenced the findings in the present study to a large degree as there 
was no evidence of co-infection or malignancy in any of the patients. Follow-up 
of patients with elevated NGAL concentrations deserves further investigation, as 
this would increase insight into the correlation of NGAL and the resolution of AKI 
or the development of chronic kidney disease.
An important limitation of biomarkers like NGAL and KIM-1 is that their availability is 
usually limited to resource-rich settings where malaria is only seen as an imported 
disease; in the regions that carry the largest burden of malaria, laboratory diagnos-
tics are often limited to basic measurements. Even in resource-rich settings, studies 
on the cost-effectiveness of these biomarkers are still to be done (42).
Conclusion
This pilot study reveals good diagnostic value of sNGAL, uNGAL and uKIM-1. 
Especially uNGAL was found to have an excellent predictive performance for AKI. 
Larger studies are needed to demonstrate whether these biomarkers are superior 
to serum creatinine as predictors for AKI in P. falciparum malaria.
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Table 1.  General characteristics
AKI
n=6
No AKI
n=33
P-value
Demographic findings
Age, years 43 (29-62) 46 (28-69) 0.89
Male gender 3 (50%) 30 (91%) <0.05
Ethnicity 1.00
 Caucasian 2 (33%) 9 (27%) 1.00
 African 4 (67%) 22 (67%) 1.00
 Asian 0 (0%) 2 (6%) 1.00
Adequate prophylaxis use 0 (0%) 0 (0%) 1.00
Symptoms ≥ 8 days 2 (33%) 6 (19%) 0.58
Risk factors for chronic kidney 
disease*
1 (17%) 4 (12%) 1.00
Nephrotoxic co-medication** 1 (17%) 4 (12%) 1.00
Clinical findings
Temperature °C 39.5 (38.3-40.1) 38.4 (35.5-40.7) 0.11
Systolic blood pressure, 
mmHg
100 (73-140) 125 (95-170) 0.08
Pulse rate beats/minute 111 (100-140) 95 (56-129) <0.05
Glasgow Coma Scale 15 (15-15) 15 (11-15) 0.54 
Laboratory findings
Creatinine, µmol/L 196 (77-1081) 96 (39-133) <0.01
Urea, mmol/L 14.8 (9.1-55.8) 5.6 (2.7-33.6) <0.001
Sodium, mmol/L 129 (120-136) 137 (127-141) <0.01
Potassium, mmol/L 3.2 (2.9-3.9) 3.7 (3.3-4.5) <0.05
Lactate, mmol/L 4.5 (1.9-5.8) 1.5 (0.6-4.6) <0.001
Parasitemia, parasites/µL 386600 
(45900-1380600)
39200 
(64-678400)
<0.05
sNGAL, ng/ml 700 (174-2287) 91 (19-204) <0.001
170
AKI
n=6
No AKI
n=33
P-value
uNGAL, ng/ml 5792 (376-22028) 9 (1-240) <0.001
uKIM-1, ng/ml 3.9 (1.8-7.8) 1.2 (0.1-8.7) <0.01
uNGAL/ sNGAL 10.1 (0.4-25.1) 0.1 (0.0-2.6) <0.001
uNGAL/uCreatinine 815.0 (5.4-2172.7) 0.8 (0.1-42.5) <0.001
uKIM-1/uCreatinine 0.04 (0.02-0.08) 0.1 (0.0-2.9) 0.04
Concomitant bacterial 
infection
1 (17%) 0 (0%) 0.15
Outcome
Severe malaria (WHO 2014) 5 (83%) 5 (15%) <0.01
Renal replacement therapy 3 (50%) 0 (0%) <0.01
ICU admission 4 (67%) 4 (12%) <0.05
Death 1 (17%) 0 (0%) 0.15
Continuous variables are given as median (range). Nominal variables are given as number (percentage). 
P-values <0.05 are considered significant. 
* Hypertension (n=4), type 2 diabetes mellitus (n=1)
** Self-reported use of non-steroidal anti-inflammatory drugs (NSAIDs), ACE-inhibitors, diuretics or 
lithium
Table 1.  Continued
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Table 2.  KDIGO stage at initial presentation and during admission in relation  
   to serum and urine NGAL and urine KIM-1 for all six patients with AKI
KDIGO 
stage at 
presen-
tation
Highest 
KDIGO 
stage 
during 
admission
RRT* Serum 
NGAL
(≤177 ng/ml)
Urine 
NGAL
(≤72 ng/ml)
Urine 
NGAL/
Urine 
creat ratio
Urine 
KIM-1
(≤5.33 ng/ml)
Urine 
KIM-1/
Urine 
creat ratio
0 3 Yes 899 22028 1368.2 1.84 0.11
0 3 No 501 8691 2172.7 3.88 0.97
1 2 No 174 376 5.4 4.40 0.06
2 2 No 2287 6452 1955.1 3.92 1.19
2 3 Yes 205 5132 261.8 3.87 0.20
3 3 Yes 2014 838 72.1 7.75 0.67
Bold: Elevated laboratory measurements. Reference ranges in brackets. *renal replacement therapy.
172
Table 3.  Descriptive statistics of diagnostic accuracy of various biomarker 
   measurements at presentation for the presence or subsequent 
   development of acute kidney injury (AKI)
Parameter and 
cut-off value^
Sensitivity Specificity PPV NPV Youden 
index
AUROC P-value*
sCreatinine
≥ 128 µmol/L
0.83
(0.36-1.00)
0.97
(0.84-1.00)
0.83
(0.36-0.99)
0.97
(0.84-1.00)
0.80 0.85
(0.60-1.00)
sNGAL
≥ 168 ng/ml
1.00
(0.54-1.00)
0.88
(0.72-0.97)
0.60
(0.26-0.88)
1.00
(0.88-1.00)
0.88 0.98
(0.93-1.0)
0.389
uNGAL
≥ 308 ng/ml
1.00
(0.54-1.00)
1.00
(0.89-1.00)
1.00
(0.54-1.00)
1.00
(0.89-1.00)
1.00 1.00
(1.00-1.00)
0.299
uNGAL/sNGAL
≥ 1.9
0.83
(0.36-1.00)
0.97
(0.84-1.00)
0.83
(0.36-1.00)
0.96
(0.84-1.00)
0.80 0.95
(0.85-1.00)
0.544
uNGAL/uCreat
≥ 5.1 ng/mmol
1.00
(0.54-1.00)
0.88
(0.72-0.97)
0.60
(0.26-0.88)
1.00
(0.88-1.00)
0.88 0.98
(0.93-1.00)
0.390
uKIM-1
≥ 1.83 ng/ml
1.00
(0.54-1.00)
0.72
(0.54-0.87)
0.40
(0.16-0.68)
1.00
(0.86-1.00)
0.72 0.87
(0.75-0.99)
0.919
uKIM-1 /uCreat 
≤ 0.085 ng/
mmol
1.00
(0.54-1.00)
0.58 
(0.39-0.74)
0.30
(0.12-0.54)
1.00
(0.82-1.00)
0.58 0.76
(0.61-0.92)
0.810
Data are given as mean (95% confidence interval). Optimal cut-off values were determined using the 
Youden index. PPV = positive predictive value, NPV = negative predictive value, AUROC = Area Under the 
ROC curve. *P-values of pair-wise comparison of Area Under ROC curves are given (with creatinine ROC 
curve as comparator).
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Supplementary Table 1. 
KDIGO criteria
Stage Serum creatinine Urine output
1 1.5–1.9 times baseline OR
≥0.3 mg/dl (≥26.5 mmol/l) increase
< 0.5 ml/kg/h for 6–12 hours
2 2.0–2.9 times baseline < 0.5 ml/kg/h for ≥12 hours 
3 3.0 times baseline OR
Increase in serum creatinine to ≥4.0 mg/
dl (≥353.6 mmol/l) OR
Initiation of renal replacement therapy
OR, In patients <18 years, decrease in 
eGFR to <35 ml/min per 1.73 m2
<0.3 ml/kg/h for ≥24 hours OR 
Anuria for ≥12 hours
Table adapted from Khwaja et al (6). eGFR estimated glomerular filtration rate
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Supplementary Table 2. 
Estimated baseline serum creatinine concentration
Age 
(years)
African ethnicity, 
males 
μmol/L
Other males 
μmol/L
African ethnicity, 
females 
μmol/L
Other females 
μmol/L
20–24 133 115 106 88
25–29 133 106 97 88
30–39 124 106 97 80
40–54 115 97 88 80
55–65 115 97 88 71
>65 106 88 80 71
Estimated glomerular filtration rate = 75 (mL/min per 1.73 m2) = 186 × (serum creatinine [sCr]) - 1.154 × 
(age) - 0.203 × (0.742 if female) × (1.210 if black) = exp(5.228 - 1.154 × In [sCr]) - 0.203 × In(age) - (0.299 if 
female) + (0.192 if black). Adapted from Bellemo et al. (26)
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Supplementary Table 3. 
WHO criteria for severe malaria (2014) 
2014 WHO malaria severity criteria
For epidemiological and research purposes, severe malaria is defined as one or more of the following, 
occurring in the absence of an identified alternative cause, and in the presence of 
P. falciparum asexual parasitemia:
Acidosis A base deficit of >8 meq/L or, if unavailable, a plasma bicar-
bonate of <15 mmol/L or venous plasma lactate >5 mmol/L. 
Severe acidosis manifests clinically as respiratory distress – 
rapid, deep and laboured breathing 
Hypoglycemia Blood or plasma glucose <2.2 mmol/L (<40 mg/dL) 
Severe malarial anemia A hemoglobin concentration <5 g/dL or a hematocrit of <15% 
in children <12 years of age (<7 g/dL and <20%, respectively, in 
adults) together with a parasite count >10,000/µL 
Renal impairment 
(acute kidney injury)
Plasma or serum creatinine >265 μmol/L (3 g/dL) or blood urea 
>20 mmol/L 
Jaundice Plasma or serum bilirubin >50 μmol/L (3 mg/dL) together with 
a parasite count >100,000/µL 
Pulmonary oedema Radiologically confirmed, or oxygen saturation <92% on room 
air with a respiratory rate >30/min, often with chest indrawing 
and crepitations on auscultation 
Significant bleeding Including recurrent or prolonged bleeding from nose gums or 
venepuncture sites; hematemesis or melena 
Shock Compensated shock is defined as capillary refill ≥3 sec or 
temperature gradient on leg (mid to proximal limb), but no 
hypotension. Decompensated shock is defined as systolic 
blood pressure <70 mm Hg in children or <80 mm Hg in adults 
with evidence of impaired perfusion (cool peripheries or 
prolonged capillary refill) 
Hyperparasitemia P. falciparum parasitemia >10%. A 4% parasitemia in non-im-
mune children or adults should be considered an indicator of 
high risk requiring supervised management but not by itself a 
criterion of severe malaria 
Table adapted from WHO 2014 criteria for severe malaria (27)
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Supplementary Table 4. 
Patients without AKI but with abnormal NGAL or KIM-1 levels
Patient Serum NGAL
(≤177 ng/ml)
Urine NGAL
(≤72 ng/ml)
Urine NGAL/
Urine 
creat ratio
Urine KIM-1
(≤5.33 ng/ml)
Urine KIM-1/
Urine 
creat ratio
1 204 128 42.5 8.72 2.91
2 184 99 3.4 3.26 0.11
3 184 129 4.8 1.86 0.07
4 138 39 1.7 5.43 0.23
5 175 240 13.4 1.64 0.09
6 41 105 3.6 1.82 0.06
7 136 98 16.6 0.56 0.09
Bold: Elevated laboratory measurements. Reference ranges in brackets
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Supplementary Table 5. 
Descriptive statistics of diagnostic accuracy of various laboratory measurements 
at presentation for the presence or development of AKI - KDIGO stage 3
Parameter and 
cut-off value^
Sensitivity Specificity PPV NPV Youden 
index
AUROC P-value*
sCreatinine
≥ 124 µmol/L
0.75
(0.19-0.99)
0.91
(0.77- 0.98)
0.50
(0.12-0.88)
0.97
(0.84-1.00)
0.66 0.75 
(0.59-0.87)
sNGAL
≥ 204 ng/ml
1.00
(0.40-1.00)
0.97
(0.85-1.00)
0.80
(0.28-1.00)
1.00
(0.90-1.00)
0.97 0.97 
(0.86-1.00)
0.199
uNGAL
≥ 376 ng/ml
1.00
(0.40-1.00)
0.97
(0.85-1.00)
0.80
(0.28-1.00)
1.00
(0.90-1.00)
0.97 0.99 
(0.88-1.0)
0.170
uNGAL/sNGAL
≥ 2.8
0.75
(0.19-0.99)
1.00
(0.90-1.00)
1.00
(0.29-1.00)
0.97
(0.86-1.00)
0.75 0.92 
(0.78-0.98)
0.359
uNGAL/uCreat
≥ 42.5 ng/mmol
1.00
(0.40-1.00)
0.97
(0.85-1.00)
0.80
(0.28-1.00)
1.00
(0.90-1.00)
0.97 0.98 
(0.87-1.0)
0.173
uKIM-1
≥ 1.82 ng/ml
1.00
(0.40-1.00)
0.68
(0.50-0.83)
0.27
(0.08-0.55)
1.00
(0.85-1.00)
0.74 0.82
(0.67-0.93)
0.679
uKIM-1 / uCreat 
≤ 0.54 ng/mmol
1.00
(0.40-1.00)
0.66
(48-81)
0.25
(0.07-0.52)
1.00
(0.85-1.00)
0.66 0.85 
(0.70-0.94)
0.603
Data are given as mean (95% confidence interval). Optimal cut-off values were determined using the 
Youden index. PPV = positive predictive value, NPV = negative predictive value, AUROC = Area Under the 
ROC curve. *P-values of pair-wise comparison of Area Under ROC curves are given (with creatinine ROC 
curve as comparator).
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Supplementary Figure 1. 
ROC- curves for serum creatinine, sNGAL, uNGAL and uKIM-1 for the prediction 
of AKI.
1 - Specificity
1.00.80.60.40.20.0
1.0
0.8
0.6
0.4
0.2
0.0
ROC Curve for uKIM-1
1 - Specificity
1.00.80.60.40.20.0
S
en
si
ti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
ROC Curve for uNGAL
1 - Specificity
1.00.80.60.40.20.0
1.0
0.8
0.6
0.4
0.2
0.0
ROC Curve for sNGAL
1 - Specificity
1.00.80.60.40.20.0
S
en
si
ti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
ROC Curve for serum creatinine
A.
C.
B.
D.
179
NGAL predicts the occurrence of AKI /  CHAPTER 9
Supplementary Figure 2. 
The course of the serum creatinine, serum NGAL and urine NGAL concentrations 
for two patients with AKI during admission.
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CHAPTER 10
Hyponatraemia in imported malaria 
is common and associated with 
disease severity
186
Abstract
Background: (serum sodium <135 mmol/L) has long been recognized as a compli-
cation of malaria. However, few studies have been done in non-immune adult 
populations. It has not been investigated previously how hyponatraemia is distrib-
uted among the various Plasmodium species, and its association with malaria 
severity is unknown. The aim of this retrospective cohort study was to determine 
the prevalence of hyponatraemia and its association with malaria severity in a large 
cohort of patients with imported malaria caused by various Plasmodium species.
Methods: All patients that were diagnosed with malaria in the Harbour Hospital 
and Institute for Tropical Diseases in Rotterdam in the period 1999-2009 and 
who had available serum sodium on admission were included. Severe malaria was 
defined according to the modified WHO criteria. Prevalence of hyponatraemia and 
its association with malaria severity were investigated by univariate comparison, 
ROC analysis and multivariate logistic regression analysis.
Results: A total of 446 patients with malaria (severe falciparum malaria n=35, 
non-severe falciparum malaria n=280, non-falciparum malaria n=131) was included. 
Hyponatraemia was present in 207 patients (46%). Prevalence and severity of 
hyponatraemia were greatest in severe falciparum malaria (77%, median serum 
sodium 129 mmol/L), followed by non-severe falciparum malaria (48%, median 
serum sodium 131 mmol/L), and non-falciparum malaria (34%, median serum 
sodium 132 mmol/L). Admission serum sodium <133 mmol/L had a sensitivity 
of 0.69 and a specificity of 0.76 for predicting severe malaria. Multivariate logistic 
regression showed that serum sodium <131 mmol/L was independently associated 
with severe falciparum malaria (odds ratio 10.4, 95% confidence interval 3.1-34.9). 
In patients with hyponatraemia, hypovolaemia did not appear to play a significant 
role in the development of hyponatraemia when prerenal azotaemia and haema-
tocrit were considered as surrogate markers for hypovolaemia.
Conclusion: Hyponatraemia is common in imported malaria and is associated 
with severe falciparum malaria. From a clinical point of view, the predictive power 
of hyponatraemia for severe malaria is limited. The precise pathophysiological 
mechanisms of hyponatraemia in malaria require further study
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Background
Hyponatraemia has long been recognized as a complication of malaria (1). The 
incidence of hyponatraemia in malaria has mostly been studied in endemic 
areas focusing on children with severe Plasmodium falciparum malaria and was 
approximately 55% (1-3). Two studies in adults in Bangladesh and Thailand 
found incidences of 57% and 37%, respectively (4, 5). However, few studies have 
been performed in non-immune populations or in patients infected with other 
Plasmodium species. 
The pathophysiology of hyponatraemia in malaria remains unclear but several 
studies have suggested that increased secretion of vasopressin, either appropri-
ately or inappropriately, plays an important role (4, 6-10). Although a recent study 
suggested that the outcome of patients with malaria and hyponatraemia is good 
(4), cerebral oedema may still occur in rare cases (11). 
The aim of this retrospective cohort study was to investigate the prevalence and 
severity of hyponatraemia in a large cohort of predominantly adult non-immune 
travellers with imported malaria caused by various Plasmodium species and its 
relationship with malaria severity. 
Methods
Patients
The Harbour Hospital is a 161-bed general hospital located in Rotterdam, The 
Netherlands. It also harbours the Institute of Tropical Diseases, which serves as 
a national referral centre. All patients diagnosed with malaria in our hospital in 
the 10-year-period between January 1st 1999 and January 1st 2009 were included. 
Patients were identified by screening the malaria database of the department of 
Parasitology. Of all patients thus identified, demographic, clinical and laboratory 
data were collected using a standardized form, and subsequently stored in an 
electronic database. 
Laboratory investigations
Available laboratory examinations included red and white blood cells, haemato-
crit, platelets, serum electrolytes, C-reactive protein (CRP), total bilirubin, serum 
creatinine and urea, liver enzymes, lactate dehydrogenase (LDH), blood glucose 
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and plasma lactate. Serum sodium concentration was measured using indirect 
potentiometry (Beckman Synchron UniCel DxC 600 analyser). Blood smears 
(thin and thick films) were obtained from finger pricks and stained with Giemsa 
for parasite counts. Malaria was diagnosed by Quantitative Buffy Coat anal-
ysis, P. falciparum Histidine-Rich-Protein 2 screening (now ICT Malaria,Binax) 
and conventional microscopy with subsequent specification of the Plasmodium 
species. Multiple malaria episodes in a single patient were only regarded as sepa-
rate cases if caused by true re-infection; recrudescent infections of P. falciparum 
and Plasmodium malariae and relapses of Plasmodium vivax and Plasmodium. 
ovale were excluded. Patients with a mixed infection of P. falciparum with another 
Plasmodium species were considered as having P. falciparum malaria.
Definitions
Severe malaria 
Patients were considered as having severe P. falciparum malaria if they met 
predefined modified World Health Organization (WHO) criteria for severe malaria 
on admission or during hospitalization (12) (“severity criteria”):
• A Glasgow Coma Scale (GCS) score < 11 (indicating cerebral malaria) or
• Anaemia (haematocrit < 0.20 L/L with parasite count > 100.000/μL) or
• Jaundice (serum bilirubin > 50 μmol/L with parasite count > 100.000/μL) or
• Renal impairment (urine output < 400 mL/24h and serum creatinine > 250 
μmol/L) or
• Hypoglycaemia (blood glucose < 2.2 mmol/L) or
• Hyperparasitaemia (> 10% parasitaemia) or
• Shock (systolic blood pressure < 80 mm Hg with cold extremities)
Hyponatraemia. 
Hyponatraemia was defined as a serum sodium concentration of less than 135 
mmol/L.
Statistical analysis
All data were not Normally distributed (Kolmogorov-Smirnov test) and are, there-
fore, presented as medians and range. Univariate comparisons were performed 
using the Kruskall-Wallis test (three groups) with Dunn’s post-hoc tests, or the 
Mann-Whitney test (two groups). Correlations were analyzed using Spearman 
rho (r
s
) and Wilcoxon signed rank test. The prognostic value of serum sodium 
for malaria severity was determined by a receiver operating characteristic (ROC) 
analysis. To analyse if hyponatraemia was also independently associated with 
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malaria severity, a logistic regression analysis was performed using a backward 
stepwise conditional approach. In the latter analysis only patients with falciparum 
malaria were included (because only the falciparum species can cause severe 
malaria) and the presence of severe malaria was defined as the outcome.
Results 
Patient characteristics
Serum sodium concentration on admission was available for 446 of the 477 
malaria cases (93.5%), and they comprised the study population. Infection was 
most commonly acquired in Africa (75%) and Asia (14%). Infections with P. falci-
parum accounted for the majority of cases (n = 315, 70.6%). P. falciparum infection 
was classified as severe (n=35) or non-severe (n=280). One hundred and thir-
ty-one patients had non-falciparum malaria, which consisted of P. vivax (n=92, 
70%,), P. ovale (n=33, 25%) and P. malariae (n=6, 5%). True re-infection occurred 
in 13 patients, and four patients had a mixed infection of P. falciparum and another 
Plasmodium species. Table 1 shows the comparison of the demographic charac-
teristics, vital signs, and laboratory data on admission in the groups with severe 
and non-severe falciparum malaria, and non-falciparum malaria. 
Characteristics of patients with severe malaria
Thirty-two patients fulfilled one or more of the severity criteria at initial presen-
tation (GCS<11 n=3; anaemia with a parasite count exceeding 100,000 tropho-
zoites per µL n=3; icterus with a parasite count exceeding 100,000 trophozoites 
per µL n=17; acute oliguric renal insufficiency n=4; hypoglycaemia n=0; hyper-
parasitaemia n=12 and shock n=2, respectively). Three patients did not fulfil the 
criteria for severe disease on admission but their clinical course deteriorated 
shortly hereafter. Admission plasma lactate levels were significantly increased in 
patients with severe malaria as compared with patients with uncomplicated falci-
parum malaria and patients with non-falciparum malaria (Table 1). Eventually, at 
admission to the intensive care unit (ICU), all 35 patients fulfilled one or more of 
the severity criteria (cerebral malaria or impaired conscious level n=9; anaemia 
with a parasite count exceeding 100,000 trophozoites per µL n=3; icterus with a 
parasite count exceeding 100,000 trophozoites per µL n=19; acute oliguric renal 
insufficiency n=5; shock n=2, respectively). The first arterial blood gas analysis on 
ICU showed a median bicarbonate level of 21 mmol/L (range 17 to 26 mmol/L) 
and a median base deficit of 2 (range -3 to 9). Two patients needed mechanical 
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ventilation, whereas three patients needed haemodialysis. Twenty-four patients 
received exchange transfusion. Details of this standardized adjunct treatment 
have been published elsewhere (13). One patient with severe falciparum malaria 
died of cerebral malaria. 
Hyponatraemia in imported malaria
Hyponatraemia was present in 207 patients (46%). The distribution of serum 
sodium in the whole population seemed to be shifted to lower values (Figure 1). 
Figure 2 shows the distribution of serum sodium in patients with severe P. falci-
parum, non-severe P. falciparum, and non-falciparum malaria. Only two patients 
(0.4%) had a serum sodium concentration exceeding 145 mmol/L. When only 
patients with hyponatraemia were considered, hyponatraemia was more severe 
in severe falciparum malaria (median serum sodium 129 mmol/L) compared with 
both non-severe falciparum and non-falciparum malaria (median serum sodium 
131 and 132 mmol/L, respectively, p < 0.05). In the whole population, prerenal 
azotaemia (defined as a serum urea : creatinine ratio > 1 : 10) was not more common 
(11/207 or 5.3% vs. 7/239 or 2.9%, p = 0.2) and haematocrit values (median 0.39 
vs. 0.39, p = 0.6) were not higher in patients with hyponatraemia and malaria. 
Other causes of hyponatraemia appeared rare. Only three patients with malaria 
and hyponatraemia also used drugs associated with hyponatraemia (1 thiazide 
diuretic, 1 several diuretics, 1 risperidone) (14). None of the patients had severe 
heart or liver failure, and none of the patients had known pre-existing hypona-
traemia. A significant correlation was demonstrated between sodium levels and 
CRP levels on admission for all patients with imported malaria (n=428; r
s
=-0.36; 
p<0.0001) but also for patients with infections solely caused by Plasmodium falci-
parum (n=298; r
s
= -0.41; p<0.0001).
Hyponatraemia and malaria severity
The area-under the ROC-curve for the predictive value of serum sodium concentra-
tion for malaria severity was 0.72 for P. falciparum infections and 0.74 for all patients 
with malaria (Figure 3). A cut-off of 133 mmol/L was identified as having the best 
discriminatory performance (sensitivity 0.69, specificity 0.76, positive predictive 
value 0.20, negative predictive value 0.97). Variables significant on univariate anal-
ysis that were not severity criteria (Table 1) were entered as dichotomous variables 
in the multivariate model using different cut-off points. The following parameters 
were independently associated with severe falciparum malaria: serum sodium < 131 
mmol/L, CRP > 175 mg/L, LDH > 750 U/L, thrombocytes < 20 x 109/L and leuko-
cytes > 6.5 x 109/L (Table 2). When the severity criteria were also entered in the 
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model, only serum sodium < 131 mmol/L and CRP > 175 mg/L remained indepen-
dent predictors of severe falciparum malaria (both p < 0.05).
Clinical course and outcome
The median duration of hospital stay is shown in Table 1  Three of the 35 patients 
with severe falciparum malaria met the criteria for severe malaria only hours 
after admission when their parasite counts increased to above cut-off levels 
or their clinical course deteriorated. Interestingly, two of them were hypona-
traemic on admission (serum sodium 130 and 132 mmol/L). Follow-up serum 
sodium concentrations were available for 24 of 27 patients with severe falci-
parum infection and hyponatraemia. Serum sodium normalized within 24 hours 
in seven patients. It took between 24 and 96 hours in seven patients, and more 
than 96 hours in eight patients. In three patients the time in which serum sodium 
normalized was unknown. Patients with more severe hyponatraemia on admis-
sion remained hyponatraemic for a longer period of time (p < 0.01). There was 
no significant correlation between sodium levels and GCS in patients with severe 
malaria (n=35; r
s
= -0.036; p=0.84).
Discussion
The present study shows that hyponatraemia is common in patients with imported 
malaria, and is associated with severe disease in P. falciparum malaria. The inci-
dence of hyponatraemia in this study (77% severe P. falciparum, 48% non-se-
vere P. falciparum, and 34% non-falciparum) is comparable to that found in other 
studies. Holst et al (7) found hyponatraemia in 13 of 17 (76%) non-immune trav-
ellers with severe P. falciparum infection whereas Kockaerts et al (15) reported an 
incidence of 53% in a cohort of 101 patients with imported malaria, although no 
differentiation according to Plasmodium species or severity of malaria was made. 
In children with imported malaria, lower incidences were found (5/20 or 25% by 
Viani et al (16), 16/192 or 8% by Ladhani et al (2)).
Interestingly, in the present study, a serum sodium < 131 mmol/L, CRP > 175 mg/L, 
LDH > 750 IU/L, thrombocyte count < 20 x 109/L, and leukocyte count > 6.5 x 109/L 
were all independently associated with severe falciparum malaria (as defined by 
the modified WHO severity criteria (12)). Some of these parameters like throm-
bocytopaenia (17) and leukocytosis (18) have been reported as risk factors for 
severe malaria or a fatal outcome but this has not been a universal finding (18, 19).
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When the severity criteria were also entered in the regression model, serum 
sodium < 131 mmol/L and CRP > 175 mg/L were the only remaining independent 
variables with Odds ratio’s of 10.4 (95% Confidence Interval 3.1 – 34.9) and 4.8 
(95% CI 1.6 – 15.0) for severe malaria, respectively, suggesting that determina-
tion of these parameters might contribute to an early recognition of patients with 
severe malaria on admission. 
However, there are some important drawbacks, which may limit its usefulness 
in clinical practice. First, sodium had a poor positive predictive value (0.20) for 
severe malaria. The observations that hyponatraemia may be seen in imported 
malaria caused by any Plasmodium species as well as in other infectious diseases 
suggest that hyponatraemia per se is unlikely to represent an exclusive feature 
of falciparum malaria but merely reflects the effects of severity of any disease 
rather than malaria itself. Second, hyponatraemia is a well recognized indicator 
of disease severity and predictor of mortality regardless of its cause, as has been 
observed in several studies with hospitalized adult patients (20, 21). As such, the 
recognition that lower sodium occurs more frequently in severe malaria will prob-
ably not significantly change the monitoring and management of the patient since 
most physicians would already have a higher index of suspicion for a complicated 
course. Third, the finding that sodium is an independent risk factor for severe 
malaria contrasts with the findings of two recent studies. In the first study (22), 
performed in several malaria-endemic countries, involving more than 1000 adults 
individuals with severe malaria (defined by the same modified WHO criteria) only 
base deficit and cerebral malaria (measured with GCS) but not sodium were found 
to be main independent predictors of outcome. Moreover, in the other study (23) 
involving 482 individuals with imported falciparum malaria, sodium was not identi-
fied as an independent risk factor for severe falciparum malaria. The reason for this 
discrepancy with the present findings is not immediately apparent but might relate 
to differences in the number of elderly patients (24) and differences in ethnicity 
(23). For example, of the 482 individuals with imported malaria (23), 68% of the 
patients were of black ethnicity, which was associated with a reduced risk of devel-
oping WHO-defined severe falciparum malaria, whereas white patients had odds 
that were 8-fold higher. In the present study patients of black ethnicity consti-
tuted only a minority of the patients. Fourth and probably most important from 
a clinical point of view, other parameters like coma and parameters of impaired 
tissue perfusion (such as acidosis (25), elevated lactate level (25, 26), or base 
deficit (22)) have been reported as more powerful risk factors for severe malaria 
or a fatal outcome than sodium. 
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Even though the predictive power of hyponatraemia for severe malaria may be 
limited in clinical practice, its pathophysiology is certainly puzzling. Suggested 
mechanisms are absolute sodium deficit due to cerebral salt wasting, excessive 
sweating or loss in the gastrointestinal or urinary tract (3), and the secretion of 
vasopressin which can be either appropriate, in case of volume depletion (4), or 
inappropriate as in the syndrome of inappropriate antidiuretic hormone secre-
tion (10) or reset osmostat (8). There is, however, no consensus as to their rela-
tive contributions Although it has been suggested that hyponatraemia is associ-
ated with worse outcome and should be corrected (27), a recent study found that 
hyponatraemia is associated with preserved consciousness and even a decreased 
mortality in severe P. falciparum malaria (4). In the setting of hypovolaemia, the 
hyponatraemia was likely related to a continued oral hypotonic fluid intake in those 
patients who had preserved consciousness and the hyponatraemia required no 
therapy beyond rehydration given the observation that plasma sodium normal-
ized with crystalloid rehydration within 24 hours after admission (4). 
Although the present study was not designed to investigate the pathophysiology 
of hyponatraemia in malaria, a number of observations might argue against a role 
for hypovolaemia in the pathophysiology of hyponatraemia in the present study. 
When prerenal azotaemia and haematocrit were considered as surrogate markers 
for hypovolaemia, prerenal azotaemia was not more common and haematocrit 
was not higher in hyponatraemic patients as compared with normonatraemic 
individuals. In addition, hyponatraemia persisted for days in one third of the 
patients despite rapid volume resuscitation with normal saline. An explanation for 
this difference could be that the patients described by Hanson et al (4) presented 
late to hospital and were more ill on admission as evidenced by the high number of 
comatose patients and the higher mortality rate. The inverse relationship between 
plasma sodium and GCS could not be reproduced in the present study but might 
be underpowered by the relatively low number of comatose patients. Although 
speculative, an other mechanism may have contributed to hyponatraemia in the 
present study. It is certainly interesting to note that the pro-inflammatory cytokine 
interleukin-6 is elevated in malaria and also implicated in the non-osmotic release 
of vasopressin (28, 29). The delayed normalization of serum sodium concentra-
tion as was observed in the present study, might reflect the persistent elevation of 
inflammatory cytokines, which are known to remain increased for several weeks 
in some patients with severe malaria (30). Previously, a relationship between the 
development of in-hospital hyponatraemia and a rise in CRP was demonstrated, 
which is not only another illustration of this mechanism (20) but also in line with 
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the observed correlation between sodium levels and CRP levels in patients with 
imported malaria in the present study. Additional studies are needed to further 
unravel the intriguing pathophysiology of hyponatraemia in malaria.
Conclusion
Hyponatraemia is common in imported malaria and associated with severe 
falciparum malaria. From a clinical point of view, however, the predictive power 
of hyponatraemia for severe malaria is limited. The precise pathophysiological 
mechanisms of hyponatraemia in malaria require further study. 
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Table 1. Patient characteristics at initial presentation
Severe 
P. falciparum
(n = 35)
Non-severe 
P. falciparum
(n = 280)
Non-
falciparum
(n = 131)
P-value*
Demographics
Age, years 44 (4 – 70) 39 (4 – 78) 35.5 (8 – 77) 0.007B
Male, female, n (%) 21 (58), 14 (42) 202 (72), 78 (28) 87 (66), 44 (34) N.S.
Vital signs on admisson
Body temperature, °C 38.2 
(36.2 – 41.2)
38.6 
(35.7 – 41.0)
38.6 
(35.0 – 41.5)
N.S.
Pulse rate, beats per minute 101 (50 – 150) 92 (45 – 150) 89 (58 – 138) 0.02A
Systolic blood pressure, mm Hg† 115 (80 – 160) 120 (80 – 90) 120 (70 – 196) N.T.
GCS < 11, n (%)† 3 (9) 0 (0) 0 (0) N.T.
Laboratory data on admission
C-reactive protein, mg/L 184 (91 – 265) 77 (5 – 320) 71 (8 – 213) < 0.0001A
Haematocrit, L/L† 0.35 
(0.17 – 0.51)
0.40 
(0.19 – 0.54)
0.38 
(0.22 – 0.53)
 N.T.
Leucocyte count, x 109/L 7.1 (3.2 – 18.5) 4.9 (1.3 – 13.2) 5.3 (1.9 – 15.3) < 0.0001A
Thrombocytes, x 109/L 36 (3 – 188) 98 (11 – 433) 94 (10 – 292) < 0.0001A
Serum sodium, mmol/L 130 (115 – 146) 135 (119 – 145) 136 (124 – 148) < 0.0001A
Serum potassium, mmol/L 3.7 (2.7 – 4.7) 3.8 (2.5 – 5.1) 3.8 (2.7 – 5.4) N.S.
Serum creatinine, μmol/L† 114 (48 – 871) 94 (41 – 228) 87 (46 – 477) N.T.
Serum glucose, mmol/L 6.3 (4.1 – 12.5) 6.6 (4.4 – 33.8) 6.4 (4.7 – 22.1) N.S.
Total bilirubin, μmol/L† 53 (15 – 416) 21 (4 – 262) 21.5 (3 – 91) N.T.
Alanine-aminotransferase, U/L 58 (11 – 655) 35 (3 – 265) 31 (6 – 198) 0.001A
Lactate dehydrogenase, U/L 890 (308 – 4113) 455 (224 – 2724) 428 (185 – 1395) < 0.0001A
Plasma lactate (mmol /L) 2,3 (1,2 – 5,8) 1,4 (0,5 – 4,4) 1,3 (0,7 – 3,0) <0.001B
Parasite load 
(trophozoites / μL) †
239,200
(520 – 1,110000)
5300 
(2 – 385,000)
N/A N.T.
Duration hospitalisation, days 8 (3 – 19) 5 (1 – 16) 2 (1 – 11) <0.0001A+C
* Using Kruskall-Wallis and Dunn’s post-hoc tests. Parameters that are included in the modified WHO 
severity criteria for severe falciparum malaria (indicated by † (12)) were not tested (N.T.). N.S. denotes 
‘not significant’. A group 1 vs. group 3; B group 1 vs. groups 2 and 3; C group 2 vs. group 3
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Table 2.  Logistic regression analysis showing independent predictors of severe 
   falciparum malaria
Variable β SE β Wald’s χ df P-value Odds ratio (95% CI)
Constant -6.1 1.32 21,400 1 < 0.001 N/A
Serum sodium < 131 mmol/L 2.3 0.62 14,286 1 < 0.001 10.4 (3.1 – 34.9)
C-reactive protein > 175 mg/L 1.6 0.58 7,472 1 0.006 4.8 (1.6 – 15.0)
Lactate dehydrogenase > 750 U/L 1.8 0.58 9,288 1 0.002 5.9 (1.9 – 18.7)
Thrombocytes < 20 x 109/L 3.7 1.03 12,761 1 < 0.001 40.0 (5.3 (302.8)
Leukocytes > 6.5 x 109/L 2.3 0.60 14,384 1 < 0.001 9.7 (3.0 – 31.5)
Figure 1. Distribution of serum sodium in patients with imported malaria
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Figure 2. Distribution of serum sodium in malaria patients grouped by 
   causative Plasmodium species
Hyponatraemia was present in 27/35 (77%) of patients with severe P. falciparum infection, in 135/280 
(48%) of patients with non-severe P. falciparum infection, and in 45/131 (34%) of patients with non- 
falciparum infection. Dashed lines indicate normal reference range. Bars indicate the median.
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Figure 3. Receiver operating characteristics curve of serum sodium
   concentration for malaria severity
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Hyponatraemia in imported malaria: 
The pathophysiological role 
of vasopressin 
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Abstract
Background: In the pathophysiology of hyponatraemia in malaria, the 
relative contribution of appropriate and inappropriate arginine vaso-
pressin (AVP) release is unknown; the trigger for inappropriate AVP 
release is also unknown.
Methods: Serum copeptin, a stable and sensitive marker for AVP release, 
was analysed in a large cohort of patients with imported malaria (204 
patients) and in a small prospective substudy (23 patients) in which urine 
sodium and osmolality were also available. Hyponatraemia was classified 
as mild (serum sodium 131-134 mmol/l) and moderate-to-severe (< 131 
mmol/l).
Results: Serum copeptin on admission was higher in patients with 
moderate-to-severe hyponatraemia (median 18.5 pmol/L) compared 
with normonatraemic patients (12.7 pmol/L, p < 0.05). Despite prompt 
fluid resuscitation, the time to normalization of serum sodium was longer 
in patients with moderate-to-severe hyponatraemia (median 2.9 days) 
than in patients with mild hyponatraemia (median 1.7 days, p < 0.001). A 
poor correlation was found between serum sodium and copeptin levels 
on admission (rs = -0.17, p = 0.017). Stronger correlations were iden-
tified between serum C-reactive protein and copeptin (rs = -0.36, p < 
0.0001) and between serum C-reactive protein and sodium (rs = 0.33, 
p < 0.0001). Data from the sub-study suggested inappropriate AVP 
release in seven of 13 hyponatraemic malaria patients; these patients 
had significantly higher body temperatures on admission.
Conclusion: In hyponatraemic patients with imported malaria, AVP 
release was uniformly increased and was either appropriate or inappro-
priate. Although the exact trigger for inappropriate AVP release remains 
unknown, the higher body temperatures, correlations with C-reactive 
protein and long normalization times of serum sodium, suggest an 
important role of the host inflammatory response to the invading malaria 
parasite. 
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Background
Hyponatraemia is a common finding in imported malaria and associated with 
severe Plasmodium falciparum malaria (1). Nevertheless, its pathophysiology 
remains incompletely understood. Hyponatraemia is primarily a water balance 
disorder and usually caused by increased secretion of arginine vasopressin 
(AVP). With regard to hyponatraemia in malaria, some studies found evidence for 
“appropriate” vasopressin release due to hypovolaemia (2) whereas other studies 
found evidence for “inappropriate” vasopressin release (3, 4). There is, however, 
no consensus regarding the relative contributions of these mechanisms in the 
pathophysiology of hyponatraemia in malaria. 
AVP is a key hormone in maintaining fluid balance and vascular tone (5). Despite 
these important physiological functions, mature AVP is rarely measured clinically, 
because the assay is difficult and subject to preanalytical and analytical errors (6). 
Recently, copeptin, a 39-amino acid glycopeptide that comprises the C-terminal 
moiety of the AVP precursor (CT-proAVP) was demonstrated to be a stable and 
sensitive marker for AVP release (6-9). Furthermore, a number of studies have now 
shown that measurement of serum copeptin or calculation of the serum copeptin 
to urine sodium ratio is useful in the differential diagnosis of fluid and electrolyte 
disorders (10, 11). In the present study, serum copeptin levels were evaluated in a 
large cohort of patients with imported malaria to further explore the role of AVP in 
the pathophysiology of hyponatraemia in malaria.
Methods
Patients
The Harbour Hospital is a 161-bed general hospital located in Rotterdam, The 
Netherlands. It also harbours the Institute for Tropical Diseases, which serves as 
a national referral centre. The Rotterdam Malaria Cohort consists of all patients 
diagnosed with malaria at the Institute for Tropical Diseases in Rotterdam. In 
the period 1999-2010 the Rotterdam Malaria Cohort comprised 519 cases of 
imported malaria. Of all patients, anonymized demographic, clinical and labora-
tory data are routinely collected and stored in an electronic database. Moreover, 
in a large number of patients serum samples taken on admission were stored. For 
the present study, anonymized data from patients who entered the Rotterdam 
Malaria Cohort between January 1999 and December 2010 were used to estimate 
206
the prevalence of hyponatraemia in imported malaria at time of first presentation 
as well as for the follow-up of sodium levels after treatment during admission. For 
those patients with stored serum samples, copeptin levels were measured retro-
spectively. In a small sub-study serum copeptin levels were measured prospec-
tively in addition to urinary sodium and osmolality. 
Laboratory investigations 
All available laboratory data were measured on admission with the use of routine 
procedures. In contrast, copeptin levels were retrospectively measured in stored 
serum samples with a commercial sandwich immunoluminometric assay 
(Brahms Copeptin, Thermo Fisher Scientific, Hennigsdorf/Berlin, Germany) as 
described (9). Normal values for serum copeptin in healthy volunteers range 
between 1.70 and 11.25 pmol/L (9). Blood smears (thin and thick films) were 
obtained from finger pricks and stained with Giemsa for parasite counts. Malaria 
was diagnosed by Quantitative Buffy Coat analysis, P. falciparum Histidine-Rich-
Protein 2 screening (now ICT Malaria, Binax) and conventional microscopy with 
subsequent specification of the Plasmodium species.
Definitions
Severe malaria
Patients were considered as having severe P. falciparum malaria if they met the 
recently updated World Health Organization (WHO) criteria for severe malaria 
on admission or during hospitalization (12).These criteria differ from the preset 
criteria (13) that were used to define severe malaria in previous studies (1). 
Coma Acidosis Malaria (CAM) score 
Of each patient with severe disease an admission CAM score, a 5-point (0-4 
points) score calculated as the sum of the base deficit score (0-2 points) and 
Glasgow Coma score (0-2 points), was given (14).
Hyponatraemia 
Hyponatraemia was defined as a serum sodium concentration of less than 
135 mmol/L. Mild hyponatraemia was defined as a serum sodium concentra-
tion 131-134 mmol/L, whereas moderate hyponatraemia was defined as a serum 
sodium concentration 125-131 mmol/L. The threshold of 131 mmol/L was chosen 
because a previous study found that a sodium level below 131 mmol/L was an 
independent predictor for severe disease in imported malaria (1). Severe hypo-
natraemia was defined as a serum sodium level below 125 mmol/L. Given the low 
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number of samples of patients with severe hyponatraemia in the copeptin study, 
these patients were grouped with the patients with moderate hyponatraemia to 
form the moderate-to-severe hyponatraemia group.
Inappropriate vs appropriate AVP secretion 
A recent study found that the serum copeptin to urine sodium ratio may be used 
to differentiate normovolaemic hyponatraemia (ratio ≤ 30 pmol/mmol) from 
hypovolaemic hyponatraemia (ratio > 30 pmol/mmol) (11). The most common 
example of normovolaemic hyponatraemia is the syndrome of inappropriate 
antidiuresis (15) and, therefore, a ratio ≤ 30 pmol/mmol was used to define inap-
propriate AVP release. Conversely, AVP release during hypovolaemic hypona-
traemia is considered “appropriate” and, therefore, appropriate AVP release was 
defined as a ratio > 30 pmol/mmol. 
Statistical analysis
All data are reported as medians (range). Univariate comparisons were performed 
using the Kruskall-Wallis test (three groups) with Dunn's post-hoc tests, or the 
Mann-Whitney test (two groups) for not normally distributed data. Normally 
distributed data were compared with unpaired t-tests or unpaired t-tests with 
Welch correction, as appropriate. Correlations were analysed using Spearman rho 
(r
s
) and Wilcoxon’s signed rank test. Kaplan-Meier survival curves for resolution of 
hyponatraemia after treatment were analysed with the Mantel-Cox log-rank test. 
Results
Prevalence of hyponatraemia in imported malaria and its distribu-
tion among the various Plasmodium species
Of the 519 cases in the Rotterdam Malaria Cohort 1999-2010, 10 (1.9%) patients 
had severe hyponatraemia on admission, 60 (11.6%) patients had moderate 
hyponatraemia, whereas 166 (32.0%) malaria patients had mild hyponatraemia 
on admission, respectively. In the remaining 283 (54.5%) patients the sodium 
level on admission was normal. Of the 54 P. falciparum malaria patients fulfilling 
the criteria for severe disease, 5 (9.3%) patients had severe hyponatraemia on 
admission, 20 (37.0%) patients had moderate hyponatraemia, whereas hypo-
natraemia was mild in 18 (33.3%) patients with severe malaria. Eleven (20.4%) 
patients with severe malaria had a normal sodium on admission, including the two 
patients who died. Of the 312 patients with uncomplicated P. falciparum malaria, 
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severe hyponatraemia was present on admission in 4 (1.3%) patients, moderate 
hyponatraemia in 33 (10.6%) patients and mild hyponatraemia was found in 105 
(33.7%) patients on admission, respectively. Serum sodium concentrations were 
normal in the remaining 170 (54.5%) patients with uncomplicated P. falciparum 
malaria. Of the 153 patients with non-P. falciparum malaria, severe hyponatraemia 
was present in 1 (0.7%) patient, moderate hyponatraemia in 7 (4.6%) patients, 
mild hyponatraemia in 43 (28.1%) patients, and 102 (66.7%) patients had normal 
serum sodium concentrations on admission, respectively. 
Characteristics of the patients with severe malaria
When focusing on the 54 patients with severe malaria, these patients presented 
with the following severity criteria: hypotension (n=1); impaired consciousness 
(n=8) or unrousable coma characterized by a GCS ≤9 (n=3); severe anaemia 
characterized by a haemoglobin level ≤3.0 mmol/L (n=2) or a packed cell volume 
<0.20 (n=6); blackwater fever (n=1); renal impairment characterized by a creat-
inine level ≥265 µmol/L (n=6); liver impairment characterized by a total bilirubin 
level ≥50 mmol/L (n=29); hyperlactataemia characterized by a lactate ≥5 mmol/L 
(n=6); hyperparasitaemia characterized by a parasite load ≥5% (n=34; on admis-
sion to the intensive care unit n=40) and schizontaemia (n=27), respectively.
Of 30 patients with severe malaria a CAM score could be calculated on admission. 
The median CAM score was 1, and the scores ranged from 0 to 3. Nine patients 
had a CAM score of 0, 16 patients a CAM score of 1, four patients had a CAM score 
of 2, whereas 1 patient had a CAM score of 3. 
Thirty-six patients received intravenous treatment with quinine, 11 patients were 
treated with intravenous artesunate. Four patients were solely treated with oral 
anti-malarials and the treatment mode was unknown in three patients. Thirty-two 
patients received exchange transfusion. Details of this adjunct therapy for severe 
malaria are published elsewhere (16). Sixteen of 54 patients were referred from 
surrounding hospitals. There were no statistically significant differences between 
blood glucose levels (glucose 6.3 ± 1.7 mmol/L vs 7.8 ± 5.0 mmol/L, p = 0.1099) and 
serum sodium levels on admission (sodium 133 ± 7 mmol/L vs 130 ± 4 mmol/L, p = 
02491) between patients referred from other hospital (n = 16) and those patients 
directly referred to the Institute for Tropical Diseases (n = 38), making a significant 
contribution of dextrose or glucose infusion on serum sodium levels on admis-
sion unlikely in the referred patients.
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Follow-up of hyponatraemia during hospitalization
In a subset of 151 malaria patients with hyponatraemia from the Rotterdam 
Malaria Cohort, serum sodium levels were measured consecutively during hospi-
talization. Fifty-eight patients had moderate-to-severe hyponatraemia (16 with 
severe P. falciparum malaria; 38 patients with uncomplicated P. falciparum malaria; 
4 non-falciparum malaria) and hyponatraemia was mild in 93 patients (11 patients 
with severe P. falciparum malaria; 76 with uncomplicated P. falciparum infection 
and 6 non-falciparum infections). As shown in Figure 1, time to normalization of 
serum sodium was significantly longer in patients with moderate-to-severe hypo-
natraemia (median time to normalization of sodium 2.9 days) than in patients 
with mild hyponatraemia on admission (median time to normalization of sodium 
1.7 days, p<0.001). In approximately 20% of the malaria patients with moder-
ate-to-severe hyponatraemia, serum sodium levels did not normalize after 1 week 
of antimalarial treatment and infusion of isotonic saline.
Evaluation of the role of copeptin in the pathophysiology of 
hyponatraemia in imported malaria
In 204 malaria patients from the Rotterdam Malaria Cohort copeptin was measured 
in stored serum samples and related to previously established laboratory parame-
ters on admission. The general characteristics of these patients are shown in Table 1. 
In general, patients with moderate-to-severe hyponatraemia presented more ill, as 
illustrated by their higher body temperatures, pulse rates, CRP and creatinine levels. 
Elevated creatinine levels were frequently observed: in 12 of 31 (38.7%) patients 
with moderate-to-severe hyponatraemia, in 10 of 68 (14.7%) patients with mild 
hyponatraemia and in 20 of 105 (19.0%) of normonatraemic patients, respectively. 
Only two patients with severe P. falciparum malaria had a creatinine level exceeding 
the WHO threshold of 265 μmol/L for renal impairment (12). These patients 
both presented with moderate-to-severe hyponatraemia on admission. Serum 
copeptin levels on admission were significantly higher in patients with moder-
ate-to-severe hyponatraemia (median 18.5 pmol/L) as compared with normon-
atraemic patients (12.7 pmol/L) but not with malaria patients who presented with 
mild hyponatraemia (13.2 pmol/L, Figure 2). Copeptin levels exceeding the 97.5 
percentile of normal healthy individuals (corresponding to a copeptin level of 
11.25 pmol/L) were significantly (p=0.0099, Chi square test for trend) more often 
observed in malaria patients presenting with moderate-to-severe hyponatraemia 
(25 of 31 [81%] patients) than in patients with patients with mild hyponatraemia 
(47 of 68 [69%] patients) and normonatraemia (60 of 105 [57%] patients). A poor 
correlation was found between serum sodium and copeptin levels on admission 
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(Figure 3, r
s
=-0.17, p=0.017). In contrast, stronger correlations were demonstrated 
between CRP and copeptin (Supplementary Figure 1, r
s
=-0.36, p<0.0001) on the 
one hand and between CRP and serum sodium (Supplementary Figure 2, r
s
=0.33, 
p<0.0001) on the other hand. 
Urine biochemistry
In a subset of 23 malaria patients urine sodium and urine osmolality were 
measured in parallel with measurement of serum copeptin. The main outcome 
measures are shown in Table 2. In none of the 13 hyponatraemic patients, serum 
glucose exceeded 10 mmol/L, excluding hyperglycaemia as a significant cause 
of hyponatraemia. When the 13 hyponatraemic malaria patients were catego-
rized according to the serum copeptin to urine sodium ratio, 7 hyponatraemic 
patients fulfilled the criteria for inappropriate AVP secretion. There were no signif-
icant differences in creatinine, haematocrit or urea to creatinine ratio between 
hyponatraemic malaria patients with inappropriate or appropriate AVP secre-
tion. Urine osmolality values were significantly higher in patients with inappro-
priate AVP release (median 780 mOsm/kg) than in patients with appropriate AVP 
release (480 mOsm/kg) or normonatraemic patients (484 mOsm/kg). Patients 
with inappropriate AVP release also had significantly higher body temperatures on 
admission than hyponatraemic patients with appropriate AVP release. 
Discussion
Copeptin, the C-terminal glycopeptide domain of pro-vasopressin, is co-se-
creted with AVP from the posterior pituitary in hyperosmolar states and upon 
multiple non-osmotic stimuli, such as hypotension, pain, and other non-spe-
cific causes of stress (6, 8). Circulating copeptin levels are therefore thought to 
reflect the activity of the neuroendocrine stress axis. To gain more insight in the 
pathophysiology of hyponatraemia in malaria and in particular the role of AVP, 
serum copeptin was measured in a large cohort of 204 patients with imported 
malaria. In malaria patients the median serum copeptin levels were three to five-
fold higher than the median level of 4.2 pmol/L observed in 359 healthy volun-
teers (8). In fact, the proportion of malaria patients with copeptin levels above the 
97.5th percentile of normal significantly increased with decreasing sodium levels 
(Figure 3). Moreover, in absolute terms, patients with moderate-to-severe hypo-
natraemia also had significantly higher copeptin levels than normonatraemic 
malaria patients on admission (Figure 2). Because the physiological stimulus 
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for AVP release is hypertonicity, elevated AVP or copeptin levels in the context of 
hyponatraemia indicates a pathological setting. That is, during normal physiology, 
the development of hyponatraemia ought to suppress AVP release and to result in 
a maximally dilute urine with a low urine osmolality (5, 17).
A recent study found that the ratio of serum copeptin to urine sodium may be 
used to differentiate inappropriate from appropriate AVP secretion (11). To further 
investigate the antidiuretic effect of AVP at the level of the target organ, urine 
sodium and osmolality were prospectively studied in parallel with measurements 
of serum copeptin levels in a subset of 13 hyponatraemic and 10 normonatraemic 
malaria patients on admission. Based on the serum copeptin to urine sodium ratio, 
six patients had appropriate AVP release, while seven patients had inappropriate 
AVP release. Hyponatraemic patients with inappropriate AVP release had signifi-
cantly higher urine osmolality values than observed in patients with an appro-
priate AVP response or in normonatraemic patients. This suggests active water 
reabsorption by the kidneys in malaria patients with inappropriate AVP release. 
Why inappropriate AVP release results in a higher urine osmolality than appro-
priate AVP release is unclear. One could speculate that in the group with appro-
priate AVP release, the renin angiotensin system was likely also activated, leading 
to increased renal sodium reabsorption. Because urine sodium is a major deter-
minant of urine osmolality, a lower urine sodium would therefore result in a lower 
urine osmolality in malaria patients with appropriate AVP release.  
From a pathophysiological point of view there may be two possible explana-
tions for the increased serum copeptin levels despite the presence of hypoto-
nicity. First, volume regulation may have overruled osmoregulation if there was 
true hypovolaemia (18) or a low effective arterial blood volume (19). This mech-
anism is mediated via baroreceptors in the vasculature and is often referred to as 
“appropriate” AVP release. In 6 of 13 hyponatraemic patients with available urine 
biochemistry data, AVP release was considered appropriate based on the serum 
copeptin to urine sodium ratio. However, in a substantial number of patients with 
moderate-to-severe hyponatraemia, the hyponatraemia persisted for more than 
seven days despite infusion of isotonic saline, rendering persistence of hypovo-
laemia an unlikely explanation (Figure 1). Hence, other mechanisms must apply in 
a substantial part of the malaria patients with hyponatraemia.
The second explanation for elevated copeptin levels despite the presence of hypo-
tonicity may involve activation of central osmoreceptors leading to vasopressin 
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release and subsequent development of hyponatraemia. This alternative mech-
anism could have been mediated through cytokines (20) and resembles the 
syndrome of inappropriate antidiuresis, a common cause of hyponatraemia (15). 
In fact, in 7 of 13 hyponatraemic malaria patients an inappropriate release of AVP 
appeared to be present. Of potential relevance, in this regard, is the observation 
that the pro-inflammatory cytokine interleukin-6 is elevated in malaria and is also 
implicated in the non-osmotic release of AVP (21, 22). The delayed normaliza-
tion of serum sodium concentration, as was observed in the present study, might 
be the consequence of the persistent elevation of inflammatory cytokines, as 
has been shown for patients with severe malaria (23). Previously, a relationship 
between a rise in CRP and the development of hospital-acquired hyponatraemia 
was demonstrated (24). This is not only another illustration of a presumed cyto-
kine-driven non-osmotic release of AVP (20) but also in line with the observed 
inverse relationship between serum sodium and CRP levels on the one hand, 
and CRP and copeptin levels on the other hand (Supplementary Figures). 
Although several drugs, such as opiates, non-steroidal anti-inflammatory drugs, 
and diuretics, can contribute to hyponatraemia, these drugs were rarely used in 
our cohort, and it is our policy not to administer these drugs to malaria patients 
because of their potentially adverse effects. Although thyroid and adrenal func-
tion were not formally tested, which is recommended before diagnosing inap-
propriate AVP release, the response of hyponatraemia to malaria treatment was 
highly suggestive of a causal relationship. 
The distinction between appropriate and inappropriate AVP release in hypona-
traemic malaria patients may be relevant with regard to selecting the optimal 
intravenous fluid regimen. Because previous studies did not separate hypona-
traemic malaria patients on the basis of appropriate or inappropriate AVP secre-
tion, future studies are necessary to give clinical guidance. In general, however, 
hypovolaemia causes appropriate AVP release and should therefore be treated 
with isotonic fluids. A caveat, however, is that serum sodium may rise too rapidly 
during treatment of hypovolaemic hyponatraemia with isotonic fluids (25). The 
risk of exceeding recommended correction rates is osmotic demyelination, 
although few cases in malaria patients have been reported. Conversely, during 
inappropriate AVP release, the emphasis of therapy should perhaps be more on 
aggressive anti-malaria treatment, given the association with a stronger cyto-
kine response. In this setting, a restrictive intravenous fluid regimen may prove 
beneficial, because even isotonic saline can worsen hyponatraemia during 
the syndrome of inappropriate antidiuresis (26). In this regard, a recent study 
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advocating restrictive IV-fluid therapy in children with malaria is also of interest, 
although no serum sodium values were reported (27). 
A potential limitation of our study is that it remains debatable whether urine 
sodium can be considered a reliable parameter for the establishment of hypovo-
laemia in malaria, since circulating cytokines have also been implied in causing 
tubular injury and therefore natriuresis (28). The evidence for the pathogenetic 
role of AVP in the pathophysiology of hyponatraemia in malaria is, however, 
substantial. The results of the small urine substudy suggest that appropriate (2, 
19) and inappropriate (3, 29) AVP secretion may both occur in the pathophys-
iology of hyponatraemia in imported malaria. Although speculative, the urine 
substudy indicated that patients with an inappropriate AVP release had signifi-
cantly higher body temperatures on admission than patients with appropriate 
AVP release, which suggests that - at least in part - the extent of the host inflam-
matory response to the invading malaria parasite may play a pivotal role in the 
aetiology of cytokine-driven non-osmotic release of AVP.
214
Table 1.  Characteristics of 204 malaria patients in the copeptin study. 
Moderate-to-severe 
hyponatraemia 
(n=31)
Mild 
hyponatraemia
(n=68)
Normonatraemia
(n=105)
P-value*
Demographics
Age, years 42
(11-64)
40
(13-69)
39
(8 – 70)
n.s.
Male, female, n (%) 22 (71), 
9 (29)
52 (76),
16 (24)
77 (73), 
28 (27)
n.s.
Malaria species
falciparum, non-
falciparum, n (%)
26 (84), 
5 (16)
54 (79),
12 (21)
61 (58), 
44 (42)
0.0008
Severe malaria, n (%) 10 (40) 10 (40) 5 (20) <0.0001
Parasite load#, 
parasites/μL
85900
(400 – 567000) B<0,001
11032
(2 – 860000)
4600
(30 – 1380600)
0.0013
Vital signs on admission
Body temperature, °C 39.0
(35.7 – 40.8)
38.9
(35.7 – 41.2)
38.2
(36.0 – 41.2)
0.0315
Pulse rate, beats per 
minute
100
(58 – 140 ) B <0,01
95
(64 – 130)
85
(60 - 130)
0.0109
Systolic blood 
pressure, mm Hg
120
(80 – 147)
120
(88 – 165)
120
(95 – 196)
n.s.
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Moderate-to-severe 
hyponatraemia 
(n=31)
Mild 
hyponatraemia
(n=68)
Normonatraemia
(n=105)
P-value*
Laboratory data on admission
C-reactive protein, mg/L 159
(32 - 352) A <0,01; B <0,001
101
(7 – 310) C<0,05
78
(7 - 407)
<0.0001
Haematocrit, L/L 0.35
(0.15 – 0.50) A <0,01
0.41
(0.12 – 0.52)
0.39
(0.26 – 0.53)
0.0006
Serum glucose, mmol/L 6.9
(4.1 – 26.0) B<0,05
7.0
(4.2 – 10.3) C<0,001
6.3
(4.1 – 14.9)
0.0003
Serum creatinine, μmol/L 111
(70 – 1081) B <0,05
97
(55 – 135) 
93
(46 – 208)
0.0180
Serum urea, mmol/L 6.4
(3.6 – 55.8) B <0,01
5.2
(2.2 – 13.5)
4.9
(2.7 – 21.1)
0.0061
Prerenal azotaemia&, n (%) 2 (6) 2 (3) 2 (2) n.s.
Copeptin, pmol/L 18.5
(3.3 – 91.5) B<0,05
13.2
(1.6 – 71.2)
12.7
(1.6 – 82.9)
0.0268
Duration
hospitalisation, days
6
(1 – 13) B <0,001
5
(0 – 11) C <0,001
3
(0 – 12)
<0.0001
Parameters at initial presentation are shown in relation to serum sodium level on admission
* Univariate comparison were performed using Kruskall-Wallis (P-values are given in the column) and 
Dunn’s post-hoc tests (P-values in superscript). A: comparison of severe hyponatraemia vs mild hypo-
natraemia; B: comparison of severe hyponatraemia vs normonatraemia; C: comparison of mild hypo-
natraemia vs normonatraemia. # P.falciparum parasite load only. & defined as ratio serum urea/serum 
creatinin > 1:10; n.s. = denotes “not significant difference”. Medians with range are shown.
Table 1.  Continued
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Table 2. Results of parallel measurements of urine and blood samples from 
   hyponatraemic and normonatraemic malaria patients on admission
Parameter Hyponatraemic patients 
(n=13)
Normonatraemic patients 
(n=10)
Inappropriate 
AVP 
secretion@
(n=7)
Appropriate 
AVP 
secretion
(n=6)
P-value# P-value*
Vital signs on admission
Body temperature, °C 38.9 (37.6-41.1) 37.4 (35.7-38.6) P=0.0153 38.3 (36.0-40.1) n.s.
Pulse rate, beats per 
minute
96 (72-121) 105 (91-120) n.s. 93 (72-125) n.s.
Laboratory data on admission
C-reactive protein, mg/L 158 (60-176) 236 (71-352) n.s. 95 (18-407) n.s.
Haematocrit, L/L 0.39
(0.15-0.44)
0.40 
(0.19-0.50)
n.s. 0.46 
(0.36-0.51)
n.s.
Serum Urea:creatinine 
ratio
0.06 
(0.04-0.11)
0.07 
(0.05-0.14)
n.s. 0.06 
(0.03-0.09)
n.s.
Serum copeptin 
> P97.5, n (%)
4 (57) 5 (83) n.s. 6 (60) n.s
Serum sodium, mmol/L 132 (131-134) 128 (124-132) P=0.012 138 (135-141) n.a.
Urine osmol, mosmol/kg 780 (540-924) 480 (298-532) P=0.0022 484 (234-906) P=0.047
Urine sodium, mmol/L 49 (38-154) 9 (9-47) n.a. 32 (9-164) n.a.
Legend to the table: @ = inappropriate AVP secretion was defined as a serum copeptin to urine sodium 
ratio of ≤ 30 pmol/mmol. #P-values of comparison of hyponatraemic patients with inappropriate vs 
appropriate AVP secretion. *P-values of univariate analysis using Kruskall Wallis followed by Dunn’s post 
hoc tests; n.s. = not significant difference; n.a. = not applicable (defining criterion). Medians with range 
are shown.
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Figure 2 Box- and whiskerplot of copeptin levels in malaria patients with a 
   normal serum sodium concentration on admission (n=105) and in 
   patients with mild hyponatraemia (n=68) and moderate-to-severe 
   (labelled as “severe”) hyponatraemia (n=31) on admission. 
The box indicates the lower and upper quartiles and the central line represents the median; the end of the 
whiskers reflect the 2.5th en 97.5th percentile of copeptin in malaria patients. 
Normonatraemia 
(n=105)
Mild 
hyponatraemia 
(n=68)
Severe 
hyponatraemia 
(n=31)
p < 0.05
Figure 1.  Kaplan-Meier survival curve of restoration of hyponatraemia 
   throughout hospitalization for malaria. 
Separate curves for patients with mild and moderate-to-severe (labelled as “severe”) hyponatraemia on 
admission are given. Mantel-Cox log-rank test showed a significant difference between the two curves 
(p=0.002).
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Figure 3.  Dot plot of relationship between serum copeptin and serum sodium. 
A weak but significant inverse relationship was observed (r
s
=-0.17, p=0.017).
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p = 0.017
219
The pathophysiological role of vasopressin  /  CHAPTER 11
C
-r
ea
ct
iv
e 
p
ro
te
in
 (
m
g/
L)
C
-r
ea
ct
iv
e 
p
ro
te
in
 (
m
g/
L)
Copeptin (pmol/L)
Sodium (mmol/L)
 Severe hyponatraemia
° Mild hyponatraemia
+  Normonatraemia
 Copeptin > P97.5
° Copeptin ≥ P97.5
Supplementary Figure 2. 
Dot plot of relationship between serum C-reactive protein and serum sodium on 
admission as a function of copeptin on admission. 
Copeptin levels above and below the 97.5th percentile of normal are separately given. A significant inverse 
correlation was present between C-reactive protein and sodium on admission (r
S
=-0.36, p<0.0001)
Supplementary Figure 1. 
Dot plot of relationship between serum C-reactive protein and serum Copeptin 
on admission as a function of sodium level on admission.
A significant correlation between C-reactive protein and serum Copeptin was present (r
S
=0.33, 
p<0.0001). Patients with moderate or severe hyponatraemia were grouped (labelled as “severe”).
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Malaria remains one of the most important causes of fever after international 
travel and must be considered in all patients who fall ill after returning from 
endemic areas. However, clinicians in non-endemic regions often have little expe-
rience with diagnosing and treating this infection and it has been demonstrated 
that lack of experience with malaria patients increases the case fatality rate (1, 2). 
Recognizing patients at risk for a severe course of the infection and awareness 
of the possible complications is essential. In this thesis we aimed to find tools to 
improve this assessment. 
Assessing and predicting the severity 
of imported malaria
Definition of severe malaria
In the year 1990, the World Health Organisation (WHO) first introduced a set of 
criteria to define severe Plasmodium falciparum infection. The purpose of this case 
definition was primarily to facilitate clinical and epidemiological studies, but it also 
aimed to offer guidance in the clinical management of cases. The WHO recom-
mends that patients fulfilling one or more of these criteria should be treated in 
an intensive care unit (ICU) (3-5). The set of criteria is based on clinical studies 
and expert opinion (6, 7), and has been modified and updated several times, 
most recently in 2014 (8). It has indeed been demonstrated that the mortality 
rate increases when a higher number of severity criteria is met (9). However, the 
frequency at which the different criteria occur differs largely between patient 
cohorts in endemic and non-endemic countries and between adults and chil-
dren (10-12). 
Predicting severity in two different worlds of malaria
In resource-limited settings, clinicians often face severe limitations in the 
capacity of ICU facilities, necessitating strict triage of patients. In this context, 
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the WHO definition for severe malaria is deemed too broad by some authors 
(6). As the WHO criteria have been found to have large disparities in their indi-
vidual predictive value for outcome (6, 9, 13), Hanson et al. introduced the 5-point 
Coma Acidosis Malaria (CAM) score, that uses the two main independent predic-
tors of mortality, acidosis and Glasgow Coma Score, which they derived from 
the Southeast Asia-located SEAQUAMAT trial (6, 14). The score performed well 
in predicting mortality and selecting patients with a need for ICU admission. 
However, in the low CAM-score group, which selects patients who may be safely 
monitored on a general ward, the mortality was still 4.2%. Moreover, in a London-
based study the CAM-score was found to have had limited value in patients with 
severe imported malaria needing intensive care monitoring (15). These findings 
illustrate that predictors and scoring systems that are highly useful in endemic 
settings may not be applicable in non-endemic regions, and vice versa.
In non-endemic countries, an important factor that limits the use of the WHO 
definition to guide therapeutic decisions is the fact that the definition requires a 
quantitative Plasmodium falciparum load. Facilities for reliable quantification of 
parasitemia are not available in all hospitals at all hours outside endemic regions. 
In these situations, rapid diagnostic tests (RDT’s) are often used to diagnose 
malaria. A marker that reliably can identify patients at risk for severe malaria would 
be of great help in these situations. Therefore, in Part I of this thesis, we aimed to 
identify parameters that may improve the identification of malaria patients at risk 
for a severe infection in non-endemic countries.
Host-related biomarkers as predictors for severe imported malaria
In recent years, biomarkers have become increasingly important within the field 
of infectious diseases and many biomarkers have been evaluated as predictors 
of outcome in bacterial sepsis. Since similarities in the pathogenesis and clin-
ical presentation of bacterial sepsis and severe malaria exist (16), we evaluated 
whether biomarkers that have proven successful in sepsis could be equally valu-
able in the prediction of severity in malaria. 
Three of those biomarkers were studied in Chapter 2. Procalcitonin is an exten-
sively evaluated marker for bacterial infections that has been found to reli-
ably predict mortality in patients with sepsis and respiratory infections (17, 18) 
and it can safely guide therapeutic decisions in septic patients on the ICU (19). 
Neopterin, a marker of activated cell mediated immunity, is produced by acti-
vated monocytes, macrophages, and dendritic cells (20), and was found to be 
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excreted after exposure to Plasmodium falciparum antigens in vitro (21). The trig-
gering receptor expressed on myeloid cells (TREM)-1 is a marker that belongs to 
the immunoglobulin superfamily and is expressed on the surface of neutrophils, 
monocytes, and macrophages (22). Soluble TREM-1 yielded promising results in 
predicting severity of sepsis (23, 24). However, in this thesis we found that TREM-1 
levels did not discriminate severe from uncomplicated disease in patients with 
imported malaria. Travellers with severe P. falciparum malaria did have significantly 
higher levels of neopterin and procalcitonin on admission than travellers with 
uncomplicated malaria. Both neopterin and procalcitonin had good areas under 
the receiver operating characteristic curve (AUROC’s) of 0.85 and 0.78 respec-
tively (Table 1). Although these biomarkers have a very high negative predictive 
value (NPV), the positive predictive value (PPV) of both markers was poor (Table 1). 
In Chapter 3, we evaluated the glycopeptide copeptin, which forms the C-terminal 
part of the arginine vasopressin (AVP) precursor and is a stable and sensi-
tive surrogate marker for AVP release (25, 26). In studies in patients with bacte-
rial sepsis and in patients with leptospirosis, it was shown that copeptin levels 
correlate better with disease severity and outcome than previously evaluated 
biomarkers like C-reactive protein (CRP) and procalcitonin (27, 28). As one of the 
key similarities between leptospirosis and severe malaria is the frequent occur-
rence of hyponatraemia (29), which can be induced by increased AVP secretion 
(30, 31), we studied the correlation between copeptin levels and the severity and 
outcome of malaria. In contrast to studies in patients with severe bacterial sepsis 
and severe leptospirosis however, copeptin was not found to be superior to CRP 
in imported malaria. 
These four biomarkers, procalcitonin, neopterin, TREM-1 and copeptin, all 
had good negative predictive values, and the first two even outperformed CRP. 
However, the PPV’s were found to be poor (Table 1). In a clinical context this means 
that particularly procalcitonin and neopterin can be safely used to exclude severe 
disease and are more accurate than CRP. However, these biomarkers will overes-
timate disease severity in a large number of patients with malaria. Although one 
could argue that, in a resource-rich setting, an inclusive ICU-admission policy is 
defendable, the low PPV limits the usefulness of these biomarkers. An additional 
drawback is that these parameters are usually not routinely measured and their 
limited additional value to the routinely used parameter CRP does not warrant the 
extra cost and effort in clinical practice.
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We therefore wondered if we could identify a routinely measured parameter that 
could help to improve the identification of severely ill patients. Lymphocytopenia 
has frequently been described in malaria patients, both in endemic and non-en-
demic areas (32-36), but results of studies on the correlation between lymphocyte 
count and malaria severity have been conflicting (32, 33, 37, 38). Both lympho-
cytopenia and the neutrophil-to-lymphocyte count ratio (NLCR) were found to 
be excellent predictors of bacteraemia and of severity and outcome of commu-
nity acquired pneumonia (CAP), with higher prognostic accuracy than traditional 
infection markers (39, 40). Therefore, these parameters are interesting candidate 
predictors for disease severity in malaria. 
As little is known about the dynamics of differential leukocyte count changes and 
the NLCR in malaria and the correlation between the differential leukocyte counts 
and P. falciparum parasitemia is not clear, we studied this in a proof-of-concept 
study. In Chapter 4, we investigated the dynamics of leukocyte count changes and 
the NLCR in a group of malaria-naïve Dutch volunteers, that were exposed to the 
bites of infected mosquitos in the setting of a controlled human malaria infec-
tion (CHMI). During the blood phase a marked decrease in total leukocyte count, 
lymphocyte count and neutrophil count and a rise of the NLCR were observed. 
Only the lymphocyte count and the NLCR correlated with parasitemia. As the 
leukocyte count changes were not observed in the subjects in the non-para-
sitemic control group, who did receive a full course of atovaquone / proguanil, a 
treatment-related effect could be excluded. We also found a rise in total leuko-
cyte count and differential lymphocyte and monocyte count during the liver 
phase; as the liver phase is traditionally regarded as immunologically silent this is 
a surprising finding that has not been described before. In Chapter 5 we explored 
the prognostic value of the differential leukocyte count changes and the NLCR 
in a clinical setting. The NLCR was found to correlate with parasitaemia, but both 
lymphocytopenia and the NLCR were inferior to CRP as markers of severe disease 
in patients with imported malaria in direct back-to-back comparisons (Table 1).
The biomarkers discussed so far are all host-related and reflect the non-specific 
inflammatory response to an invading micro-organism. It is clear form our studies 
that markers which outperform traditional parameters like CRP in bacterial sepsis 
do not perform equally well in malaria. This is possibly a consequence of differ-
ences in pathogenesis. Although important similarities exist between sepsis 
and malaria, the latter obviously has its own specific pathophysiological mecha-
nisms, most prominently the extensive microvascular obstruction by sequestered 
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parasites that may occur in severe malaria. Possibly, parasite-related parameters 
could be more accurate. We therefore studied two of these parameters: the aldo-
lase co-reactivity of the rapid diagnostic tests and the presence of schizonts in 
peripheral blood.
Parasite-related biomarkers as predictors for severe 
imported malaria
Rapid diagnostic tests (RDTs) are highly sensitive tools to diagnose malaria in 
returning travellers (41), but are not designed to quantify parasitaemia, one of the 
major determinants of disease severity (42). In Chapter 6, we describe a multi-
centre operational laboratory study in which we have shown that the widely used 
Binax NOW® Malaria Test can be used for the semi-quantitative assessment of 
parasitaemia by differentiating between reactivity of only the P. falciparum specific 
Plasmodium falciparum histidine-rich protein 2 (PfHRP-2) or both the PfHRP-2 and 
the pan-plasmodial aldolase. Co-reactivity of aldolase and PfHRP-2 was present 
in all patients with a parasitaemia above 50,000 asexual parasites/μl and also in 
all patients with severe malaria. While microscopic determination of peripheral 
blood smears might underestimate the total parasitaemia due to sequestration 
of parasitized erythrocytes in the microvasculature, the reactivity of PfHRP-2 and 
aldolase seems to be preserved. Aldolase co-reactivity had a high NPV but a poor 
PPV for severe malaria, as aldolase co-reactivity was also present in the majority of 
patients with uncomplicated malaria (Table 1). However, in settings where RDT’s 
are performed in absence of possibilities for conventional quantification of the 
parasite load, it can be safely used to exclude high parasitaemia or severe malaria.
The second parasite-related biomarker that we evaluated is the presence of schi-
zonts in peritherpal blood. During the erythrocytic cycle of P. falciparum, infected 
erythrocytes tend to adhere to the vascular endothelium and therefore the 
peripheral parasite count does not always correlate well with the total parasite 
load (43). The appearance of schizonts in peripheral blood smears is thought to 
reflect a high volume of sequestered parasites and, as rupturing schizonts release 
up to 32 merozoites, can be expected to precede a rise in parasitaemia (44-46). 
In Chapter 7 we found the presence of schizonts in peripheral blood smears to be 
associated with the need for ICU admission, renal replacement therapy, mechan-
ical ventilation and a longer hospital stay. Schizontaemia has a high NPV for 
presence of severe disease and, as compared to other parameters, a good PPV. 
Schizontaemia was shown to be an independent predictor for severe malaria in a 
binary logistic regression analysis. As artemisinin derivatives like artesunate have 
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an anti-malarial efficacy to the broadest spectrum of parasite stages, including 
the generally less drug-sensitive schizonts (44, 47, 48), the presence of schizonts 
warrants the use of this class of antimalarial drugs.
With the evaluation of these two parasite-related biomarkers we showed that 
valuable additional information can be obtained from routinely performed diag-
nostic tests. In settings where quantification of parasitaema cannot be obtained, 
the aldolase co-reactivity on the widely used Binax NOW® Malaria Test can be 
used as a surrogate marker of parasitaemia as its absence reliably excludes high 
parasitaemia or severe disease. If blood slide microscopy can be performed, the 
presence of schizonts is an independent predictor for severe malaria that should 
elicit vigilance for complications of the infection, even at low peripheral parasi-
taemia. Schizontaemia should be used as an additional argument for treatment 
with intravenous artesunate.
Acute kidney injury and hyponatraemia
In Part II of this thesis, we focused on two frequently observed complications in 
patients with malaria; acute kidney injury (AKI) and hyponatraemia.
AKI occurs in up to 40% of adult patients with severe P. falciparum malaria in 
endemic areas and is reported in 34 to 52% of non-immune travellers with severe 
P. falciparum infection (12, 15, 49-54). In these studies, AKI is usually defined 
according to the WHO criteria for severe malaria, with a creatinine threshold of 265 
μmol/L. This threshold however, is relatively high and consequently less severe or 
early forms of renal failure are not taken into account in these studies. In Chapter 
8 we analysed a large cohort of 485 patients with an imported P. falciparum infec-
tion using the Kidney Disease: Improving Global Outcomes (KDIGO) staging, 
which includes early or less severe forms of AKI. We found KDIGO-defined AKI 
to occur in 8% of all malaria patients and in 38% of patients with severe malaria. 
Renal replacement therapy (RRT) was needed in only a small minority of eight 
patients, and in five of them renal function recovered fully during admission. 
In our study, 12 (31%) of 39 patients with malaria-induced AKI had a normal 
serum creatinine at presentation. This finding illustrates the limitation of serum 
creatinine-based prediction models; significant renal injury can already have 
occurred while the serum creatinine level is still normal, as this starts to increase 
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substantially only 48 to 72 hours after the initial injury to the kidney (49). As struc-
tural kidney injury precedes this functional decline, a marker of structural damage 
could be expected to detect AKI much earlier, and for this reason markers of struc-
tural kidney damage have been under intense investigation for the early detec-
tion of AKI in recent years (56). In Chapter 9, we describe the predictive value 
of two markers of structural kidney damage: Neutrophil Gelatinase-Associated 
Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1). good diagnostic value 
of serum NGAL, urine NGAL and urine KIM-1 for AKI in patients with imported 
malaria was demonstrated. Particularly urine NGAL at presentation was found to 
have an excellent predictive performance for the occurrence of AKI during admis-
sion, with a PPV of 1.00 (95% CI 0.54-1.00) and a NPV of 1.00 (95% CI 0.89-1.00). 
However, as only a small number of patients was evaluaterd, larger studies are 
needed to confirm our findings and to evaluate whether routine measurement of 
NGAL should be introduced for patients with malaria.
Although the pathophysiology of AKI is not fully understood, blockage of renal 
microcirculation by sequestered erythrocytes, immune-mediated glomerular 
injury and volume depletion are likely to contribute (57, 58). One could expect 
that a more rapid clearance of parasitaemia will abate the injuring processes 
and reduce the risk of the development or progression of AKI. Whether the use 
of artemisinine derivates, which results in faster clearance of parasitaemia than 
other classes of antimalarial drugs, reduces progression of AKI in patients with 
an elevated urine NGAL at presentation, would be an interesting question to be 
answered in future research.
In Chapter 10 we focus on hyponatraemia in malaria. Although hyponatraemia 
has previously been described as a complication of P. falciparum infection(59), the 
incidence has mostly been studied in endemic areas (59-63) and few studies have 
been performed in non-immune populations or in patients infected with other 
Plasmodium species. We studied the occurrence of hyponatraemia in patients 
with imported P. falciparum but also in non-falciparum infections and a high inci-
dence in all patient groups: 77% in severe P. falciparum infection, 48% in non-se-
vere P. falciparum infection, and 34% in patients with infections with non-falci-
parum species. Serum sodium <131 mmol/L was independently associated with 
severe disease. Despite its common occurrence, the pathophysiology of hypo-
natraemia in malaria remains a matter of debate. Hyponatraemia can be consid-
ered to be a water balance disorder, and is usually caused by increased secre-
tion of arginine vasopressin (AVP). AVP is released by the posterior pituitary, most 
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commonly in response to hyperosmolarity or hypotension, which is regarded as 
appropriate AVP release. Its secretion can also be stimulated by pain and other 
non-specific causes of stress, which is seen as inappropriate AVP secretion (30, 
31). In hyponatraemic patients with malaria, some studies found evidence for 
appropriate vasopressin release due to hypovolaemia (62) whereas other studies 
found evidence for inappropriate vasopressin release (64, 65). In Chapter 11 we 
evaluate the role of AVP in the pathophysiology of hyponatraemia in a large cohort 
of 204 patients with imported malaria by measuring copeptin. AVP release was 
found to be uniformly increased, and in a small prospective substudy, AVP release 
was found to be appropriate seven of 13 hyponatraemic patients. The inappro-
priate AVP release in the other hyponatraemic patients is possibly triggered by 
the host cytokine response to the parasite. The distinction between appropriate 
and inappropriate AVP release in hyponatraemic malaria patients may be relevant 
with regard to selecting the optimal intravenous fluid regimen. The subject of fluid 
resuscitation in malaria is controversial; some studies have advocated aggressive 
fluid resuscitation in severe malaria as it was hypothesized to play an important 
role in the development of acidosis (67), but more recent studies found acidosis 
to correlate more closely with the level of sequestration and demonstrated that 
liberal fluid resuscitation did not improve acidosis and even leads to an increased 
risk for acute pulmonary oedema (66, 67). These studies however, did not separate 
hyponatraemic malaria patients on the basis of appropriate or inappropriate AVP 
secretion. In general, patients with appropriate AVP release will benefit from treat-
ment with isotonic fluids. One could hypothesize that this could also be the case 
for malaria patients with appropriate AVP release, while restrictive fluid therapy 
and more aggressive anti-malaria treatment would be preferable for patients with 
inappropriate AVP release. Further studies are needed to test this hypothesis. 
Implications and future perspectives 
Malaria is a potentially lethal infection and patients clearly benefit from specific 
medical expertise and the availability of appropriate laboratory facilities and 
medication. Therefore, the care for patients at risk for a severe infection should be 
centralised, while patients with a low risk for a severe course of the disease can be 
managed on the ward of a non-specialised centre, on condition that it’s staff feels 
sufficiently capable to care fore a malaria patient. How do we select these patients 
at risk? In our studies we have demonstrated that the aldolase co-reactivity on 
the malaria RDT is a particularly useful tool for this. This parameter has a high 
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NPV for severe disease, and, as the RDT is routinely performed, does not require 
specific laboratory skills or extra costs. In settings where procalcitonin is part of 
the routine laboratory examinations, this can be involved in the clinical decision 
making as well. If high parasitaemia can be excluded by a negative aldolase co-re-
activity on the RDT, and, if available, a procalcitonin < 0.9 ng/ml, patients can 
be safely treated with oral antimalarials on the ward of a non-specialised centre. 
However, if at risk for a severe infection, patients should be transferred to a facility 
with possibilities for reliable species determination, quantification and detection 
of peripheral schizontaemia, and with intravenous artesunate in stock. There, if 
after blood slide examination the patient meets the WHO severity criteria or, as 
this is an independent predictor for severity, schizonts are seen in the peripheral 
blood slide, the treatment should involve intravenous artesunate.
The search for more accurate parameters to predict malaria severity is ongoing. 
Possibly, combining existing biomarkers can improve the predictive performance. 
A promising novel parasite-related parameter is the quantitative load of PfHRP-2, 
of which the plasma levels were found to correlate better with severity than para-
sitemia in studies in endemic areas (68-70). A recent study yielded promising 
results in imported malaria as well (71) and a proof-of-concept study demon-
strated diagnostic potential of quantitative PfHRP-2 levels in saliva, which would 
enable non-invasive measurements, but these findings need confirmation in 
larger clinical studies. A pitfall for these PfHRP-2-based models however, is that 
P. falciparum parasites that lack the PfHRP-2 protein, which have predominantly 
been found in South America (72), will not be detected. Molecular detection 
methods are also increasingly in use. Real-time polymerase chain reaction (PCR) 
based quantification of parasitaemia has been demonstrated to correlate closely 
with microscopy-based quantification and multiplex PCR methods can be partic-
ularly useful for the identification of mixed plasmodial infections (73) . However, 
as these methods take at least several hours to perform and are usually not avail-
able out of hours, they are currently of limited value in the clinical setting and are 
still predominantly used in clinical trials (74) and for the confirmation of species 
identification (75). Further research is needed to show which novel biomarkers or 
combinations of biomarkers will lead to a more accurate prediction of severity and 
complications of imported malaria.
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Table 1  Summary of the performance of the analyzed parameters.
Parameter Cut-off 
value
Sensitivity Specificity PPV NPV AUROC
CRP >141 mg/L 0.80
(0.67-0.89)
0.76
(0.71-0.80)
0.33
(0.25-0.42)
0.96
(0.93-0.98)
0.84
(0.79-0.89)
Neopterin ≥ 10 ng/ml 0.93
(0.64-1.00)
0.67
(0.54-0.78)
0.38
(0.23-0.56)
0.98
(0.86-1.00)
0.85
(0.76-0.94)
Procalcitonin ≥ 0.9 ng/
ml
1.00
(0.70-1.00)
0.53
(0.40-0.66)
0.30
(0.17-0.47)
1.00
(0.87-1.00)
0.78
(0.66-0.91)
Copeptin ≥ 21 
pmol/L
0.60
(0.39-0.78)
0.73
(0.66-0.79)
0.31
(0.25-0.38)
0.93
(0.87-0.96)
0.66
(0.59-0.72)
Total leukocyte 
count
≥ 6.5 x 
109/L
0.59
(0.46-0.71)
0.75
(0.71-0.80)
0.28
(0.21-0.37)
0.92
(0.88-0.95)
0.70
(0.63-0.78)
Neutrophil 
count 
≥ 3.4 x 
109/L
0.64
(0.51-0.76)
0.56
(0.51-0.61)
0.19
(0.14-0.25)
0.91
(0.86-0.94)
0.61
(0.53-0.69)
Lymphocyte 
count
< 0.7 x 
109/L
0.33
(0.22-0.46)
0.72
(0.67-0.76)
0.16
(0.10-0.24)
0.87
(0.83-0.90)
0.51
(0.43-0.59)
NLCR ≥ 2.8 0.77
(0.64-0.86)
0.44
(0.39-0.49)
0.18
(0.14-0.24)
0.92
(0.87-0.96)
0.57
(0.50-0.64)
Aldolase 
coreactivity
N/A 1.00
(0.85-1.00)
0.32
(0.25-0.40)
0.21
(0.11-0.25)
1.00
(0.93-1.00)
N/A
Schizontaemia N/A 0.53
(0.40-0.66)
0.95
(0.92-0.97)
0.67
(0.52-0.80)
0.92
(0.88-0.94)
N/A
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Malaria is een van de belangrijkste oorzaken van koorts na internationale reizen 
en moet worden overwogen bij alle patienten die ziek worden na terugkeer uit een 
malaria-endemisch gebied. Medisch personeel in niet-endemische gebieden 
hebben echter vaak maar weinig ervaring met het vaststellen en behandelen 
van malaria, en het is aangetoond dat een gebrek aan ervaring met malaria bij de 
behandelaars het risico op sterfte bij de patient doet toenemen. Het herkennen 
van patienten met een verhoogd risico voor een ernstig beloop van de infectie en 
kennis over de mogelijke complicaties is essentieel. In dit proefschrift hebben we 
gezocht naar methoden om deze herkenning te verbeteren. 
Het inschatten en voorspellen 
van de ernst van importmalaria
In 1990 introduceerde de World Health Organisation (WHO) een lijst met criteria 
om een ernstige Plasmodium falciparum infectie te definiëren. Het doel van deze 
casusdefinitie was primair het faciliteren van klinische en epidemiologische studies, 
maar diende ook als leidraad bij de behandeling van patiënten. De WHO adviseert 
om patiënten die aan een of meer van deze criteria voldoen te behandelen op een 
intensive care (IC) afdeling. In niet-endemische gebieden wordt het gebruik van 
de WHO definitie echter beperkt door het feit dat deze een kwantitatieve bepaling 
van de P. falciparum parasitemie vereist. Faciliteiten hiervoor zijn niet in alle zieken-
huizen op elk moment van de dag beschikbaar, en vaak worden er alleen sneltesten 
gebruikt om malaria vast te stellen. Een parameter die op een betrouwbare manier 
de patiënten met een verhoogd risico op een ernstig beloop zou kunnen identifi-
ceren zou in deze situaties van belangrijke toegevoegde waarde kunnen zijn.
In Deel I van dit proefschrift hebben we gezocht naar dergelijke parameters. 
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Gastheer-gerelateerde biomarkers 
Biomarkers zijn de laatste jaren steeds belangrijker geworden binnen de infectie-
ziekten en reeds veel verschillende biomarkers zijn geëvalueerd als voorspellers 
van uitkomst in patiënten met bacteriële sepsis. Omdat er belangrijke overeen-
komsten bestaan in de pathogenese en het klinisch beeld van bacteriële sepsis 
en ernstige malaria, hebben we onderzocht of biomarkers die succesvol zijn 
gebleken bij septische patiënten ook bruikbaar kunnen zijn in de voorspelling van 
de ernst van malaria. Drie van deze biomarkers werden bestudeerd in Hoofdstuk 2, 
te weten procalcitonine, neopterine en triggering receptor expressed on myeloid 
cells (TREM)-1. In onze studie kon met TREM-1 geen onderscheid worden gemaakt 
tussen ernstige en ongecompliceerde malaria. Wel hadden reizigers met ernstige 
P. falciparum infecties bij opname significant hogere waarden van neopterine en 
procalcitonine dan reizigers met ongecompliceerde malaria. Zowel neopterine als 
procalcitonine hadden een zeer goede negatief voorspellende waarde, maar hun 
positief voorspellende waarde was beperkt.
In hoofdstuk 3 evalueerden we copeptine, een glycopeptide dat deel uitmaakt van 
precursor van arginine vasopressin (AVP) en een stabiele en sensitieve marker is 
voor productie van AVP. In studies in patiënten met sepsis en leptospirose corre-
leerde copeptine beter met ernst van de infectie dan C-reactive protein (CRP) en 
procalcitonine. Een opvallende overeenkomst tussen leptospirose en malaria is 
het frequente optreden van hyponatriemie, hetgeen meestal het gevolg is van 
toegenomen AVP productie. In tegenstelling tot de studies in sepsis en leptospi-
rose bleek copeptine in onze studie echter niet superieur aan CRP voor het voor-
spellen van ernst van importmalaria. 
Ondanks de hoge negatief voorspellende waarde van de geëvalueerde biomar-
kers, waarbij die van procalcitonine en neopterine zelfs hoger was dan die van CRP, 
wordt hun bruikbaarheid beperkt door het feit dat ze niet routinematig worden 
gemeten. We zochten daarom verder naar bruikbare markers die wel routinematig 
worden bepaald. 
Lymfocytopenie is frequent beschreven bij malaria, zowel in endemische 
gebieden als bij importmalaria, maar studies naar de correlatie tussen het lymfo-
cytenaantal en de ernst van malaria hebben tegenstrijdige resultaten laten zien. 
Zowel lymfocytopenie als de verhouding tussen neutrofielen en lymfocyten, de 
neutrophil-to-lymphocyte count ratio (NLCR) zijn uitstekende voorspellers van 
de aanwezigheid van een bacteriëmie en van ernst en uitkomst van bacteriële 
243
Nederlandse samenvatting  /  CHAPTER 13
luchtweginfecties, met hogere prognostische waarde dan traditionele markers. 
Omdat er weinig bekend is over de dynamiek van de het totale aantal leukocyten 
en leukocytensubpopulaties en van de NLCR bij malaria hebben we dit onder-
zocht in de setting van een gecontroleerde malariainfectie, een controlled human 
malaria infection (CHMI) in hoofdstuk 4. We keken hierbij naar de veranderingen 
van de totale en differentiële leukocytenaantallen en hun ratio’s in een groep 
malaria-naïeve Nederlandse vrijwilligers, die werden blootgesteld aan de beten 
van met malaria geïnfecteerde muggen. Er werd een afname van het totale aantal 
leukocyten en de lymfocyten en neutrofielen gezien tijdens de bloedfase, met een 
stijging van de NLCR, en er was een correlatie tussen de parasitemie enerzijds en 
het lymfocytenaantal en de NLCR anderzijds. Naast deze bevindingen werd er 
ook een stijging van het aantal leukocyten, monocyten en lymfocyten tijdens de 
leverfase gevonden. Deze bevindingen zijn niet eerder beschreven. In hoofdstuk 5 
hebben we de prognostische waarde van de differentiële leukocytenaantallen en 
hun ratio’s bij patiënten bekeken. De NLCR correleerde ook hier met parasitemie, 
maar was inferieur aan CRP als marker voor ernstige infectie bij importmalaria.
Parasiet-gerelateerde biomarkers
Sneltesten zijn zeer sensitief voor het vaststellen van malaria bij reizigers, maar 
zijn niet gemaakt om de parasitemie ook te kwantificeren. Een hoge parasitemie 
is echter een belangrijke determinant van een ernstige infectie. In hoofdstuk 6, 
beschrijven we een we een multicenter laboratoriumstudie waarin we hebben 
aangetoond dat de veel gebruikte Binax NOW® Malaria Test kan worden gebruikt 
voor een semi-kwantitatieve bepaling van de parasitemie door te differentiëren 
tussen reactiviteit van alleen het P. falciparum specifieke Plasmodium falciparum 
histidine-rich protein 2 (PfHRP-2) bandje of zowel het PfHRP-2 als het pan-plas-
modiale aldolase bandje. Co-reactiviteit van aldolase en PfHRP-2 werd gezien bij 
alle patiënten met een parasitemie boven de 50,000 aseksuele parasieten/μl en 
ook bij alle patiënten met ernstige malaria. Aldolase co-reactiviteit had een hoge 
negatief voorspellende waarde maar een matige positief voorspellende waarde 
doordat aldolase co-reactiviteit ook aanwezig was bij de meerderheid van de pati-
enten met ongecompliceerde malaria. Echter, in een situatie waar er sneltesten 
worden gebruikt zonder dat er mogelijkheden zijn voor conventionele kwantifi-
catie van de parasitemie, kan het veilig worden gebruikt om een hoge parasitemie 
of ernstige malaria uit te sluiten.
De tweede parastiet-gerelateerde biomarker die we onderzochten is de aanwe-
zigheid van schizonten in het perifere bloed. Rode bloedcellen die geparasiteerd 
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zijn door P. falciparum hebben de neiging vast te plakken aan het vasculaire endo-
theel en daarmee uit het perifere bloed te verdwijnen. Daarom correleert de peri-
fere parasitemie niet altijd goed met de totale parasietenload. Het verschijnen van 
schizonten in het perifere bloed wordt gezien als een teken van een hoog volume 
van gesekwestreerde geparasiteerde erythrocyten, en aangezien rupturerende 
schizonten tot 32 dochter-merozoïeten kunne vrijlaten, kan het verschijnen van 
schizonten ook voorafgaan aan een sterke stijging van de parasitemie. In hoofd-
stuk 7 vonden we dat de aanwezigheid van schizonten geassocieerd was met de 
noodzaak tot IC opname, nierfunctievervangende therapie, kunstmatige beade-
ming en een langere opnameduur. Schizontemie is een onafhankelijke risico-
factor voor ernstige malaria. Omdat artemisininederivaten een goede schizonto-
cide werking hebben gaat de voorkeur bij schizontemie uit naar behandeling met 
deze klasse middelen.
Acute nierinsufficientie en hyponatriEmie 
In het tweede deel van dit proefschrift richten we ons op twee veelvoorkomende 
complicaties bij importmalaria: acute nierinsufficiëntie en hyponatriëmie.
In hoofdstuk 8 onderzochten we de incidentie van nierinsufficiëntie in een groot 
cohort patiënten met importmalaria. Anders dan in de meeste eerdere studies 
gebruikten we hiervoor de Kidney Disease: Improving Global Outcomes (KDIGO) 
stadiering, waarmee niet alleen ernstige maar ook vroege of minder ernstige 
nierinsufficiëntie wordt geincludeerd. We vonden dat nierinsufficiëntie optrad 
bij 8% van alle patiënten met malaria en bij 38% van de patiënten met ernstige 
malaria. Nierfunctievervangende therapie was in slechts een klein aantal pati-
enten nodig en bij de meerderheid van hen herstelde de nierfunctie nog tijdens 
opname volledig. Ook in onze studie echter had 31% van de patiënten met een 
acute nierinsufficiëntie bij opname nog een normale kreatininewaarde. Deze 
bevinding illustreert de beperking van het gebruik van deze waarde: de kreatini-
neconcentratie begint pas 48 tot 72 uur na het ontstaan van de structurele nier-
schade te stijgen. In hoofdstuk 9 onderzoeken we daarom de diagnostische 
waarde van twee markers van structurele nierschade: Neutrophil Gelatinase-
Associated Lipocalin (NGAL) en Kidney Injury Molecule-1 (KIM-1). We vonden 
een goede diagnostische waarde van serum NGAL, urine NGAL en urine KIM-1. 
Met name urine NGAL bij presentatie had een uitstekende voorspellende waarde 
voor het ontstaan van acute nierinsufficiëntie tijdens opname met een positief 
voorspellende waarde van 1.00 (95% CI 0.54-1.00) en een negatief voorspellende 
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waarde van 1.00 (95% CI 0.89-1.00). Omdat dit een pilot-studie was met slechts 
een klein aantal patiënten zijn er grotere studies nodig om deze bevindingen te 
bevestigen. 
In hoofdstuk 10 onderzoeken we hyponatriëmie bij malaria. Hoewel hypona-
triëmie eerder is beschreven als complicatie van P. falciparum infecties in ende-
mische gebieden is er weinig bekend over de incidentie bij importmalaria of bij 
patiënten met non-falciparum infecties. In onze studie naar het optreden van 
hyponatriëmie bij importmalaria vonden we een hoge incidentie in alle patienten-
groepen; 77% bij ernstige P. falciparum infecties, 48% bij ongecompliceerde P. falci-
parum infecties en 34% bij non-falciparum malaria. Serum natrium <131 mmol/L 
was een onafhankelijke voorspeller voor ernstige malaria. 
In hoofdstuk 11 evalueren we de rol van het antidiuretisch hormoon, ook wel 
bekend als arginine vasopressine (AVP) in de pathofysiologie van hyponatri-
emie in malaria. Hyponatriëmie kan worden beschouwd als een verstoring van de 
waterbalans, en wordt meestal veroorzaakt door waterretentie door een toege-
nomen secretie van AVP. Deze AVP afgifte kan ‘terecht’ zijn, zoals bij hyperosmo-
laliteit of hypotensie, maar kan ook ‘onterecht’ worden afgegeven als respons op 
aspecifieke stimuli als stress en pijn. In cohort van 204 patiënten met importma-
laria vonden we een uniform verhoogde AVP afgifte. Bij een kleine prospectieve 
substudie bleek dat er bij ongeveer de helft van de patiënten met hyponatriëmie 
sprake was van een terechte, en bij de andere helft van een onterechte AVP afgifte. 
Dit onderscheid zou van belang kunnen zijn in het bepalen van het optimale rehy-
dratiebeleid.
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Toen ik als arts-assistent interne geneeskunde in het Havenziekenhuis kwam 
werken, was promoveren niet direct een doel. Wel waren er boeiende patiënten, 
interessante ziektebeelden en vragen. Zo begon ik aan mijn eerste artikel over 
importmalaria. Na dat eerste artikel volgden er meer en zo ontstond dit proef-
schrift eigenlijk nog voordat ik mij er zelf bewust van was. 
Zonder mijn co-promotor, dr. P.J.J. van Genderen, zou het echter nooit zo ver 
gekomen zijn. Perry, jij hebt me van dit traject weten te overtuigen, geholpen er 
richting aan te geven en mij steeds weer kunnen prikkelen om door te gaan. Heel 
veel dank voor je vertrouwen en de zeer prettige samenwerking de afgelopen jaren.
Prof. dr. A. Verbon, beste Annelies, dank je dat je mij de kans hebt gegeven bij jou 
te promoveren. Door mijn tijdelijke aanstelling als internist-infectioloog in het 
Erasmus MC heb je mij niet alleen de gelegenheid gegeven om op mijn vertrouwde 
plek ervaring op te doen in een nieuwe rol, maar kreeg ik ook de rust en ruimte om 
dit proefschrift af te ronden. 
Graag bedank ik ook in het bijzonder een aantal van mijn co-auteurs. Dr. J.J. van 
Hellemond, beste Jaap. Je bent bij vrijwel alle hoofdstukken betrokken geweest 
en jouw expertise en kritische blik waren iedere keer weer essentieel. Dr. D.A. 
Hesselink en dr. E.J. Hoorn, Dennis en Ewout, dank dat jullie steeds weer de tijd 
hebben genomen voor onze besprekingen en voor alle hulp bij onze gezamenlijke 
artikelen.
Tijdens mijn opleiding in Rotterdam heb ik samen mogen werken met een hele-
boel inspirerende, bijzondere en behulpzame mensen. Een paar wil ik er in het 
bijzonder noemen. Dr. P.J. Wismans, beste Pieter, toen ik in 2007 bij jou aanklopte 
voor een baan, mijn artsenbul nog niet eens op zak, was ik helemaal nog niet zeker 
van de richting van mijn carrière. Jouw aanstekelijke enthousiasme voor het vak 
heeft zonder twijfel een rol in gespeeld in mijn keuze voor de interne geneeskunde. 
CHAPTER 15
Dankwoord
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Aan mijn periodes in het Havenziekenhuis zal ik altijd met veel liefde en een beetje 
heimwee terugdenken. 
Mijn opleiders in de infectieziekten, dr. J.L. Nouwen en dr. C.A.M. Schurink, Jan en 
Karin, ik ben er trots op in Rotterdam en door jullie te zijn opgeleid en ben jullie heel 
erg dankbaar voor de letterlijk onbegrensde mogelijkheden die ik van jullie kreeg 
om een persoonlijke draai aan mijn opleiding te geven. Jiri, Mark en Femke, mijn 
voormalige mede-fellows, heel veel dank voor de onvoorwaardelijke collegialiteit 
en alle gezelligheid binnen en vooral ook buiten het ziekenhuis. Dat laatste hou ik 
graag nog heel lang met jullie vol.
Inmiddels heb ik in het zuiden van het land een nieuw thuis gevonden. Mijn nieuwe 
collega’s in Maastricht, in het bijzonder Selwyn, Astrid en Dirk, dank jullie wel voor 
de warme ontvangst in jullie midden; ik heb het enorm getroffen met deze gewel-
dige werkplek.
Emmeline en Klaske, ik ben heel erg blij met jullie als paranimf en steun en toever-
laat. Dank voor al jullie praktische en morele steun in de laatste maanden voor de 
verdediging, maar bovenal ook voor jullie jarenlange vriendschap. 
Mijn lieve ouders, boer en zus, zonder de stimulerende omgeving waarin ik zorge-
loos kon opgroeien, zou ik nooit zijn gekomen waar ik nu ben. Dank voor jullie 
onvoorwaardelijke steun.
Van alle dingen die sinds het eerste artikel van dit proefschrift zijn gebeurd is er 
één mooier en bepalender dan al het andere. Mijn lieve Geert, wat is het toch 
fantastisch dat jij in mijn leven bent gekomen, want niets op deze wereld, ook niet 
de mooiste en verste reis, maakt mij zo gelukkig als samenzijn met jou.
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Improving assessment of
severity and complications
Voor het bijwonen van de publieke 
verdediging van mijn proefschrift
Op woensdag 6 september 
om 11.30 in de Prof. Andries
Queridozaal in het onderwijs-
centrum van het Erasmus MC 
(gebouw E, kamer Eg-370), 
Wytemaweg 80 te Rotterdam.
Aansluitend is er een receptie 
ter plaatse.
Dezelfde avond bent u vanaf 
20.00 van harte welkom op de 
borrel in Bierlokaal Locus Publicus, 
Oostzeedijk 364 te Rotterdam.
Koopvaardijhof 23
3071 PK Rotterdam
mvanwolfswinkel@gmail.com
06-42985957
paranimfen 
Klaske Vliegenthart
klaske@vliegenthart.org
Emmeline Buddingh�
epbuddingh@hotmail.com
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